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ABSTRACT 
 
Adoptive cell transfer (ACT) immunotherapy using genetically modified antigen (Ag)-
specific T cells is a rapidly evolving field. Although evidence from pre-clinical and clinical 
studies suggests the use of Ag-specific T cells can be effective treating different malignancies, 
several challenges remain in order to improve these therapeutics. Host factors that can affect Ag-
specific T cells during ACT immunotherapy remain understudied. Evidence of this lack in 
research includes characterizing the effects of sex and sex hormone receptor signaling on Ag-
specific T cell function. Males and females have great differences in their circulating T cell 
populations and subset phenotypes. While some of these sex-differences in T cell phenotype are 
genetically and environmentally mediated, many of these differences heighten or decrease with 
puberty and reproductive senescence indicating a sex hormone receptor involvement. Estrogen 
was shown to modulate the development and differentiation of T cells. The effect of estrogen on 
T cell function remains controversial and incompletely understood. With most of the important 
aspects concerning the role of estrogen on T cells previously investigated in autoimmunity 
models and at hormone concentrations limited to physiological and pregnancy estrogen levels, 
the role of estrogen signaling through its canonical receptors, estrogen receptor  and  (ER 
and ER) at other ranges of estrogen dosage need to be investigated. Knowing that sex and 
estrogen have direct effects on T cell differentiation and function, it is important to carefully 
characterize their effects on Ag-specific T cells for immunotherapy in order to identify possible
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mechanisms that can be targeted to enhance T cell anti-tumor immune responses and 
immunotherapy efficacy. 
The effects of sex and estrogen signaling on T cells and other immune cells result in 
differences on pathogenesis of malignancies including hepatocellular carcinoma (HCC). HCC is 
significantly more prevalent in males and post-menopausal females not undergoing estrogen 
hormone replacement therapy compared to pre-menopausal females, demonstrating a protective 
role of estrogen against HCC. The role of estrogen signaling was investigated in transformed 
hepatocytes and infiltrating innate immune cells but was not reported in tumor infiltrating T 
cells. ACT immunotherapy using genetically modified T cells showed some success on treating 
HCC in pre-clinical and clinical studies but the efficacy of ACT fighting HCC remains 
unsatisfactory. In this study, it was hypothesized that the protective role of estrogen against HCC 
is partially due to the estrogen-mediated enhancement of the T cell anti-tumor immune 
responses. Thus, if the T cell anti-tumor immune response is enhanced by estrogen, then estrogen 
signaling can be used to increase the efficacy of adoptive T cell transfer immunotherapy.  
The work performed in this dissertation was aimed to characterize the role of estrogen 
signaling on T cell function in vitro, and during ACT immunotherapy against HCC in vivo. 
Using human male and female Ag-specific T cells, the effect of estrogen receptor signaling on 
overall T cell function and anti-tumor immunity was determined. Estrogen signaling through 
ER was shown to enhance the expression and secretion of Type I effector cytokines including 
interferon  (IFN), tumor necrosis factor  (TNF), and Granzyme B in male and female Ag-
specific T cells activated with their cognate tumor Ag. Estrogen signaling through ER was also 
shown to modulate the overall expression of the Type 2 cytokine interleukin 4 (IL-4) in male and 
 
 
xxii 
 
female Ag-specific T cells. These results indicated that estrogen signaling through ER mediates 
the balance between Type I and Type II Ag-specific T cell responses. Estrogen signaling through 
ER enhanced the polyfunctionality, or the ability of a T cell to express several markers 
simultaneously upon activation, of male and female Ag-specific T cells activated with their 
cognate Ag. T cell polyfunctionality is correlated with enhanced T cell receptor (TCR) signaling, 
indicating that estrogen signaling through ER enhances TCR downstream signaling pathways. 
These results demonstrated for the first time that estrogen signaling through ER and ER can 
enhance the function of human Ag-specific T cells. Using an HCC mouse model treated using 
ACT immunotherapy, the effect of estrogen on the Ag-specific T cell anti-tumor immune 
response was measured. The presence of estrogen resulted in reduced tumor burden through 
higher Ag-specific T cell tumor infiltration, survival, activation state, and cytokine expression. 
Removal of physiological estrogen during ACT immunotherapy reduced the survival of CD4+ 
Ag-specific T cells resulting in reduced tumor infiltration. Lack of physiological estrogen during 
ACT also caused hindered cytokine production and polyfunctionality of CD4+ Ag-specific T 
cells. These results revealed for the first time that estrogen signaling can enhance the survival 
and function of CD4+ Ag-specific T cells which results in enhanced anti-tumor responses and 
reduced tumor burden. 
In summary, estrogen signaling enhances male and female Ag-specific T cell cytokine 
expression and secretion, and polyfunctionality which lead to enhanced tumor infiltration, 
survival, activation state, and function during ACT immunotherapy. This indicates that inducing 
estrogen signaling on Ag-specific T cells can enhance the efficacy and therapeutic outcome of 
ACT immunotherapy. 
 1 
 
CHAPTER I 
LITERATURE REVIEW 
Immunotherapy 
 The immune system has the ability to recognize and destroy tumor cells without affecting 
normal cells through a mechanism called immune surveillance, and thus functions as a primary 
anti-cancer defense mechanism [1]. The immune system can also prevent cancer through 
generating long-term memory T cell responses [1]. Immunotherapy involves the enhancement of 
immune responses in cancer patients to increase tumor recognition and initiation of anti-tumor 
responses [2]. Because of the success obtained in recent years treating specific cancers with this 
therapeutic approach, immunotherapy has become the fourth pillar of cancer treatment together 
with surgery, radiation, and traditional chemotherapy. Most clinically approved immunotherapies 
have T cells central to their mechanism and fall broadly into two categories: first, agents that 
directly target and modulate endogenous T cell responses; and, second, cellular therapies where 
genetically modified T cells are used as treatment. T cells are immune cells that can be activated 
by tumor antigens, they can specifically destroy tumor cells in response to tumor antigen 
stimulation, and further generate memory responses that last long periods of time. While 
immunotherapy enhances the anti-tumor immune response, tumors can avoid it and still develop 
in the presence of an active immune system through a mechanism called immune tolerance. 
Therefore, the focus of ongoing immunotherapy research is on not only the recognition and 
destruction of specific tumor cells but also toward overcoming immune tolerance posed by the
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tumor microenvironment (TME), and finally in discovering new host pathways that can be 
targeted to enhance its efficacy. The work performed in this dissertation was aimed at identifying 
novel roles of host factors present in the TME, like the sex hormone estrogen, that can be 
modulated in order to enhance T cell-based immunotherapy. In the upcoming paragraphs, T cell 
function and subsets are described as well as the different current  types of T cell-based 
immunotherapies and the challenges that immunotherapy is faced with in the clinic. 
T cell Signaling and Function 
 
T cells play a central role in mediating cellular immunity. T cells are multi-functional 
effector cells that protect humans from disease throughout their entire lives with their ability to 
recognize bacterial, viral, and cancer antigens. The specificity of T cells is mediated by the T cell 
receptor (TCR), a surface receptor that facilitates target antigen recognition in the context of a 
major histocompatibility complex (MHC) molecule. Cell surface expression of the TCR requires 
its association with the CD3 complex (Figure 1) [3]. The CD4 and CD8 co-receptors enhance the 
binding of the TCR to MHC class II and I respectively and promote downstream signaling by 
localizing the lymphocyte-specific protein tyrosine kinase (lck) to the TCR/CD3 complex 
(Figure 1) [3, 4]. Upon recognition and binding to the antigen-bearing MHC, a signaling cascade 
begins downstream from the TCR consisting on phosphorylation of immunoreceptor tyrosine-
based activation motifs (ITAMs) by lck in the CD3 chain and recruitment of -chain associated 
protein (Zap70), which induces assembly of the remaining signaling components (Figure 1) [5]. 
Several signaling pathways are triggered downstream from the TCR including the activation of 
phospholipase C  (PLC) which hydrolyzes membrane-bound phosphatidylinositol 4, 5-
biphosphate (PIP2) into inositol-3-phosphate (IP3) and diacylglycerol (DAG). IP3 triggers the 
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activation of the calcium (Ca+2)-dependent nuclear factor of activated T cells (NFAT) signaling 
pathway [6]. DAG activates several major signaling pathways including the mitogen activated 
kinase (MAP kinase) pathway, and the nuclear factor kappa-light-chain-enhancer of activated B 
cells (NFB) pathway induced by protein kinase C (PKC) activation [6]. Activation of these 
signaling pathways induce intracellular Ca2+ release, actin polymerization, integrin activation, T 
cell proliferation, cytokine secretion, and degranulation [7]. This T cell functional response 
varies depending on the subset of activated T cell. Naïve T cells can differentiate into various 
subsets depending on the activating stimulus and the cocktail of cytokines present during Ag 
recognition [8, 9]. T cell subsets are identified by cell surface markers, transcription factors 
expression, and cytokines secreted.  
A well characterized example of T cell subsets being distinguished by cytokine secretion 
and transcription factor expression is the Th1 and Th2 CD4+ helper T cell subsets. Th1 CD4+ T 
cells express the transcription factor T-Bet and secrete mainly interferon  (IFN), interleukin-2 
(IL-2), and tumor necrosis factor  (TNF) upon activation [9]. Th1 mediate pro-inflammatory 
cell mediated immunity and were shown to induce delayed-type hypersensitivity and mediate the 
response to some protozoa. On the other hand, Th2 CD4+ T cells express the transcription factor 
GATA3 and secrete mainly IL-4, -5, -6, -10, and -13 [9]. Th2 cells promote non-inflammatory 
immediate immune responses and are essential in B cell production of immunoglobulin G (IgG), 
IgA, and IgE [9]. Th1 and Th2 development routes are mutually antagonistic, giving rise to the 
model of polarization of the T cell immune response. Other CD4+ helper T cells subsets that 
differentiate based on transcription factor expression and cytokine production are the Th17 
subset which expresses RORt and produces IL-17a and IL-22, the regulatory T cells (Tregs) 
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subset which expresses forkhead box P3 (FoxP3) and secretes IL-10 and transforming growth 
factor  (TGF), and the Th9 subset which produces IL-9 [9].  
 
 
 
 
 
 
Figure 1. T Cell Receptor (TCR) Mediated Target Recognition and T Cell Activation. Depicted 
is a target cell, such as a tumor cell, presenting an antigen in the context of the MHC to a T cell’s 
TCR. The TCR  and  chains form a complex with CD3 components and the CD8 or CD4 co-
receptors stabilize the TCR-MHC interaction. Upon antigen recognition and TCR ligation, Lck 
phosphorylates the ITAMs on the CD3 chains which recruit Zap70 which facilitates TCR 
downstream signaling which results in T cell activation. MHC: major histocompatibility complex, 
Lck: lymphocyte-specific protein tyrosine kinase, ITAM: immunoreceptor tyrosine-based activation 
motif, Zap70: -chain associated protein. 
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CD8+ cytotoxic T lymphocytes (CTLs) are derived from naïve CD8+ T cells, proliferate 
in the presence of IL-2, and can expand their number by a thousand-fold upon activation at the 
peak of a primary immune response [9]. Rapid expansion and the ability of CD8+ CTLs to 
destroy more than one target while sparing bystander cells, make CTLs very efficient Ag-
specific effector cells [9]. Destruction of target cells by CTLs requires Ag recognition which 
initiates the release of cytotoxic granules such as perforin and Granzyme B into the 
immunological synapse between CTL and target cells, or the initiation of Fas/Fas-ligand-
mediated apoptosis. Similarly to CD4+ T cells, cytotoxic CD8+ effector T cells fall into two 
subpopulations based on cytokine secretion. Type I CD8+ T cells secrete IFN, whereas Type II 
CD8+ T cells secrete IL-4, IL-5, and IL-10 [10]. Both Type I and Type II CD8+ T cells were 
shown to provide strong immunity against tumors and differentiate into CD8+ memory T cells. 
Long-lasting protection by Type I and Type II CD8+ effector cells was dependent on IL-4, IL-2, 
and INF production indicating both subsets are required for the generation of superior anti-
tumor responses [10]. Overall, the immunology field generally accepts that T cells are 
functionally restricted by the subset into which they differentiate, each CD4+ and CD8+ T cell 
subset has different functions based on the cytokines and factors they secrete upon TCR 
activation [9].   
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Types of Immunotherapy 
Immune Checkpoint Blockade  
Upon Ag encounter, to ensure robust T cell activation, two independent signaling 
pathways are involved. The first signal requires recognition of the Ag-bearing MHC on the 
surface of antigen presenting cells (APCs) or tumor cells by the corresponding TCR. The second 
signal, which is Ag independent, is delivered by the engagement of co-stimulatory molecules 
[11, 12]. Positive co-stimulation is mainly mediated by CD28 receptors expressed on T cells 
binding to B7.1 (CD80) and B7.2 (CD86) on APCs [13]. This interaction leads to a cascade of 
intracellular signal transducers and regulators, and results in T cell activation and proliferation, 
as well as the production of various cytokines, including IL-2, thus avoiding anergy [11, 14]. 
CD4+ and CD8+ T cells have severely impaired proliferation and produce reduced levels of 
effector cytokines in the absence of CD28 [15, 16]. T cells can also express several inhibitory co-
stimulatory factors, such as cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) and 
programmed cell death protein-1 (PD-1) which are denominated immune checkpoints. Binding 
of these negative co-stimulatory factors to their ligands antagonizes T cell activation. T cell 
immunosppression by immune checkpoints is relevant in order to avoid T cell responses against 
self Ag which can promote autoimmunity. In the TME, the expression of immune checkpoints by 
TILs results in T cell hyporesponsiveness and immune exhaustion contributing to tumor immune 
scape. Blocking the interactions of TIL inhibitory co-stimulatory molecules results in sustained 
activation of the anti-tumor immune response thereby making checkpoint blockade an 
efficacious immunotherapy.  
 Activated T cells express CTLA-4 which binds to ligands B7.1 (CD80) and B7.2 (CD86) 
with much higher affinity than CD28 [17]. Binding of CTLA-4 to B7.1 or -2 induces powerful 
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inhibitory signaling that dampens T cell activation, leading to decreased cell cycle progression, 
proliferation, and IL-2 secretion [17]. CTLA-4 inhibition with monoclonal antibodies prevents 
the binding of CTLA-4 to B7.1, 2, thereby promoting T cell activation and successful anti-tumor 
immune responses. Several CTLA-4 blocking monoclonal antibodies such as Ipilimumab and 
Tremelimumab were approved by the Food and Drug Administration (FDA) to treat melanoma. 
Although CTLA-4 blockade was successful for some patients, the objective response rates 
(ORR) for stage III or IV melanoma patients treated with Ipilimumab was 15-20%, and only 
11% for those treated with Tremelimumab [18-21]. Progression free survival rates (SR) for 
melanoma patients treated with CTLA-4 inhibitors were around 2.8 months.  
The surface receptor PD-1, which is homologous to CD28, is also expressed in activated 
T cells and it is primarily involved in inhibitory immune signaling. PD-1 binds to the 
programmed cell death ligand 1 (PD-L1) and elicits intracellular signaling that results on the 
dephosphorylation of TCR proximal components such as CD28 [22-24]. Interfering with CD28 
signaling, PD-1 signaling therefore results in reduced cytokine production, reduced T cell 
proliferation and survival, and reduced expression of T cell effector functions such as T-Bet and 
Eomes [23-25]. PD-L1 expression is observed in both cancer cells and tumor-infiltrating immune 
cells such as macrophages. PD-L1 expression on the cells present in the TME is upregulated in 
response to IFN signaling [26]. PD-L1 expression therefore indicates an active anti-tumor 
immune response and it is a way for the tumor cells to escape it through immunosuppression. 
Blockade of PD-1 and PD-L1 using monoclonal antibodies was approved by the FDA as a 
therapy for cancers including melanoma, renal cell carcinoma, squamous cell carcinoma, and 
non-small cell lung cancer (NSCLC). PD-1 inhibitors such as Nivolumab and Pembrolizumab 
 
 
 
 
8 
showed encouraging ORR of over 40% on stage III or IV melanoma patients with progression 
free survival rates of over 7 months [18, 21]. PD-1 inhibitors were also used to treat NSCLC 
(ORR of 20% and SR of 3 months), renal carcinoma (ORR of 25% and SR of 5 months), 
Hodgkin’s lymphoma (ORR of 87%), ovarian cancer (ORR of 15% and SR of 4 months), and 
metastatic colorectal cancer (ORR of 40% and SR of 5 months) [27-31]. PD-L1 inhibitor 
Atezolizumab was found to be successful in solid tumors with ORR of 16% and 23% in NSCLC 
and urothelial carcinoma respectively [32, 33]. Better outcome was observed when both 
Nivolumab and Ipilimumab were used to treat stage III and IV melanoma (ORR of 57% and SR 
of over 11 months) indicating that blocking both PD-1 and CTLA-4 simultaneously can induce 
stronger anti-tumor immune responses [21, 34].   
Immune checkpoint blockade treatment proves to be initially effective but unfortunately 
many patients eventually relapse. Due to the selection pressure caused by checkpoint blockade 
monoclonal antibody therapy, resistant tumor cells can arise. These checkpoint blockade 
immunotherapy resistant tumor cells upregulate or downregulate pathways that allow them to 
evade immune recognition and T cell anti-tumor immune responses. Tumor cells from relapsing 
anti-PD-1 treated patients were shown to downregulate IFN response elements including MHC 
class I through deactivating mutations to avoid T cell recognition [35]. Also, immune cells in 
anti-PD-1 treated melanoma or prostate cancer patients exhibited upregulation of other immune 
checkpoints like TIM-3 [36]. Tumor-associated macrophages (TAMs) present in the TME of 
relapsing patients were shown to be able to phagocytize the therapeutic monoclonal antibody 
bound to the surface of T cells, rendering them again susceptible to PD-1 inhibitory signaling 
[37]. A better understanding of these immune escape mechanisms in the TME limiting the 
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effectiveness of immune checkpoint blockade immunotherapy will therefore allow for 
improvement of cancer treatment. 
Adoptive T cell Transfer Immunotherapy 
 
Adoptive T cell therapy (ACT) consists on generating robust T cell anti-tumor immune 
responses by the ex vivo manipulation of patients’ endogenous T cells. ACT has multiple 
advantages compared to other forms of immunotherapy that rely on generating enough numbers 
of functionally active and tumor reactive T cells in vivo. For use in ACT, large numbers of anti-
tumor T cells can be readily generated and selected for high-avidity recognition of the tumor, as 
well as for the effector functions required to mediate tumor destruction. In addition, these anti-
tumor T cells are generated from the patient’s own circulating T cells so there is no risk of graft-
versus-host disease. The first type of ACT was generated by isolating autologous Ag-specific 
tumor infiltrating lymphocytes (TILs) from resected melanomas [38]. Melanoma Ag-specific 
TILs were expanded in vitro and transferred into the patient in combination with IL-2 to enhance 
T cell activation and function. Using TILs for ACT immunotherapy, the ORR of metastatic 
melanoma patients reached 50% and durable remissions were achieved [38-41]. Even if TILs can 
be grown in vitro from many tumor types, only melanomas consistently give rise to TILs with 
effective tumor reactivity [42]. In order to develop ACT for other tumor types, techniques were 
developed to genetically introduce anti-tumor receptors into normal T cells that could be used for 
therapy. The specificity of T cells can be redirected by the integration of genes encoding either 
conventional  TCRs or CARs. 
The first successful clinical application of ACT using genetically engineered T cells 
treated melanoma patients using autologous T cells transduced with a human TCR recognizing 
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the MART-1 melanoma-melanocyte differentiation antigen [43]. These initial studies 
demonstrated that TCR gene-modified T cells were generally tolerated by patients and safe to 
use as cancer therapeutics. Then, this approach was expanded to larger metastatic melanoma 
patient numbers who received T cells modified with high-avidity TCRs recognizing MART-1 
(ORR of 30%) and gp100 (ORR of 19%) [44]. Even if this treatment was efficacious it showed 
severe off-tumor on-target toxicity in the skin, eyes and ears due to melanocyte presence in these 
organs. Fortunately, in this case such toxicities resolved naturally or with administration of 
topical steroids. These earliest studies suggested TCR gene-modified T cells could reach clinical 
benefit, but that the choice of TCR was important in order to limit toxicities. Since the early 
studies, numerous TCR genes capable of recognizing tumor antigens were identified, and 
improvements in TCR gene transfer have allowed for recognition of a variety of other antigens 
and malignancies. These include, but are not limited to, carcinoembryonic antigen (CEA) 
expressed in epithelial cancers like colorectal cancer [45], cancer-testis antigens such as NY-
ESO-1 and MAGE expressed in breast, bladder, colon, lung, ovarian, thyroid cancers and 
myeloma [46-48], and viral proteins expressed in cancers derived from viral infections. The use 
of these TCR engineered T cells to treat patients showed some limitations especially regarding 
severe side effects. Colorectal cancer patients treated with CEA-specific T cells experienced life 
threatening colitis and colonic hemorrhage which prevented further use of this TCR even if 
partial response on liver metastases was achieved [45]. Unexpected brain toxicity and gray 
matter destruction were observed when using MAGE-specific T cells to treat melanoma patients 
[43]. TCR engineered T cells that are specific for viral proteins include targets such as 
cytomegalovirus (CMV) [49], human immunodeficiency virus (HIV) [50], hepatitis C virus 
(HCV) [51, 52], and human papilloma virus (HPV) [53]. No clinical reports have yet been 
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published testing virus-specific TCR expressing T cells in humans, however this is a good 
approach to avoid off-tumor on-target effects since viral proteins are not expressed by non-
infected human tissues.  
Chimeric antigen receptors (CARs) are assembled by linking the variable regions of the 
antibody heavy and light chains, specifically reactive to a tumor antigen, to intracellular 
signaling molecules such as CD3 CARs often include the sequences of co-stimulatory domains 
including but not limited to CD28 or CD137 (4-1BB) in order to fully activate T cells [54-56]. 
The antibody part of the CAR is specific for an antigen expressed in the tumor providing non-
MHC-restricted recognition of cell surface components. CARs can be introduced into T cells 
with high efficiency using viral vectors [42].  Tumor antigens that are shared with nonessential 
organs represent potential targets for ACT immunotherapy. A prominent example is the 
molecule CD19 expressed in more than 90% of B cell malignancies and differentiating B cells 
excluding plasma cells. Administration of autologous T cells expressing the anti-CD19 CAR to 
patients with follicular lymphoma, large-cell lymphomas, chronic lymphocytic leukemia, and 
acute lymphocytic leukemia was shown to successfully reject the tumors with ORRs from 80 to 
100% [55, 57-59]. Anti-CD19 CAR ACT immunotherapy not only elicits dramatic regression of 
lymphomas and leukemia but also provides patients lifelong protection since CAR T cells can 
become memory T cells detectable on circulation years after ACT [60]. Due to its success, anti-
CD19 CAR T cell immunotherapy was approved by the FDA to treat B cell lymphoblastic 
leukemia and certain types of non-Hodgkin’s lymphoma in 2017. A wide variety of other CARs 
were designed to target several antigens showing promise as potential cancer immunotherapies. 
Other targets that were pre-clinically evaluated include but are not limited to CD33 and CD123 
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for myeloid leukemia [61, 62], GD2 for neuroblastoma (ORR of 27%) [63], HER-2 and MUC-1 
for breast cancer [64, 65], and MUC16 for ovarian cancer [66].  
There are some limitations using CAR T cells for immunotherapy. For example, CARs 
target surface antigens, rendering them ineffective against intracellular antigens that would 
otherwise be processed and presented by MHC. A search for tumor-specific surface antigens 
expressed on tissues that are not essential for survival remains in progress. Also, the antibody-
antigen interaction is much stronger than the TCR-antigen interaction which negatively impacts 
T cell function since T cells are more likely to undergo activation induced cell death (AICD) [67, 
68]. Also, there were several reports of adverse events after CAR T cell immunotherapy due to 
tumor lysis syndrome and cytokine storm which are deadly side effects resulting from massive T 
cell activation, cytokine production, and tumor cell killing [69-71].  
An important question concerning the use of genetically engineered cells for the 
treatment of cancer involves selection of the ideal T cell population unto which the gene should 
be introduced. T cells can be categorized into distinct memory subsets based on their 
differentiation states. CD8+ T cells follow a progressive pathway of differentiation from naïve T 
cells into central memory and effector memory T cell populations [72]. Preclinical studies 
strongly suggest that improved anti-tumor responses are seen when T cells in early stages of 
differentiation (such as naïve or central memory cells) are transduced, a result supported by 
studies in monkeys showing improved in vivo persistence of infused central memory compared 
with effector memory cells [73, 74]. Also, the differentiation state of CD8+ T cells is inversely 
correlated with their ability to undergo homeostatic proliferation. Homeostatic proliferation of 
adoptively transferred cells and the presence of homeostatic cytokines such as IL-7 and IL-15 
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were shown to increase ACT efficacy [75, 76]. Adoptively transferred younger CD8+ T cells 
need to get activated upon antigen stimulation, lyse the tumor target cells by secreting factors 
like Granzyme, and secrete cytokines such as IFN and TNF [77]. CD4+ T cells are also critical 
for tumor rejection and success of immunotherapy. Adoptively transferred CD4+ T cells were 
shown to be required for supporting the CD8+ cytotoxic anti-tumor response [78-80]. CD4+ T 
cells do not merely enhance CD8+ T cell function, but they also play a more direct role in tumor 
elimination during immunotherapy [81]. The roles that CD4+ T cells play in the antitumor 
immune response depend on their polarization, which is determined by their expression of key 
transcription factors. Adoptively transferred Th1, Th2 and Th17 CD4+ T cells can directly clear 
the tumor and promote long-lived antitumor immunity [82-85]. On the other hand, Tregs are 
immunosuppressive and were shown to inhibit T cell anti-tumor responses and promote immune 
escape [86, 87]. Overall, in order to achieve ACT immunotherapy success, not fully 
differentiated cytotoxic CD8+ and CD4+ T cells need to be genetically modified to recognize a 
suitable tumor antigen that is not expressed in an essential organ. 
Immune Escape 
 
 Once adoptively transferred T cells reach the tumor, the major challenge they face is to 
overcome the multiple mechanisms the tumor can elicit to avoid immune-mediated elimination. 
The ability of T cells to recognize and destroy tumors relies on the antigenicity of tumor cells. 
Tumors can express a variety of mutated and endogenous antigens that can be recognized by T 
cells. However, to avoid anti-tumor responses the tumor cells can lose antigenicity [88]. Cancer 
cells can lose antigenicity due to lack or mutation of tumor antigens, as well as through the 
acquirement of defects and deficiencies in antigen presentation [89]. Downregulation of the cell 
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surface expression of MHC class I molecules was found in approximately 20% to 60% of solid 
tumors, including melanoma, lung, breast, renal, prostate, and bladder cancer [90, 91]. Tumors 
can not only lose antigenicity but also immunogenicity in order to escape immune responses. 
IFN produced by TILs can induce the upregulation of immunoinhibitory molecules on 
malignant cells, surrounding stromal cells, and other immunosuppressive infiltrating immune 
cells [36, 92]. Some of this immunoinhibitory molecules include but are not limited to ligands of 
the PD-1, CTLA-4, LAG-3, TIM-3, and VISTA inhibitory receptors [93]. As described before, 
these inhibitory pathways alter the balance between activation and inhibitory signals received by 
T cells and lead to dampened antitumor T cell responses. In addition to these mechanisms, tumor 
cells can also metabolically restrict T cell function via glucose and oxygen restriction. High 
glucose intake by tumor cells creates a hypoglycemic TME and dampen TIL mTOR activity, 
glycolytic capacity, and IFN production [94]. Solid tumors have large hypoxic areas which can 
also interfere with immunity and cause T cell dysfunction [95, 96].  
Non-neoplastic infiltrating cells can contribute to tumor progression and metastasis by 
hindering the anti-tumor function of T cells and other immune cells. Tregs are immunosuppressive 
CD4+ T cells that contribute to tumor immune evasion by secreting TGF and IL-10 which are 
cytokines that help create an immunosuppressive environment that blunts the anti-tumor 
functions of CD4+ and CD8+ effector T cells, and NK cells [97, 98]. Tregs also express an IL-2 
receptor that has 100-fold higher affinity for IL-2 than the receptor form expressed in effector T 
cells resulting in Tregs acting as competitive sinks for IL-2 in the TME [99]. In addition, Tregs can 
secrete copious levels of the nucleoside adenosine [100]. Adenosine binds to its receptor (A2AR) 
in effector T cells and downregulates the intracellular levels of 3’, 5’-cyclic AMP which result in 
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T cells function inhibition and subsequent immunosuppression [101, 102].  In addition, the 
adenosine pathways promotes further polarization, proliferation and expansion of Tregs and 
myeloid derived suppressor cells (MDSCs) [103]. MDSCs are myeloid cells found in the TME 
that can also mediate immune escape through several mechanisms. MDSCs express high levels 
of nitric oxide synthase arginase 1 which results in the metabolism of arginine and the 
production of nitric oxide (NO) [104, 105]. The depletion of arginine from the TME impairs the 
local proliferative capacity of T cells. NO has a direct suppressive role on effector T cells by the 
induction of apoptosis, inhibition of STAT5 signaling, and formation of peroxynitrite, a potent 
oxidant of amino acids that are essential for T cell function [104, 105]. Other mechanisms of 
MDSC-mediated immune suppression include the sequestration of cysteine leading to the limited 
availability of this essential amino acid for T cells [106], the secretion of suppressive cytokines 
including IL-10 [107], and the overproduction of reactive oxygen species [108]. Other myeloid 
cells with immunosuppressive abilities that play a role in immune escape are TAMS and tumor 
associated dendritic cells (TADCs). TAMs produce lower levels of proinflammatory cytokines, 
such as IL-1, TNF, and IL-12, and higher levels of immunosuppressive mediators IL-10, 
TGF, and vascular endothelial growth factor (VEGF) indicating that TAMs not only suppress T 
cell function but promote tumor angiogenesis [109]. TAMs are also stunted in their ability to 
mediate direct lysis of malignant cells.  TADCs express no or low levels of costimulatory 
molecules CD40, CD80, and CD86, and express indoleamine 2, 3-dioxygenase, an enzyme that 
degrades the essential amino acid tryptophan that leads to the suppression of T cell functions 
[110, 111]. TADCs also possess defects in the machinery to effectively present antigen to T cells 
and downregulate MHC class I and II molecules in addition to other proteins important for this 
process like transporter associated with antigen processing (TAP) [112].  
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 Overall, tumors are complex structures composed of both malignant and nonmalignant 
cells that support cancer growth and prevent immune destruction. The understanding of the 
cellular constituents of the tumor microenvironment has helped guide the design of powerful T 
cell therapies that can cause the regression of large tumor burdens. Finding appropriate tumor 
antigens, overcoming the immunosuppressive and immunotolerant tumor microenvironment, and 
reducing are major obstacles being investigated today in order to improve the efficacy of cancer 
immunotherapy.  
Sexual Dimorphism in Immune Responses: The role of Estrogen 
 
 Other examples of host specific factors that can affect the efficacy of immunotherapy are 
the patient’s age, sex, and reproductive stage in life. While the lethal side-effects of 
immunotherapy are markedly exacerbated with aging [113, 114], age was shown to not 
significantly affect the outcome or clinical efficacy of checkpoint blockade immunotherapy 
[115]. Elucidating the effect of patient’s sex on the outcome and efficacy of immunotherapy was 
proven to be controversial and there are very few studies investigating this. Meta-analysis of 
checkpoint blockade immunotherapy treated melanoma and NSCLC patients showed that men 
had overall better survival rates than women indicating a sex-difference in immunotherapy 
efficacy [116]. This conclusion cannot be generalized to all patient populations since other group 
found no sex-effect on the efficacy of Nivolumab in melanoma patients [117]. On the other hand, 
a preclinical model of melanoma treated with checkpoint blockade immunotherapy showed 
increased tumor rejection and overall survival in females compared to males [118]. This was 
found to be through mechanisms involving estrogen signaling in Tregs and Ag-specific CTLs 
[118]. While all these studies investigated the role of sex in checkpoint blockade 
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immunotherapy, there are no reports on the effect of sex and hormone signaling on ACT 
immunotherapy due to the lack of adequate sample size and statistical power. It is well known, 
though, that there are marked physiological differences in T cell immunological responses and 
tumor incidence between males and females [119-122]. While some of these sex-specific tumor 
and immunological differences are genetically and environmentally mediated, many of them 
accentuate with puberty and reproductive senescence indicating an involvement of sex 
hormones, androgen and estrogen. This indicates that sex and sex hormone signaling could be an 
important factor to consider in order to improve efficacy of anticancer immunotherapies and 
further research in this field is highly necessary. In this dissertation, the role of sex and estrogen 
receptor signaling on Ag-specific T cells for ACT immunotherapy is studied utilizing novel 
approaches to characterize the role of estrogen receptor signaling on T cell cytokine production 
and anti-tumor function. 
Circulating estrogen is present physiologically in females, and in lower concentrations in 
males. Additionally, adult women are exposed to exogenous estrogen in therapeutic forms as oral 
contraceptives and hormone replacement therapy (HRT). The next sections focus on describing 
the signaling and downstream effects of physiological estrogen (17-estradiol or E2), which is 
the most common form of active estrogen in the body, and the principal hormone employed in 
the studies for this dissertation. Then, the effect of estrogen signaling on main immune cell types 
which account for the observed sex-specific differences in immunity is described as well. 
Sources of Estrogen 
 
 Physiologically available estrogens are predominantly produced in the ovaries, the corpus 
luteum and the placenta [123]. There are three major forms of physiological estrogens in 
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females, estrone (E1), estradiol (E2 or 17-estradiol), and estriol (E3), and they are all 
synthesized from cholesterol by a series of reactions called estrogen biosynthesis [123]. E2 is the 
major estrogen biosynthesis product and plays a major role during women’s pre-menopausal 
period. In the ovaries, E2 is synthesized in theca and granulosa cells. The luteinizing hormone 
(LH) stimulates cholesterol uptake by theca cells where it is converted into progesterone and 
later into androstenedione [124, 125]. In response to LH, androstenedione is then diffused into 
granulosa cells. Follicle-stimulating hormone (FSH) stimulates the enzyme aromatase in 
granulosa cells to convert androstenedione into testosterone and testosterone into E2 by 
aromatization of the A-rings of androgens [125]. Then, E2 is released into general circulation 
and targets distal estrogen-responsive tissues including reproductive and non-reproductive 
organs [123]. Circulating E2 reaches highest concentrations immediately before ovulation. 
During the follicular phase, pre-ovulatory phase, and luteal phase serum E2 concentrations are 
50-140 pg/mL, 110-410 pg/mL, and 50-160 pg/mL respectively (ranging from 0.5-1 nmol/L or 
nM) [124]. During the menopausal transition, serum estrogen concentrations decrease by 85-
90% [123]. Circulating E2 concentrations in menopausal women and men are below 35 pg/mL 
(under 0.1 nmol/L or nM) [124]. E1 can also be synthesized in the ovaries but plays a major role 
after menopause when it is synthesized by adipose tissue [123]. E3 is the least potent form of 
estrogen and it is synthesized in the placenta from E1 hydroxylation during pregnancy [123].  
 In addition to the ovary, extra gonadal estrogen biosynthesis takes place in astrocytes in 
the hypothalamus and hippocampus regions of the brain, in stromal cells and adipocytes in the 
breast, in osteoblasts and chondrocytes of the bone, in adrenocortical cells of the adrenal glands, 
in skin fibroblasts and in hepatocytes [126]. These peripheral sites biosynthesize estrogen which 
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tends to act locally at high concentrations, and which signaling is especially important in 
menopausal women and men [127]. High concentrations of locally produced estrogen can also be 
found in the TME of some cancers including breast cancer and hepatocellular carcinoma (HCC). 
These high estrogen concentrations found in the TME are partially due to aromatase expression 
dysregulation in tumor and stromal cells [128, 129]. Overexpression of aromatase in breast 
cancer was found in tumor, stromal and parenchymal cells and it was upregulated by factors 
including inflammatory cytokines and secreted factors like prostaglandins [130, 131]. Elevated 
aromatase expression was detected in cirrhotic and malignant HCC tissue [128, 132-134]. This 
elevated aromatase expression results on high local estrogen concentrations in the liver. In 
addition, estrogen metabolism is abnormal in patients with cirrhosis and HCC which show 
decreased conversion of E2 into E1 and E3 via hydroxylation, and subsequent accumulation of 
E2 in the liver or tumor tissue [135, 136]. 
Estrogen Receptors (ERs) 
 
 Estrogen exerts its physiological functions on target tissues through ER-dependent and 
ER-independent mechanisms [137]. Estrogen can bind three specific but distinct receptors 
including the nuclear receptors estrogen receptor alpha and beta (ER and ER) and the G-
protein coupled estrogen receptor (GPER). ER and ER are ligand activated transcription 
factors which are located intracellularly and to some degree on the cell membrane [138]. Apart 
from the gonads, each ER is differentially expressed in various tissues. ER is expressed in high 
concentrations in the mammary glands, the pituitary, the kidney, the epididymis, the liver, bone 
and the adrenal gland but it has very low or undetectable expression in the prostate, the pineal 
gland, the thyroid gland, the urinary tract, and erythroid tissue [126, 139]. ER is expressed 
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predominantly in the prostate, the lungs, the bladder, and the hypothalamus [139, 140]. GPER is 
ubiquitously expressed in the membrane of cells throughout the body including the heart, brain, 
pancreas, skeletal muscle, kidney, vessels, and reproductive organs [141]. 
Structure of Estrogen Receptors 
 
ER and ER belong to the steroid nuclear receptor family, which is composed of 
proteins with four independent but interacting protein domains [142]. The A/B domain in the 
amino (NH2) terminal, the C or DNA-binding domain, the D domain which is a hinge region, and 
the E/F or the ligand binding domain in the carboxyl (COOH) terminal [143, 144] (Figure 2). 
The NH2 terminal domain encodes a ligand-independent activation function (AF-1) which is a 
region of the receptor involved in protein-protein interactions with other transcription factors and 
co-activators of target-gene expression [144]. In ER this region was shown to be very active in 
stimulating target-gene expression, and AF-1 was shown to be active even in the absence of 
estrogen ligand [145]. In ER the activity of AF-1 is negligible and most of the protein-protein 
interactions happen through AF-2 found in the ligand binding domain (LBD) (Figure 2) [146]. 
The DNA binding domain (DBD) is 97% homologous between ER and ER and contains a 
zinc finger structure necessary for receptor dimerization and binding of the receptors to specific 
DNA sequences denominated estrogen response elements (EREs) [144, 147]. The hinge region 
contains the nuclear localization signal and links the C domain to the multi-functional COOH-
terminus E/F domain [142] (Figure 2). The hormone dependent AF-2 region in the E/F LBD is 
important in estrogen ligand binding dependent transcriptional activity and co-activator protein-
protein interactions [148]. Besides ligand binding, the E/F region is necessary for nuclear 
translocation, heat shock proteins interactions, and transactivation of target gene expression 
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[144]. Heat shock protein such as Hsp90 act as ER chaperones in the absence of ligands, binding 
to unliganded ERs and maintaining the receptors in an inactive yet functional state [149]. The 
LBD of ER and ER are highly homologous in both primary amino acid sequence and tertiary 
structure which results in similar affinity of both receptors for E2 and other antagonistic and 
agonistic compounds [139, 150] (Figure 2). 
 
 
 
 
 
 
GPER is a membrane bound Gs-protein coupled receptor. GPER associates with a 
Gs/G complex in its inactive state. Upon estrogen ligand binding and GPER activation, Gs 
and G quickly dissociate from GPER. Gs and G can then activate several signaling 
pathways some of them which result in gene expression regulation [151]. GPER was also found 
Figure 2. Structure of Estrogen Receptor  and  and Percent Homology between Them. 
Estrogen receptor  and  (ER and ) are nuclear receptors that can act as transcription factors 
upon ligand binding. ER and  are highly homologous and contain four different functional 
domains: the A/B domain in the amino (NH2) terminus which contains the AF-1, the C or DNA-
binding domain, the D domain or hinge region, and the E/F carboxyl (COOH) terminus domain 
which contains the ligand binding domain and the AF-2 important for receptor dimerization. 
AF: activating function. 
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to be expressed intracellularly in some specific tissues including the mammary glands, the 
ovarian epithelium, and breast and ovarian cancer cells [141]. This indicates that GPER 
expression and signaling is not restricted to the plasma membrane but can also signal from the 
intracellular membranes of the endoplasmic reticulum (ER) and the Golgi apparatus [151].  
Estrogen Receptor Signaling 
 
Ligand-bound ER and ER can regulate the transcription rates and overall expression of 
target genes by binding to EREs on their promoters or by assembling transcription regulation 
complexes with other transcription factors. It was also previously shown that ERs can regulate 
target gene expression in a ligand-independent manner. Membrane bound GPER signals upon 
estrogen ligand binding and can activate several signaling pathways that regulate many cell 
processes and can ultimately result in gene expression modulation.  
Ligand-Dependent Estrogen Signaling 
The classical pathway: the ERE-dependent genomic pathway (Figure 3A). 
 
Transcription activation by ligand-bound ER is a multistep process that occurs in a sequential 
order and requires the interaction of the ER with several enzymatic activities in order to obtain a 
productive interaction with the transcription complexes [152]. Ligand-operated transcription by 
ERs is initiated when the estrogen ligand binds to the inactive ER-chaperone complex [152]. The 
estrogen ligand binds to the ER C-terminal LBD causing a conformational change which 
mediates the dissociation of the ER from its chaperones [152]. Shedding the chaperones exposes 
the dimerization, nuclear localization, and DNA binding domains. Dimerization of the ER 
strengthens the stability of the receptors and ensures binding to the EREs on target-gene 
promoters [152]. EREs are direct or indirect palindromic sequences separated by three non-
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specific nucleotides (TCCAGTnnnACTGGA or AGGTCAnnnTGACCT) [153]. Once bound to 
the DNA, ER transcriptional ability depends on the AF-1 and AF-2 activating functions. 
Although AF-1 and AF-2 can function independently, maximal ER transcriptional activity is 
achieved when there is synergy between them [154]. AF-1 and AF-2 serve as sites for interaction 
with several co-activator or co-repressor proteins. Co-activator proteins enhance gene expression 
by remodeling chromatin and allowing interactions with the transcription machinery. The AF-1 
region of the ER interacts with co-activators from the p160 family which include the steroid 
receptor co-activators 1, 2 and 3 (SRC-1, 2, 3) [155]. p160/SRC function predominantly by 
recruiting chromatin modifying enzymes such as histone acetylases (HATs) to the ER-DNA 
complex [156]. Histone deacetylation results in chromatin de-condensation and increased 
transcription of target genes. p160/SRC can also recruit other co-activators such as CREB 
binding protein (CBP) and p300 [157, 158]. The hydrophobic region of the AF-2 domain binds 
co-activator proteins such as GRIP1 and TIF2 [159, 160].   
AF-1 and AF-2 can also recruit negative co-repressors to the ER-DNA complex which 
inhibit gene activation or turn off activated genes. Negative coregulatory factors RIP140 and 
LCoR compete with the p160/SRC co-activators for AF-1 and AF-2 binding [161, 162]. 
Repression by RIP140 and LCoR occurs through the recruitment of histone deacetylases 
(HDACs) which results in chromatin condensation and suppression of the estrogen target genes 
expression [156]. Other molecules found in the ER-DNA transcription complex can also recruit 
co-repressors. While p300 is considered a co-activator of the ER due to its activity enhancing 
transcription initiation when recruited to ER and ER, it was shown that p300 can also recruit 
the co-repressor C-terminal-binding protein 1 (CtBP1) to the ER transcription factor complex. 
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CtBP1 can stop and inhibit the transcription of target genes by recruiting HDACs which 
deacetylate histone 3 lysine 9 (H3K9) and H3K13 [163]. Overall, transcription of estrogen target 
genes is predominantly enhanced by the binding of the ligand-bound ER homo or heterodimer to 
EREs on gene promoters and the recruitment of co-activators but in some cases, co-repressors 
compete with co-activators for ER complex binding which results in target gene expression 
downregulation. 
Both ER and ER can signal this way in order to regulate target gene expression. 
Interestingly, ER and ER can form homo or heterodimers upon ligand binding (ERER, 
ERER or ERER) [164]. These homo or heterodimers show differential transcriptional 
activities and could explain the selective actions of estrogen in different cell types and target 
genes. Although both ER and ER are expressed in tissues and form functional heterodimers; 
when co-expressed, ER can inhibit the transcriptional ability of ER and vice versa [165, 166]. 
Therefore, overall estrogen responsiveness in specific tissues depends on the ER versus ER 
ratio.  
The ERE-independent genomic pathway (Figure 3B) 
 
 In addition to the classical mechanism of ER function, ERs can regulate gene expression 
of genes that lack EREs. Estrogen-bound ER dimers can bind to Jun and Fos dimers located on 
gene activating protein-1 (AP-1) binding sites [167]. The co-activators (p160/SRC) recruited by 
the ERs to Jun/Fos subunits of the AP-1 transcription factor which can then activate transcription 
of the AP-1 site containing genes [167, 168]. Another way that ERs can affect transcription of 
genes is by physically interacting with the Sp1 transcription factor. Ligand-bound ERs enhance 
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Sp1 DNA binding which upregulates target gene expression [169]. ERs can also repress the 
transcription of genes in an ERE-independent manner. ER can interact with and sequester the c-
Rel subunit of the NFB transcription factor complex [170]. This interaction prevents NFB 
from binding and stimulating expression of NFB response element containing genes [171].  
Ligand-independent estrogen signaling (Figure 3C) 
 
Another mechanism of ER action involves the ligand-independent ER activation through 
ER phosphorylation by protein kinases or growth factor receptors. The epithelial growth factor 
receptor (EGFR) and the insulin-like growth factor receptor (IGFR) are able to bind the AF-1 
domain but not the AF-2 domain and phosphorylate ER via the MAP kinase or the PI3 kinase 
(PI3K)-Akt pathways [172, 173]. ERs can also be directly phosphorylated by protein kinase A 
(PKA) or PKC [174, 175]. Phosphorylated non-ligand bound ERs can then homo or 
heterodimerize and translocate into the nucleus where they regulate expression of ERE-
containing and non-ERE containing genes even in the absence of estrogen ligand.  
Non-genomic membrane bound estrogen signaling (Figure 3D) 
 
In addition to the nuclear genomic actions, estrogen signaling can exert rapid effects non-
accounted for by the transcriptional mechanisms. These non-genomic changes by rapid signaling 
are provoked by membrane-bound ER and GPER. Palmitoylation of ER anchors a pool of 
ER to the plasma membrane where they can interact with other  signaling proteins such as Src 
and p85, the regulatory subunit of PI3K [176]. Estrogen signaling through GPER occurs through 
transactivation of EGFR and involves activation of non-receptor tyrosine kinases of the Src 
family [177]. Estrogen binding to GPER induces activation of metalloproteinases which induce 
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the release of heparin-binding EGF, which binds and activates EGFR leading to rapid activation 
of downstream signaling molecules such as the MAP kinase pathway including ERK1/2 [177]. 
Estradiol activation of GPER also stimulates production of intracellular cyclic adenosine 
monophosphate (cAMP), induces intracellular Ca2+ mobilization, and PI3K activation. In 
addition to these rapid signaling events, GPER was also shown to be internalized from the 
plasma membrane and was demonstrated to regulate gene transcriptional activity of genes such 
as c-Fos, one of the monomers of the AP-1 transcription factor complex [178]. Overall, signaling 
though membrane-bound ERs is more rapid than genomic ER signaling and leads to rapid 
activation of signaling pathways that result in cellular processes such as increase DNA synthesis 
and cell proliferation, and further gene transcription regulation. 
Estrogen Effect on Key Cells of the Immune System 
 
Estrogen receptors are expressed ubiquitously on immune cells and estrogen is known to 
modulate the survival, development, differentiation, and function of key cells of the immune 
system such as T and B cells, macrophages, dendritic cells (DCs) and natural killer cells (NK) 
[179]. In the following paragraphs, the effects of estrogen signaling on different cells of the 
immune system are described. 
T cells & T cell cytokines 
 
In the peripheral blood of humans, around 30% of white blood cells are lymphocytes and 
around 85-90% of these lymphocytes are T cells [180]. Although the total lymphocyte count in 
males is equivalent to females, the percentage of T cells within the total lymphocyte population 
is higher in females compared to males and post-menopausal females [181].  Females have 
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higher CD4+ T cell counts and higher CD8+/CD4+ ratios than age-matched males and post-
menopausal females; whereas males have higher CD8+ T cell frequencies [182-184]. 
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Figure 3. The Different Types of Estrogen Signaling in the Cell. The ligand-dependent and ERE-dependent or ERE-independent 
classical genomic estrogen receptor pathway consists on ERs binding to the estrogen ligand in the cytoplasm of the cell, dimerizing, 
and translocating into the nucleus where they bind A) EREs in gene promoters, or B) form complexes with other transcription factors 
such as AP-1 and regulate gene expression.  C) The ligand-independent genomic estrogen receptor pathway happens when growth 
factor tyrosine kinase receptors or protein kinases phosphorylate the ERs promoting dimerization and translocation into the nucleus 
where they regulate gene expression in a ERE-dependent or independent manner. D) The non-genomic G-protein coupled estrogen 
receptor signaling happens through GPER which activated the MAP kinase pathway upon estrogen ligand binding promoting 
downstream signaling and gene expression regulation. E2: 17-estradiol, ERE: estrogen response element, AP-1: activator protein-
1, PKC/A: protein kinase C/A, MAPK: mitogen activated kinase, PI3K: phosphoinositide-3 kinase. 
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Following in vitro T cell stimulation, females have higher numbers of proliferating T 
cells and higher numbers of CD8+ and CD4+ activated T cells compared to males [181]. 
Transcriptional analysis of these activated T cells showed greater cytotoxic activity in T cells 
from adult females, with stimulated female T cells upregulating more antiviral and pro-
inflammatory genes compared to male activated T cells [185]. Notably, over half of these 
activated genes have EREs in their promoters indicating direct involvement of estrogen signaling 
on T cell function [185].  Both CD8+ and CD4+ T cell subsets express ER and ER and 
estrogen signaling was shown to also affect T cell development and differentiation.  
Estrogen stimulation was shown to cause structural changes in the thymus and to affect 
immature T cell development. Ovariectomized mice that were treated with estrogen showed dose 
dependent thymic atrophy with a decrease proportion of early T cell progenitors, and an 
increased proportion of mature T cell populations [186]. Estrogen inhibits thymic development 
by decreasing the number of triple negative immature T cells (CD3-CD4-CD8-) and depleting the 
rest of the maturation stages such as CD44+ CD25+, CD44-CD25+, and CD44- CD25- T cells 
[186]. On the other hand, estrogen treatment increased the numbers of thymic CD8+ and CD4+ 
single positive mature T cells. All these effects were mediated by ER AF-1 and AF-2 functions 
simultaneously since the deletion of the receptor or any of these functions abolished the 
inhibitory effects of estrogen on the thymus [187]. Ovariectomized mice showed reduced levels 
of CD8+ splenic T cells and the CD8+/CD4+ single positive cell ratio was increased after 
physiological estrogen stimulation agreeing with the human observation on pre-menopausal 
females [188]. Overall these data indicated that estrogen signaling though ER induces 
differentiation of mature CD8+ and CD4+ T cells.  
 
 
 
 
30 
Besides affecting the development of T cells, estrogen is capable of affecting T cell 
activation and T cell function. T cells stimulated with post-menopausal estrogen levels showed 
decreased activation-induced phosphorylation of the CD3/TCR complex and reduced expression 
of the Janus kinases 2 and 3 (JAK2 and 3 kinases) compared to T cells treated with physiological 
estrogen [189]. JAK2 and 3 are non-receptor tyrosine kinases that mediate cytokine-mediated 
signals via the JAK-STAT pathway in response to IL-2 which secretion was also downregulated 
in T cells treated with low estrogen [189]. In a model of colitis, it was observed that ER-
deficient mice showed decreased T cell proliferation and activation state, and increased FoxP3 
expression compared to WT mice indicating that T cells in ER-deficient mouse were skewed 
towards a regulatory phenotype decreasing the severity of the autoimmune inflammation [190]. 
In addition to enhancing T cell activation, physiological estrogen stimulation was shown to 
induce Th1 effector T cell responses. IFN is a major cytokine involved in cytotoxic and effector 
Th1 T cells responses and it is sensitive to estrogen stimulation in mice and humans. Estrogen 
can modulate IFN secretion by enhancing Ifn gene expression in CD4+ and CD8+ T cells [190]. 
This happens through direct interaction of ER with an ERE in the promoter of the Ifn gene 
[191, 192]. Administration of physiological estrogen to ovariectomized mice resulted in an 
increase of IFN producing cells as well as an increase of Th1 CD4+ antigen-specific T cell 
responses [193]. Overall this indicates that physiological estrogen signaling through ER 
promotes effector and Th1 responses which are reduced in the presence of low estrogen 
concentrations like the ones found in post-menopausal females and males.  
Most of the important aspects concerning the role of estrogen signaling on T cell function 
were studied using T cells from autoimmune disease patients, and autoimmunity mouse models 
 
 
 
 
31 
including multiple sclerosis (MS) and colitis. Using primary T cells from MS patients that were 
treated with estrogen, it was shown that estrogen signaling mediated a dose dependent 
enhancement on the secretion of IL-10 by CD4+ T cells [194]. The secretion of IFN by T cells 
was also increased by estrogen in a dose dependent manner confirming the genomic regulation of 
IFN through the ERE on its promoter [194]. The effects of estrogen on expression of TNF 
expression were shown to be controversial. Physiological estrogen concentrations were shown to 
enhance TNF expression, while pregnancy estrogen levels inhibited TNF expression [194]. 
On the other hand, in bone research studies, ovariectomy of mice enhanced the production of 
TNF by CD8+ and CD4+ T cells, and the subsequent bone loss which was abolished by estradiol 
replacement therapy [195].  
Estrogen-induced changes in IL-4 mRNA or protein expression were not observed in 
response to estrogen stimulation in MS patient’s primary T cells [194]. Interestingly, studies 
characterizing the role of estrogen during pregnancy, a state where estrogen levels are higher 
than physiological, demonstrated that the T cell immune response skewed toward the Th2 type 
compared to Th1 type response [189]. Estrogen at pregnancy levels increased IL-4 secretion and 
GATA3 expression in ER+CD4+ cells but not on ER- ones [190]. IL-4 is a common cytokine 
secreted by Th2 cells and its expression is induced by GATA3 which is the transcription factor 
that drives Th2 T cell differentiation. Peripheral mononuclear blood cells (PBMCs) stimulated 
with different estrogen levels showed that those cells treated with physiological estrogen 
enhanced production of IFN, IL-12, and IL-10 which is a Th1 skewed immune response [191]. 
On the other hand, cells treated with pregnancy estrogen levels had decreased IL-12 and IFN 
ratio while IL-10 production was enhanced [191]. Overall, the estrogen mediated enhancement 
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of cytokines such as IL-10 and IL-4 by T cells switches the T cell immune response from Th1 to 
Th2. 
Estrogen signaling has also been shown to affect immunosuppressive Tregs. Pregnancy 
estrogen levels were reported to increase the expression of FoxP3 expression on CD4+CD25+ 
cells [196-199]. Pregnancy estrogen levels were able to enhance FoxP3 expression in vivo and in 
vitro and increase CD25+ cell number, which are reduced in ER-CD4+ cells [198]. Mouse 
studies also showed that physiological estrogen concentration could induce expression of FoxP3 
and enhance the number of CD25+ regulatory CD4+ T cells [188]. The role of estrogen 
modulating Treg differentiation proves to also be controversial since post-menopausal women 
were shown to have enhanced numbers of circulating Tregs compared to pre-menopausal women 
[189]. 
 While many studies have reported the effect of estrogen signaling on T cell function and 
cytokine production, many of the reported results are contradicting and indicate opposite roles of 
estrogen signaling on T cell function especially in cytokine expression and production. Overall 
the studies summarized in this section indicate that the effect of estrogen on T cell function and 
cytokine production is highly concentration dependent. Different effects were observed when T 
cells were exposed to physiological, post-menopausal and pregnancy estrogen concentrations. 
The effects of estrogen on T cell function and cytokine production were also affected by the 
species in which they were tested with contradicting results obtained when testing the role of 
estrogen signaling on human compared to mouse T cells. This indicates differences in T cell 
biology and estrogen signaling between these species. Regarding T cell differentiation, estrogen 
was reported to promote Th1, Th2, or Treg CD4+ T cell differentiation depending on the 
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concentration of the hormone, again indicating concentration dependent effects. While these 
studies demonstrated the effect of estrogen in signaling in T cell function and differentiation, not 
many of them reported through which receptor estrogen is signaling through on each case. Most 
of the time, estrogen signaling through ER was investigated while ER and GPER were not 
mentioned. This indicates there is a high need for research characterizing the effects of estrogen 
signaling at different concentrations through each of its receptors and signaling pathways on T 
cell function, including the expression of several cytokines, as well as T cell differentiation.  
B cells and Antibody Production 
 
Regardless of age, females show greater B cell numbers, higher antibody responses, and 
higher basal immunoglobulin levels than males [181]. Estrogen affects the development and 
activity of B cells at different stages of differentiation and function, which can also vary among 
lymphoid organs. For example, in the bone marrow, estrogen was shown to decrease the number 
of B cells by negatively affecting the viability, proliferation and differentiation of early B cell 
precursors [200]. On the other hand, estrogen treated ovariectomized mice showed increase 
splenic weight and enlarged volumes of white and red pulp [201]. Even if estrogen treatment 
promoted a decrease in B220+ splenic lymphocytes, there was a 10-fold increase in plasma cell 
numbers and this effect required signaling though both ER and ER [202, 203]. Estrogen was 
also shown to increase splenic B cell activation and plasma cell antibody secretion [204, 205]. It 
was also shown that estrogen increases the expression of the anti-apoptotic gene bcl-2, and other 
genes such as cd22, shp-1, and vcam-1 in B cells that result in increased survival and activation 
[206, 207]. Estrogen signaling also modulates B cell function by increasing immunoglobulin 
secretion such as IgG and IgM through ER signaling but not ER [208]. This overall indicates 
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that while estrogen signaling inhibits B cell lymphopoiesis in the bone marrow, it enhances 
mature B cell survival and differentiation into plasma cells as well as antibody production upon 
activation.  
Macrophages and Dendritic Cells 
 
Antigen presenting cells, such as macrophages and dendritic cells, which are crucial for 
induction of immune responses are another target of estrogen. Macrophages express ER, ER, 
and GPER and estrogen signaling was shown to modulate macrophage polarization, activation, 
and cytokine production [209]. Macrophages can be classified into classically (inflammatory) or 
alternatively (anti-inflammatory) activated macrophages depending on the activation stimuli. 
Classically activated macrophages result from activation in the presence of Th1 cytokines 
including IFN or NF, while alternatively activated macrophages are activated in presence of 
Th2 cytokines including IL-4 or IL-13 [210].  Classically activated macrophages downregulate 
ER expression while they maintain ER and GPER expression, while alternatively activated 
macrophages retain ER and ER expression [210]. Many studies have described how 
physiological estrogen can upregulate inducible nitric oxide synthase (iNOS) and NO 
production, increased production of proinflammatory cytokines and increased cell surface 
expression of Toll-like receptor 4 (TLR4) in human and mice classically activated macrophages 
probably through mechanisms involving ER or GPER [211-215]. This leads to increased 
macrophage activation and killing thus to increased resistance to extracellular bacteria and 
infections in the presence of estrogen [216]. On the other hand, high dose estrogen stimulation 
reduced the production of inflammatory cytokines such as IL-1, IL-6, and TNF in activated 
macrophages indicating a dose dependent effect of estrogen [217].  
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Dendritic cells express ER and ER and estrogen signaling was shown to affect 
functional DC differentiation from bone marrow progenitors. Differentiation of DC bone marrow 
progenitors stimulated with granulocyte macrophage-colony-stimulating factors (GM-CSF) was 
inhibited when cells were cultured in estrogen-deficient media or in vivo in ovariectomized mice 
[218-220]. DC differentiation was restored when physiological estrogen concentrations were 
introduced back. The estrogen-mediated DC bone marrow progenitor differentiation was found 
to be mediated by ER and not ER signaling. ER signaling increases the expression of IRF4, 
a key transcription factor induced by GM-CSF and critical for DC development [218, 219]. 
These estrogen-treated mature DCs were CD11c+CD11bintermediateLy6C- and expressed high 
levels of MHC class II and co-stimulatory molecules B7.1, B7.2 and CD40 [220, 221]. These 
DCs were able to stimulate the proliferation of CD4+ T cells and were able to produce higher 
levels of the inflammatory cytokines IL-16 and IL-12 [221]. Short-term estrogen stimulation had 
no effect on DC survival or surface marker expression. However, estrogen stimulation enhanced 
activated DC IL-6, IL-8, and monocyte chemoattractant protein 1 (MCP-1) production and it 
enhanced the migration of mature DCs towards chemokine C-C motif ligand 19 (CCL19) [222]. 
Overall, these data indicate that estrogen signaling enhances the differentiation and function of 
DCs which can further result on more potent immune responses from DC-activated B cells and T 
cells. 
NK cells 
 
NK cells are large granular lymphocytes from the innate immune compartment which 
attributed with the ability to directly lyse virus-infected cells or tumor cells, and to produce and 
release type I cytokines such as IL-2 or IFN. Surprisingly, the number and activity of NK cell 
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changes during the menstrual cycle of human females [223]. NK cell activity increases during 
the first trimester of pregnancy, but it significantly decreases during the second and third 
trimesters indicating an important role of estrogen in regulating NK cell activity [224]. NK cells 
express both ER and ER and estrogen signaling was shown to affect NK cell function. 
Prolonged high concentration estrogen stimulation was shown to increase overall NK cell 
numbers but to reduce NK cell activity in a dose dependent manner [224-226].  NK cell numbers 
were increased by the estrogen mediated upregulation of minichromosome maintenance 
component 7 and 10 (MCM7 and MCM10) expression which are proteins required for DNA 
replication and NK cell proliferation [226]. On the other hand, the suppressed cytotoxicity of NK 
cells was attributed to the estrogen down-regulation of activating receptors NKp46, NKG2D, and 
CD244 which resulted in reduced secretion of Granzyme B and Fas ligand [226]. This 
suppression of NK cell activity was observed in several mouse strains and human cells when the 
duration of the estrogen treatment was prolonged over one month, and it was mediated by 
ER signaling since no differences were observed when ER knockout (KO) mice were used 
[224]. This overall indicates that while estrogen signaling enhances NK cell proliferation, it 
decreases NK cell activation and cytotoxic function especially when NK cells are exposed to 
high dose estrogen for long periods of time like in the case of pregnancy. 
Estrogen and Disease 
 
 As described in the previous section, estrogen signaling has profound effects on the 
development, differentiation, and function of key immune cells indicative that estrogen signaling 
also affects those diseases that arise from immune cell function dysregulation, like 
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autoimmunity, or those that are heavily controlled by immune responses, like infections and 
cancer. In the next paragraphs the known effects of estrogen on these diseases are described.  
Estrogen and autoimmunity 
 
About 8% of the world’s population suffers from autoimmune diseases, of which 78% of 
all autoimmunity cases are women [227]. The female to male autoimmune disease ratio ranges 
from 2:1 in rheumatoid arthritis (RA) to 3:1 in MS, and to 9:1 in systemic lupus erythematosus 
(SLE) [227, 228]. The effects of estrogen on autoimmune diseases cannot be generalized since 
estrogen signaling differs depending on concentration, the estrogen receptor, and the target cell 
type. Estrogen was shown to enhance the severity of some autoimmune diseases. Estrogen 
signaling promotes systemic inflammation and induces B cell activation and anti-double stranded 
DNA antibody production which increases reactivity to endogenous antigens that are expressed 
in SLE [208, 229]. Altered expression of ER was shown in immune cells of SLE patients which 
have upregulated expression of ER and decreased expression of ER compared to healthy 
controls [230]. Increased ER expression in CD4+ and CD8+ T cells, macrophages, and DCs in 
SLE enhances Th1 type autoimmune responses by the production of cytokines including IFN 
and IL-12 [231]. T cells from SLE patients also have upregulated expression of the co-
stimulatory ligand molecule CD40L which is shown to be important for activated Th1 T cells 
priming and IFN production [232]. In a T cell dependent inflammatory bowel disease (IBD) 
model, estrogen signaling through ER worsens prognosis by promoting the accumulation of 
Th1 and Th17 T cells, and increasing T cell activation and proliferative state [233].  
Contrary to other autoimmune disorders, estrogen has a protective role against MS, a 
disease characterized by the presence of myelin reactive CD4+ T cells in the central nervous 
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system which leads to demyelination of axons and neuronal death [234-236]. Estrogen signaling 
through ER decreases autoantigen-specific proinflammatory molecules such as TNF, IL-17, 
iNOS, and MCP-1 and inhibits autoimmune inflammation [236]. ER signaling was also shown 
to be necessary for the estrogen-mediated protection against MS and for enhancing endogenous 
myelination [237]. Pregnant mice showed reduced CNS pathology when compared to non-
pregnant animals, and the rates of relapse increases post-partum at a phase where there is a 
marked decrease in estrogen levels compared to pregnancy [238].  
Estrogen was shown to have different effects in various autoimmune disorders. Given 
that estrogen affects all cells of the immune system as well as non-lymphoid tissue that is in 
proximity of target tissue, it is understandable that estrogen has different effects dependent on 
the context of each autoimmune disorder.  While estrogen plays a role in sex differences in 
autoimmune diseases, clearly estrogen alone does not exclusively contribute to this sex 
differential susceptibility.  
Estrogen and infection 
 
 Females and males differ in the severity, prevalence, and pathogenesis of infections 
caused by bacteria, virus, fungi and parasites, with males being generally more susceptible to 
these infections than females [239]. Males exhibit higher incidence rates for leptospirosis (4-fold 
increased incidence compared to females), schistosomiasis (1.5-fold), brucellosis, rabies, 
leishmaniasis (3-fold), pulmonary tuberculosis (2.5-fold), and hepatitis A, B and C (1.5 to 3-fold) 
[119, 240-243]. Similarly, premenopausal women are significantly less likely to develop 
meningococcal or pneumococcal infections [119]. Estrogen is thought be protective against 
infections due to the pro-inflammatory effects of estrogen signaling on immune cells. 
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Physiological estrogen concentrations were used to treat different kinds of infections in murine 
models and humans. Physiological estrogen administration was shown to reduce infection in 
males and females that suffered viral infections with encephalomyocarditis or Friend virus [244, 
245], bacterial infections with Salmonella typhimurium [246], fungal infections with Candida 
albicans and Paracoccidioides brasiliensis [247, 248], and even infections with parasitic 
protozoa like L. Mexicana [249]. Overall, these data indicate that estrogen signaling has a 
protective role against some infectious diseases through the enhancement of immune cell 
function against pathogens. Heightened immunity to pathogens among females contributes to 
lower intensity, such as lower viral load found in the serum of hepatitis or HIV female patients 
[250], and prevalence of infected individuals within a population compared to males, but it may 
increase disease symptoms and severity among females compared with males as seen in 
infections including malaria or HIV [251].  
Estrogen and cancer 
 
 Sex is an important factor in the pathogenesis and prognosis of cancers that occur outside 
of the reproductive tract [121]. For the majority of cancers throughout life, males have a higher 
risk of malignancy compared to females [252, 253]. Males have two-fold greater rates of 
mortality from malignant cancers compared to females, with sex-dependent outcomes being 
greatest for larynx, esophagus, lung and bronchus, skin, and liver cancers [253]. This male-
biased incidence and mortality is hypothesized to reflect a combination of factors including but 
not limited to sex-differences in genomic predisposition, infection, immune function, gene 
expression, and hormonal regulation. Estrogen is thought to have a protective role against cancer 
which is supported by the observation that cancer incidence and mortality rates increase after 
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menopause in women not undergoing hormone replacement therapy [254]. In some specific 
cancers such as melanoma or liver cancer, estrogen signaling has an antitumor role by enhancing 
antitumor immune responses [255-257]. Despite the normal and beneficial actions of 
physiological estrogen in women, estrogen was classified as a carcinogen after the Women’s 
Health Initiative research program discovered that postmenopausal women treated with HRT had 
a significant increase in the incidence of breast cancer after at least 5 years of treatment [258]. 
The effects of estrogen are tissue-specific and depend on which ER is predominantly expressed 
and further which downstream signaling pathways become activated.  
Estrogen receptor signaling is well known to be cancer promoting in ER-positive (ER+) 
breast tumors.  In breast cancer cells, ERα regulates various genes that play key roles in cell 
cycle progression and proliferation. ERα can transcriptionally upregulate c-Myc (as early as 15 
minutes after estrogen stimulation) and cyclin D1 which are necessary for the G1-to-S phase 
transition [259, 260]. On the other hand, ERβ signaling can induce G2 cell cycle arrest and 
inhibit the estrogen-induced cancer cell proliferation [261-263]. Expression of ER and ER in 
human NSCLC is correlated with worse prognosis and more aggressive disease [264, 265]. ER 
and ER are found in the nucleus and cytoplasm of NSCLS cells and are phosphorylated in 
residues commonly modulated by growth factors indicating ligand-independent ER signaling 
[266, 267]. ER signaling promotes the early activation of the MAP kinase pathway which is 
oncogenic in NSCLC [266].  In ovarian cancer, estrogen signaling was correlated with both 
worse and better disease prognosis. Estrogen levels are often observed in ovarian cancer patients 
and ER signaling promotes metastasis by inhibiting cell-cell adhesion and cell survival and 
proliferation [268, 269]. On the other hand, ER expression in ovarian cancer predicts longer 
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overall survival [270-272]. There is also contradicting evidence about the role of ER in ovarian 
cancer. Some early studies correlate ER expression with worse ovarian cancer prognosis [273], 
but ovarian cancer meta-analyses showed that ER expression is downregulated as disease 
progresses and ER is predominantly expressed in advanced and metastatic disease [272, 274, 
275].  
In some cancers including endometrial, prostate, liver cancer and melanoma estrogen 
signaling contributes to decreased tumor risk and better disease prognosis. Meta-analyses 
revealed that ER expression of both ER and ER simultaneously correlate with better overall 
survival of endometrial carcinoma [276]. Even if meta-analyses were not able to correlate 
prostate cancer prognosis with ER expression, prostate cancer cells express ER, ER and 
GPER and decreasing estrogen concentrations were observed to be associated with increased 
prostate cancer risk [277, 278]. Melanoma tumors express both ERα and ERβ, and ER 
expression decreases as the melanoma tumor develops. Although the mechanisms remain 
unclear, it is thought that ER acts as a tumor suppressor but it is downregulated as the tumor 
progresses [257, 279]. Estrogen can suppress the growth of human melanoma by inhibiting IL-8 
production and subsequent chronic inflammation through ER signaling [280]. Estrogen is a key 
molecule in cellular development and cell cycle regulation and therefore impacts many varieties 
of cancer cells directly. In summary, R expression is correlated with better prognosis and 
survival, and it can be concluded that ERβ acts as a tumor suppressor in most cancers. ERα acts 
as an oncogene in breast, lung and ovarian cancers, even if ER expression is correlated with 
better prognosis on melanoma, prostate, and endometrial cancer. 
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Another cancer that is heavily affected by sex and estrogen receptor signaling is HCC. 
HCC is the main disease model used in the studies of this dissertation. The next paragraphs 
describe current knowledge on the causes and treatments of HCC, as well as the role of estrogen 
on tumorigenesis.   
Hepatocellular Carcinoma 
 
 Primary liver cancer consists of a heterogeneous group of malignant tumors not 
including liver metastases from other cancer sites [281]. Primary liver cancer is the second 
leading cause of cancer-related deaths worldwide, and it accounts for approximately 800,000 
deaths each year [282, 283]. Hepatocellular carcinoma (HCC) is the most common primary liver 
cancer and it accounts for 80-90% of all cases [284]. The incidence of HCC is highest in East 
and Southeast Asia, and East and Western Africa but HCC incidence has risen in areas with 
historically low rates in the last decades, such as Western Europe and North America making it a 
major global health burden [285]. Life expectancy of HCC patients depends on the stage of the 
cancer at the time of diagnosis. In advanced stage, survival of only few months is expected, 
however, if diagnosis is early and effective treatment is performed, then five-year survival rate 
can be achieved [286].  
Causes  
 
Around 90% of HCC tumors develop from the induction of liver fibrosis and/or cirrhosis 
resultant from chronic inflammation of the liver caused by diseases such as chronic hepatitis B 
virus (HBV) and HCV, autoimmune hepatitis, excessive alcohol consumption, non-alcoholic 
fatty liver disease (NAFLD), diabetes mellitus, and excessive tobacco use [283, 287-289]. The 
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liver has the unique ability to repair itself after acute damage. Differentiated hepatocytes have 
the ability to re-enter the cell cycle and replace themselves [290]. However, under chronic 
inflammatory conditions, the altered immune response and constant cell death of hepatocytes 
promote liver fibrosis and tumorigenesis [284, 291]. Altered survival and proliferative signals 
during chronic inflammation, cellular stress, epigenetic modifications, and senescence promote 
tumorigenesis [283]. Chronic inflammation also promotes DNA damage, replication stress, and 
genomic instability which are detectable before transformation fully occurs [292]. Cytokines 
such as IL-6 and TNF, which activate the STAT3 and NF-B pathways respectively, were 
reported to be responsible for chronic inflammatory conditions and development of HCC [293, 
294]. Chronic inflammation of the liver can result on activation of oncogenic pathways and 
suppression of tumor-suppressive mechanisms. The main oncogenic pathways involved in HCC 
are PI3K-Akt and MAPK pathways, the Wnt/-Catenin pathway, c-myc, and the sonic hedgehog 
(HH) pathway.  
Activation by ligand binding and phosphorylation of growth factor tyrosine kinase 
receptors such as c-MET and EGFR lead to activation of the MAPK and PI3K pathways [295]. 
MAPK pathway activates the oncogene cFos and transcription factor AP-1/c-Jun which induce 
transcription of genes that drive cell proliferation of tumor cells [296]. Activation of the PI3K-
Akt pathway results on activation of the mammalian target of rapamycin (mTOR) pathway 
promoting carcinogenesis [297]. This pathway can also be dysregulated by constitutive 
activation of PI3K due to loss of function of the tumor suppressor PTEN by either mutations or 
epigenetic silencing [298]. C-myc amplification is observed in around 33% of all HCCs and it 
normally corresponds to large, less differentiated tumors in younger patients [299]. C-myc 
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overexpression in HCC induces tumor cell stemness, cell proliferation, and increases glutamine 
metabolism and cell growth [300-302]. Mutations on the Wnt/-Catenin pathway are observed in 
around 50% of HCCs [303]. Activating mutations result in stabilization and hyperactivation of -
Catenin signaling [304]. Additionally, inactivation mutations in negative regulators of the Wnt 
pathway and the tumor suppressor gene adenomatous polyposis coli (APC) further contribute to 
Wnt pathway activation [304]. While mature hepatocytes show no HH signaling activity, 
hyperactivation of HH and its pathway components were observed in 50% of HCCs [295, 305]. 
In HCC cells, reactivation of the HH pathway maintains tumor cell stemness and induces 
epithelial-to-mesenchymal transition which increases risk of metastasis [305, 306].  
Overall, several conditions including hepatitis infection, NAFLD, and excessive alcohol 
consumption can result in chronic inflammation of the liver. Chronic inflammation of the liver 
induces cell stress and cell death which can result in liver fibrosis and cirrhosis and subsequent 
oncogenic transformation into HCC. Many signaling pathways can induce HCC including those 
that enhance liver cell proliferation, stemness and metastatic capacity.  
Estrogen and HCC 
 
 The age-adjusted incidence ratios of HCC in men and women are extremely consistent in 
157 registries worldwide [253, 307]. Significantly higher incidence and mortality ratios of HCC 
in men compared to women are well documented. Worldwide, male-to-female HCC incidence 
rates range from 2 to 4, being greatest for age-matched males and females under 53 years of age 
[308]. Women have significantly longer survival rates than age-matched men. While the overall 
survival for women between 18-45 years old is 25 months, it is only 10 months for age-matched 
men [309, 310]. The incidence and mortality of HCC significantly increase in post-menopausal 
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women over 55 years old indicating that reproductive senescence increases the risk of HCC. The 
HCC overall survival in women between 45-55 years old decreases to between 10 and 15 months 
which almost matches the overall survival of age-matched men (8-9 months) [309, 310].  
Interestingly, those menopausal women using estrogen hormone replacement therapy showed 
decreased incidence of developing HCC compared to the non-estrogen users [311]. This 
indicates that estrogen has a protective role against HCC and estrogen signaling inhibits tumor 
formation and development making HCC significantly more prevalent in males compared to 
females. Thus, male sex, menopause, and female therapeutic ovariectomies are considered risk 
factors for HCC [312].  
Estrogen signaling is protective against HCC in several ways. Estrogen signaling inhibits 
chronic inflammation of the liver, the main cause of HCC. Estrogen signaling through ER 
directly inhibits transcription and expression of IL-6 by binding to its promoter and impairing c-
rel and RelA binding to the NF-B promoter site [170, 313]. This mechanism was observed upon 
estrogen treatment in hepatocytes and Kupffer cells, the resident macrophages of the liver [293]. 
ER signaling also inhibits STAT3 activity, a critical factor regulating liver chronic 
inflammation in hepatocytes [294]. ER transcriptionally activates protein tyrosine phosphatase 
receptor type O (PTPRO) which dephosphorylates STAT3 and subsequently attenuates STAT3 
signaling [314].  
HCV infection, a cause for chronic inflammation of the liver that results in cirrhosis and 
HCC, was shown to be inhibited by estrogen signaling through GPER in hepatocytes [315]. 
GPER signaling promotes the cellular export of matrix metallopeptidase 9 (MMP-9) which leads 
to cleavage of occluding, which is a tight junction protein and HCV receptor, overall reducing 
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HCV hepatocyte infection and viral RNA production [315]. Estrogen signaling through ER in 
hepatocytes was also shown to transcriptionally activate microRNA 34a (miR-34a) which 
enhances activation of p53, a well-known apoptosis inducer and tumor suppressor [316]. These 
data indicate that estrogen signaling not only reduces HCV infection of hepatocytes but also 
reduces overall inflammation and induces apoptosis in a p53 dependent manner.  
Estrogen signaling was also shown to affect HCC tumor infiltrating immune cells like 
macrophages. During HCC progression, TAMS replace Kupffer cells as the main modulators of 
chronic inflammation of the liver by secreting IL-6 and TNF. TAMs not only induce chronic 
inflammation but also secrete immunosuppressive molecules such as TGF and IL-10 that 
suppress the anti-tumor immune response and increase the fibrotic, hard to infiltrate, tumor 
microenvironment [317]. Estrogen signaling functions as suppressor for macrophage alternative 
activation into TAMs by inhibiting the JAK1-STAT6 pathway though ER . Overall these 
data indicate that estrogen signaling suppresses tumor growth partially via regulating the 
polarization of macrophages. Although this is promising in order to develop new therapies based 
on estrogen, the role of estrogen signaling on other HCC tumor infiltrating immune cells remains 
unclear and needs further investigation.   
Treatments for HCC 
Treatments for early stage HCC 
 
 According to the Barcelona Clinic Liver Cancer (BCLC) staging classification, HCC 
patients are categorized into four different stages according to the tumor burden, the number of 
tumors, the presence of vascular invasion, and the spread of nodules or presence of extrahepatic 
metastases. According to these parameters, HCC patients are considered stage 0 or very early 
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stage, stage A or early stage, stage B or intermediate stage, stage C or advanced stage, or stage D 
or terminal stage [319, 320]. Resection, ablation, and transplantation are considered for patients 
in the early HCC stages (0 and A).  Surgical resection or radiofrequency ablation are indicated to 
treat patients with preserved liver function, single nodule occurrence, and absence of cirrhosis. 
Even if the five-year survival rate is high after these therapies (50-75%), the tumor recurrence 
rate can reach 50% making resection and ablation not appropriate for patients with vascular 
invasion or metastasis [281, 321]. In early stage HCC patients with cirrhosis, liver 
transplantation is performed.  Liver transplantation ensures reduced tumor recurrence rates and 
increased survival however, there is a great lack of organs available for transplantation [322, 
323]. Surgical resection, tumor ablation, and liver transplantation are efficacious treatments for 
HCC but due to problematic HCC diagnosis that reveals high levels of false negatives and high 
percentage of asymptomatic patients, these treatments can only be performed in under 20% of all 
HCC cases [324].  
Sorafenib 
 
Intermediated or advanced stage (B and C) HCC patients with preserved liver function 
are treated with Sorafenib. Sorafenib is an oral multi-kinase inhibitor with anti-angiogenic and 
anti-proliferative properties [325]. In vascular endothelial cells, Sorafenib inhibits the receptor 
tyrosine kinases VEGFR1, 2 and 3 and platelet-derived growth factor receptor-β (PDGFR-β) 
which are involved in promoting tumor angiogenesis [325-327]. In tumor cells, Sorafenib targets 
the MAP kinase pathway and induces apoptosis by inhibiting RAF isoform signaling [326, 327]. 
Sorafenib can also induce apoptosis in a MAP-kinase independent way by inhibiting the 
phosphorylation of the translation initiation factor eIF4E which promotes the translation of anti-
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apoptotic protein myeloid cell leukemia-1 (Mcl-1) [327, 328]. Sorafenib increases overall 
survival by 2.3-2.8 months and it is the current standard of care for patients with advanced HCC 
[329]. Overall however, the median survival for Sorafenib treated patients with advanced stage, 
unresectable HCC is less than one year (11 months) [330]. Sorafenib treatment in advanced HCC 
patients also results in major side effects such as diarrhea, fatigue, and hand-foot syndrome, a 
troublesome condition characterized by painful, erythematous, blistering patches on palms and 
soles of the feet [330]. Overall, even if treatment with the multi-kinase inhibitor Sorafenib 
provides some therapeutic benefit for advanced HCC cases, a great unmet need remains for 
patients indicating that the development of new therapies to increase the overall survival of 
advanced HCC patients is highly necessary. 
Immunotherapy for HCC 
 
Immunotherapy is an emerging treatment modality that could become a promising 
treatment option for HCC as, first, it is an inflammation-associated cancer which makes 
immunotherapy more likely to be effective [331]. Second, it was observed that HCC patients 
whose tumors contain increased lymphocytic infiltration including CD8+ and CD4+ T cells show 
longer overall survival and lower risk of recurrence than those patients with no immune tumor 
infiltrates [332-334]. Third, the liver is an ‘immune privileged’ organ and it is tolerogenic to 
immune responses to antigens by various immune-suppressive mechanisms, including immune 
checkpoint expression, Treg recruitment, cytokine secretion dysregulation, and changes in the 
local TME that suppress APCs and T cells [335-338]. Considering all these facts, the blockade of 
immune checkpoints and the enhancement of the T cell anti-tumor immune response are 
treatment possibilities that can be highly effective against HCC. 
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Treatment of HCV-induced HCC patients with CTLA-4 inhibitor Tremelimumab showed 
20% partial response rates and increased overall survival by around 7 months [339]. Moreover, 
viral loads of HCV were significantly decreased indicating anti-viral immune responses, and no 
patients experienced immune-related adverse events or hepatotoxicity [339]. High PD-L1 and 2 
expression was observed in HCC tissue [340]. Several clinical trials were conducted treating 
advanced HCC patients with PD-1 inhibitors Nivolumab and Pembrolizumab. Nivolumab treated 
patients showed manageable adverse events and 5% of them showed complete response rate 
while 20% showed partial response rate [341, 342]. The overall survival rate at 6 months was 
72% indicating that Nivolumab did activate sustained tumor-specific immune responses [341, 
342]. Furthermore, Sorafenib resistance in HCC was shown to be mediated by enhanced DNA 
(cytosine-5)-methyltransferase 1 (DNMT1) expression induced by PD-L1 [343]. These data 
indicate that PD-L1 blockade and Sorafenib combinatorial treatment could not only enhance the 
anti-tumor immune response but also target the tumor cells themselves.  
ACT immunotherapy for HCC consists on the use of genetically modified autologous T 
cells that express a TCR specific for a HCC tumor antigen (Figure 4). ACT immunotherapy was 
shown to be partially successful in treating HCC in preclinical models and clinical trials. ACT 
shows unique advantages over Sorafenib and checkpoint blockade immunotherapy in treating 
HCC since it improves the quality and quantity of cells destroying the tumor in order to 
overcome immune tolerance [330]. ACT immunotherapy using the patient’s autologous TILs 
expanded with IL-2 in vitro after liver surgical resection showed 68% overall survival rates [344, 
345]. However, due to small tumor burden collected during biopsies and low T cell survival after 
extraction, it is hard to isolate TILs from HCC patients [346]. Genetically modified T cells 
including CAR T cell and TCR transduced T cells are being tested for ACT immunotherapy for 
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HCC in phase I and II clinical trials targeting tumor antigens such as glypican-3 (GPC3) 
expressed in the majority of HCCs [347-350] (Clinical trial IDs: NCT02715362, NCT03130712, 
NCT03198546, NCT03146234), -fetoprotein (AFP) expressed in 60-80% of HCCs [351, 352] 
(NCT03349255), mucin-1 (MUC-1) expressed in 60% of HCCs [353, 354] (NCT02587689), and 
epithelial cell adhesion molecule (EpCAM) (NCT03013712). ACT immunotherapy for virally-
induced HCC was also clinically tested using HBV or HCV viral proteins as tumor antigens. 
During chronic hepatitis infection, HBV and HCV can integrate its genetic material into the 
hepatocyte’s genome, and HBV and HCV antigens are found in HCC tumors even after viral 
infection clearance [355, 356]. Patients treated with HBV Ag-specific T cells showed positive 
ORRs including volumetric reduction of lung metastases with no new lesions observed in the 
liver or lungs [357]. In addition, no therapy-related adverse events were observed [357]. HCV 
Ag-specific T cells for ACT immunotherapy were generated and tested in preclinical models 
where they showed success, but they have not been tested in humans yet [51, 52, 358].  
Overall, checkpoint blockade and ACT immunotherapy for HCC were proven to be a 
partially successful and safe antitumor and antiviral method for advanced HCC, but the efficacy 
of this therapies needs to be optimized to obtain higher response rates. Even if ACT 
immunotherapy brings hope for the treatment of HCC, there are several aspects of it that need to 
be further improved. These include the facilitation of greater T cell tumor infiltration, avoiding T 
cell exhaustion and tumor immune scape, and reducing adverse side effects such as cytokine 
storm. 
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Figure 4. Adoptive T Cell Transfer Immunotherapy Using TCR Gene-Modified T Cells. 
A) Viral or cancer antigen specific T cell clones are isolated from hepatocellular carcinoma 
tumor infiltrating lymphocytes or peripheral blood and expanded in vitro to identify a 
therapeutic Ag-specific TCR candidate. B) TCR  and  genes are identified and cloned into 
retroviral vectors. C) Packing and producer cell lines are engineered to produce high titers of 
retrovirus containing the Ag-specific TCR. D) Retrovirus are used to transduce activated 
peripheral mononuclear blood cells from hepatocellular patients which are then expanded in 
vitro, and E) re-infused back into the patient. These autologous Ag-specific T cells have 
redirected specificity to provide anti-tumor immunity. 
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Summary 
 
 The field of immunotherapy has shown great advances for the treatment of solid tumors 
and hematopoietic malignancies in the last fest years. The use of genetically modified T cells that 
express TCRs specific for tumor antigens for ACT immunotherapy represents a promising 
approach to treating cancer patients [359]. Despite of the recent clinical success, there are many 
issues that remain in optimizing the efficacy of this type of immunotherapy. Many studies have 
focused on understanding the mechanisms of immune escape posed by the tumor including the 
role of the immunosuppressive TME. Malignant and non-malignant immune cells in the TME 
were characterized as well as their mechanisms to inhibit T cell anti-tumor function. On the other 
hand, other host factors that can affect T cell function and ACT immunotherapy efficacy remain 
well understudied. An example of this is the effect of sex and sex hormone signaling on the T 
cell anti-tumor function during immunotherapy. The sex hormone estrogen is present at 
physiological concentrations in females, and lower concentrations in males and post-menopausal 
females. Interestingly, some tumor and tumor-adjacent cells were shown to upregulate the 
expression of aromatase, the enzyme that synthesizes estrogen, which results in significantly 
increased estrogen concentrations in the TME. This indicates that adoptively transferred T cells 
will be exposed to different concentrations of estrogen throughout the body including the 
peripheral circulation depending on the sex of the patient, and then the TME. 
  Estrogen signaling can affect the differentiation, maturation and function of immune cells 
depending on various factors such as the concentration of hormone present, and the different 
estrogen receptor signaling pathways. Given that, one important mechanism of estrogen 
modulation of the immune system is by altering the differentiation, function, and cytokine 
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production of T cells. Estrogen signaling at physiological concentrations is generally pro-
inflammatory and enhances the function of T cells. However, the effect of estrogen on T cell 
function at non-physiological concentrations like the ones found the TME remains unclear.  
The effects of estrogen signaling on T cells and other immune cells results on differences 
on pathogenesis of diseases that arise from immune cell function dysregulation, like 
autoimmunity, or diseases that are heavily controlled by immune responses, like infections and 
cancer. Estrogen generally enhances the pathogenesis of autoimmunity while is protective 
against some infections and non-reproductive cancers. One malignancy that is heavily affected 
by estrogen is HCC. HCC is significantly more prevalent in males compared to pre-menopausal 
females [360, 361]. Post-menopausal females that are not undergoing estrogen HRT are also 
more prone to develop HCC than pre-menopausal females and estrogen users. The protective 
role of estrogen against HCC was shown to be mediated by estrogen receptor signaling inhibition 
of IL-6-mediated chronic inflammation and tumor infiltrating macrophage polarization. The role 
of estrogen signaling on other HCC tumor infiltrating immune cells remains unclear and needs 
further investigation.   
The goal of this dissertation is to better understand the effect of estrogen signaling on 
genetically modified T cells used in ACT immunotherapy. The effect of estrogen signaling on T 
cell function, cytokine production and polyfunctionality will be investigated at physiological and 
non-physiological high estrogen concentrations. In addition, due to the many possibilities in 
estrogen receptors and different downstream signaling, the receptors through which estrogen 
predominantly signals in T cells from males and females, and the signaling happening 
downstream from the estrogen receptors will be investigated in the context of immunotherapy. 
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Lastly, using a novel HCC preclinical model, the effect of estrogen presence during ACT 
immunotherapy will be measured. Taken together, these studies will help to understand how 
estrogen can be beneficial or disadvantageous for T cell function in anti-tumor immune 
responses and will aid to design better and stronger T cells for adoptive cell transfer ACT 
immunotherapy. 
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CHAPTER II 
MATERIALS AND METHODS 
T Cells 
All human female and male PBMCs samples used for T cell transductions were obtained 
from HLA-A2+ buffy coats purchased from Zenbio Inc. (Research triangle Park, NC). T cells 
were derived from the PBMCs of healthy donors isolated from buffy coats using Ficoll-Hypaque 
(Sigma-Aldrich, St. Louis, MO) density gradient centrifugation. T cells were then maintained on 
AIM-V serum-free media (Gibco) containing 10% pooled human male AB serum (Sigma-
Aldrich), 300 IU/mL recombinant human IL-2, and 100 ng/mL recombinant human IL-15 (rhIL-
2 and rhIL-15, National Institute of Health, Biological Resources Branch Bethesda, MD) at 37ºC 
in a humidified 5% CO2 incubator.  
HCV1406 TCR Retroviral Vector 
 
 The retroviral vector containing the TCR specific for the HCV antigen was generated by 
introducing the TCR chain genes and a truncated CD34 (CD34t) molecule lacking its 
intracellular signaling domain into an original SAMEN vector described by Treisman et al. [362-
364]. The modified SAMEN vector, denominated HCV1406, contains the sequence for the  and 
 chains of the TCR specific for the HCV non-structural protein 3 (NS3) antigen (amino acids 
1406-1415) separated by a P2A-self-cleaving linker, and then it contains the CD34t sequence 
separated by a T2A self-cleaving linker (Figure 5) [51, 358, 365]. The HCV1406 TCR retroviral 
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vector was used to generate a high viral titer producer PG13 cell line which retroviral supernatant 
was used to transduce human male and female primary T cells.  
 
 
 
 
 
 
 
 
Generation of High Viral Titer Producer PG13 Cells 
 
 To generate stable virus producer cells, 3×106 HEK-293gp cells were plated in a 10 cm 
tissue culture plate in DMEM medium (Gibco) containing 10% FBS. The next day, the HEK-
293gp cells were transfected with 20 g of the HCV1406 TCR retroviral vector and 5g of a 
plasmid encoding the vesicular stomatitis virus envelope gene in 50 L of Lipofectamine 2000 
(LifeTechnologies). After six hours, the supernatant was carefully removed and replaced with 10 
mL of fresh DMEM containing 10% FBS. After 48-hour incubation at 37ºC in a humidified 5% 
CO2 incubator the viral supernatant was collected and filtered through a 0.45 m cellulose 
acetate syringe filter (VWR). 2×106 PG13 cells were plated in a 10 cm tissue culture plate and 
the viral supernatant from the HEK-293gp cells was used to transduce them over three days 
while incubated at 37ºC in a humidified 5% CO2 incubator. Transduction efficiency was 
quantified by measuring CD34 expression via flow cytometry with an anti-human CD34-PE 
Figure 5. Structure of the HCV1406 TCR Retroviral Vector Used to Transduce Human Male 
and Female T Cells. TCR retroviral vector containing the HCV1406 TCR  and  chain genes 
fused by a P2A self-cleaving peptide linker. A truncated version of the CD34 molecule (CD34t) 
missing the intracellular signaling domain serves as a marker for transduction and it is fused to 
the 3’ end of the TCR b chain via a T2A self-cleaving peptide. LTR: long terminal repeat, SD: 
splicing donor, SA: splicing acceptor, ’: packaging signal. This retroviral vector was previously 
described by Rosen et al. J. Immunol. 2004.  
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antibody (BioLegend), and transduced cells were sorted for high and uniform CD34 expression 
using a FACS Aria Illu cell sorter (BD BioSciences).  
 In order to generate HCV1406 TCR retrovirus for transductions, 10x106 sorted stable 
producer PG13 cells were plated in a T-175 flask and treated with IMDM media supplemented 
with 10% FBS, 1 M sodium butyrate (Sigma-Aldrich), and 10 mM HEPES (Gibco) for 8 to 10 
hours. After treatment, sodium butyrate containing media was replaced with IMDM 
supplemented with 10% FBS and cells were incubated overnight. Then, fresh retroviral 
supernatant was collected and filtered through a 0.45 m cellulose acetate syringe filter and used 
for T cell transduction.  
HCV1406 Retroviral T cell Transduction 
 
Primary human male and female T cells obtained from HLA-A2+ buffy coats were transduced 
via inoculation [366, 367]. Prior to retroviral transduction, primary human male and female T 
cells were activated with 50 ng/mL of anti-CD3 mAb OKT3 (BioLegend, San Diego, CA) for 
four to five days. 24-well flat-bottom non-tissue culture plates (VWR) were coated with 30 
mg/mL Retronectin (Takara, Otsu, Japan) in 0.5 mL of DPBS (Dulbecco’s modified phosphate 
buffered saline) (Gibco) overnight at 4ºC. Before transduction, Retronectin coated plates were 
blocked with 2% PBSA (bovine serum albumin in PBS) for 30 minutes at room temperature 
(RT) and washed with DPBS. Then, 2 mL of fresh retroviral supernatant was added to each well 
and plates were spun for 2 hours at 32ºC at 2,000×g. Then, viral supernatants were aspirated and 
2×106 activated T cells were placed on each well in 1 mL of AIM-V media containing 10% 
human serum, 600 IU/mL rhIL-2, and 200 ng/mL rhIL-15 in combination with 1 mL of retroviral 
supernatant. Plates were spun for 2 hours at 32ºC at 2,000×g. Plates were then incubated 
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overnight at 37ºC in a 5% CO2 humidified incubator and then cells were transferred to tissue-
culture treated plates in supplemented AIM-V medium. Three or four days after, transduction 
efficiency was measured via flow cytometry using human anti-human CD3-APC-Cy7 and anti-
CD34-AlexaFluor700 antibodies (BioLegend).  
Transduced cells were sorted by adding anti-CD34 magnetic microbeads (Miltenyi) to the 
T cells and passing them through a magnetic column (positive selection sorting). T cells that 
remained magnetically attached to the column were eluted and purity of selection was confirmed 
via flow cytometric analysis. All experiments described in this dissertation were performed using 
>90% pure CD34+ transduced T cell populations. 
Cell Lines and Media 
 
The PG13 cell line (stable viral producer cell line) and the T2 cell line (CD3 negative, 
TAP-deficient HLA-A2-expressing APC) were gifts from Dr. Nishimura, Loyola University 
Chicago, Maywood. PG13 cells were maintained in IMEM medium (Gibco) supplemented with 
10% fetal bovine serum (FBS) (VWR, Radnor, PA). T2 cells were maintained in RPMI 1640 
medium (Gibco) supplemented with 10% FBS, 5% penicillin and streptomycin (Gibco), and 5% 
L-glutamine (Gibco). 
Sorting of CD4+ and CD8+ Ag-specific T cells 
 
 Human male and female HCV1406 TCR transduced T cells were sorted into CD4+ or 
CD8+ populations using CD4 or CD8 negative selection magnetic microbead kits (Miltenyi 
Biotec). Non-CD4+ or non-CD8+ cells were labeled with a cocktail of biotin-conjugated 
antibodies as indicated by the manufacturer. Subsequently, non-CD4+ cells or non-CD8+ target 
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cells were magnetically labeled with beads and passed through a magnetic column that captured 
them. The column flow-through was collected and contained >90% pure unlabeled CD4+ or 
CD8+ T cells. Flow cytometry was used to ensure purification with antibodies anti-human CD3-
APCyCy7, CD4-PECy7, and CD8-FITC (BioLegend).  
Estrogen and Estrogen Receptor Antagonists and Agonists 
 
17-estradiol (≥98% purity) powder suitable for cell culture was obtained from Sigma-
Aldrich and reconstituted in DMSO at a 10 M concentration. Human female and male Ag-
specific T cells were treated with 0.5 nM (physiological) or 50 nM (super-physiological) 17-
estradiol for 2 hours and control cells were treated with DMSO alone for 2 hours prior to co-
culture with target T2 cells. The ER antagonist 1,3-Bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-
piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride (MPP-dihydrochloride) (≥98% purity), 
and the ER antagonist 4-[2-Phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-
yl]phenol (PHTPP) (≥99% purity) were obtained from Tocris Biotechne and were reconstituted 
in  in DMSO at a 10 M concentration [368, 369]. Human female and male Ag-specific T cells 
were treated with 100 nM of either antagonist or both simultaneously for 2 hours in combination 
with 0.5 or 50 nM 17-estradiol for 2 hours prior to co-culture with target T2 cells.  
Isolation of Cytoplasmic and Nuclear Extracts 
 
 As previously described in Navarro & Watkins (Gender and the Genome, 2017), 3×106 
Ag-specific T cells from male and female donors were treated with none, 0.5, or 50 nM E2 for 2, 
10, 30, 60, or 120 minutes and nuclear and cytoplasmic protein extracts were obtained using the 
NE-PER Nuclear Cytoplasmic Extraction Reagent Kit (Pierce, Rockford, IL) according to the 
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manufacturer's instructions. Treated cells were washed twice with ice-cold phosphate buffered 
saline (PBS) and centrifuged at 500×g for 5 minutes. Cell pellets were resuspended in 100 L of 
cytoplasmic extraction reagent I (CER I) by vortexing and incubated on ice for 10 minutes 
followed by the addition of 5.5 L of CER II. They were then vortexed for 5 seconds, incubated 
on ice for 1 minute, and centrifuged for 5 minutes at 16000×g. The supernatant fraction 
(cytoplasmic) was transferred to a pre-chilled tube and stored at -80°C. The insoluble fraction 
was resuspended in 50 L of nuclear extraction reagent and vortexed every 10 minutes for a total 
of 40 minutes. Tubes were centrifuged at 16000×g for 10 minutes, and the resulting supernatant 
was collected (nuclear fraction) and stored at -80°C until further Western Blot analysis. 
Western Blot Analysis 
 
As previously described in Navarro & Watkins (Gender and the Genome, 2017), equal 
amounts of nuclear and cytoplasmic protein isolated from estrogen treated male and female Ag-
specific T cells were loaded onto a sodium dodecyl sulfate (SDS)/polyacrylamide gel. After 
electrophoresis, proteins were transferred into a polyvinylidene fluoride membrane (Bio-Rad) 
and blocked for 1 hour with 5% BSA in Tris-buffered saline containing Tween-20. After 
blocking, membranes were incubated overnight with the anti-human ER primary antibody 
clone D8H8 (1:1000) (Cell Signaling Technologies) at 4°C while shaking. After washing, 
membranes were incubated for 1 hour at RT with the horseradish peroxidase-conjugated anti-
rabbit IgG secondary antibody (1:5000) (Cell Signaling Technologies). Proteins were detected 
using an enhanced chemiluminescence substrate kit (Thermo Fisher). All blots were stripped and 
re-probed with anti-human β-actin antibody (1:2000) or anti-human Lamin A/C (1:1000) (Cell 
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signaling Technologies). Western blots were imaged using a ChemiDoc MP imaging system 
(Bio-Rad) and quantified using the software ImageJ.  
Peptides 
 
HCV-NS3 (1406–1415): KLVALGINAV and tyrosinase (368–376): YMDGTMSQV 
peptides were obtained from Synthetic Biomolecules (San Diego, CA). Peptides were 
reconstituted in dimethyl sulfoxide (DMSO) and stored at -20ºC. For all the experiments 
described, T2 cells were pulsed with 5µg/mL of either peptide for 2 to 4 hours at 37ºC in a 5% 
CO2 humidified incubator. 
Cytokine Release Assays 
 
T cell cytokine secretion was measured in cytokine release assays such as enzyme-linked 
immune absorbent spot (ELISPOT) and enzyme-linked immunosorbent assay (ELISA). 2.5×104 
T2 cells loaded with peptides or HCV-expressing tumor cells were used as target cells. T2 cells 
were pulsed with 5 g/mL of HCV1406 or tyrosinase peptides for 2-4 hours, and 2.5×104 human 
male and female HCV Ag-specific T cells were treated with 0, 0.5, or 50 nM estrogen for two 
hours. IFN and Granzyme B secretion was measured via ELISPOT by coating ethanol activated 
ELISPOT plates with anti-human IFN (BD Biosciences) or anti-human Granzyme B (R&D 
Systems) capture antibodies overnight at 4°C. Plates were blocked with RPMI containing 10% 
FBS for 2 hours at RT. Treated T cells were co-cultured with pulsed T2 target cells at a 1:1 ratio 
on coated ELISPOT plates for 18 hours at 37ºC in a 5% CO2 humidified incubator. Co-cultures 
were then aspirated and the relevant biotinylated secondary and streptavidin–horseradish 
peroxidase antibodies (Streptavidin-HRP, BD Biosciences) were added and plates were 
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incubated for 2 hours or 1 hour respectively at RT. Plates were developed using 3-Amino-9-
ethylcarbazole (AEC) substrate (BD Biosciences) and spots were quantified using a CTL 
ImmunoSpot S6 reader. After each step of this process, the plate was thoroughly washed 5 times 
with PBS containing 0.05% Tween-20. 
 TNF and IL-4 secretion was measured via ELISA by coating 96-wells ELISA plates 
with anti-human TNF or IL-4 (MabTech) capture antibodies overnight at 4°C. Plates were 
blocked using PBS with 10% FBS for 1 hour at RT. Then, 100 L of co-culture supernatant and 
standards were added to the plate and incubated for 2 hours at RT. This was followed by 
incubating the plate with the relevant biotinylated secondary and streptavidin-HRP antibodies for 
1 hour at RT. Plates were developed using tetramethylbenzidine (TMB) substrate and stopped by 
adding 1 M sulfuric acid. The absorbance was then read at 450 nm in iMark Microplate 
absorbance reader (Bio-Rad). After each step of this process, the plate was thoroughly washed 5 
times with PBS containing 0.05% Tween-20. 
Flow Cytometry 
 
 Fluorochrome-conjugated antibodies were used to detect human transduced Ag-specific 
T cell surface markers (CD3, CD34, CD4 and CD8) and activation markers (CD25, CD69). In 
functional assays, Ag-specific T cells were also stained for the lytic marker CD107a and 
intracellular cytokines (IFN, TNF, IL-2, IL-4, IL-17a, IL-22, and Granzyme B). Intra-nuclear 
staining was used to detect T cell transcription factors (T-Bet, GATA3, RORt, and FoxP3). A 
table summarizing all flow cytometry antibodies used can be found in Table 1. 
 
 
 
 
63 
Flow cytometry staining standard protocols were followed for measuring extra and 
intracellular protein expression. Cells were spun in 5 mL polystyrene tubes (VWR) and washed 
with PBS containing 2% FBS and 0.01% sodium azide (FACS buffer) twice. Cell suspensions 
were treated with anti-CD16/32 antibody (BD Pharmigen) for 10 minutes to block Fc receptors 
and non-specific staining. Next, cell suspensions were incubated with extracellular marker 
antibodies for 30 minutes at 4°C in the dark. Cells were washed to remove antibody excess and 
incubated with intracellular fixation buffer (BioLegend) for 20 minutes at 4°C in the dark and 
then washed twice with permeabilization buffer (BioLegend). Fixed and permeabilized cells 
were then incubated with intracellular marker antibodies for 30 minutes at 4°C in the dark. Then, 
cells were washed with permeabilization buffer and staining was measured in a BD Fortessa flow 
cytometer. Data were analyzed using FlowJo software package. 
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For transcription factor staining, cells that had been stained for extracellular markers 
were incubated in 1 mL of Foxp3 Fixation/Permeabilization working solution (eBioscience) for 
45 minutes at RT in the dark and then washed twice with permeabilization buffer (eBioscience). 
Fixed and permeabilized cells were then incubated with transcription factor antibodies for 45 
minutes at RT in the dark. Then, cells were washed with permeabilization buffer and staining 
was measured in a BD Fortessa flow cytometer. Data were analyzed using FlowJo software 
package. 
Table 1. Antibodies Used for Flow Cytometry Staining.  
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Multi-Intracellular Cytokine Assay 
 
2.5×105 human male and female sorted HCV Ag-specific T cells were treated with 0, 0.5, 
or 50 nM estrogen in combination with 100 nM MPP-dihydrochloride (ER inhibitor), or 100 
nM PHTPP (ER inhibitor), or 100 nM of both MPP-dihydrochloride and PHTPP 
simultaneously for 2 hours. Treated T cells were then co-cultured with 2.5×105 T2 cells that had 
been pulsed with 5g/mL of HCV NS3 or tyrosinase peptides at 37ºC for 5 hours in the presence 
of protein transport inhibitors GolgiPlug and GolgiStop (BD Biosceinces).  Then extracellular 
staining for markers CD3, CD34, CD4, CD8, and CD107a was performed as described before. 
Subsequently, cells were fixed and permeabilized and staining for intracellular markers IFN, 
TNF, IL-2, IL-4, IL-17a, IL-22 was performed as described before. Samples were ran in a BD 
Fortessa flow cytometer and analyzed using FlowJoX. 
Gating strategy to analyze these data consisted on selecting the singlet population (FSC-
A vs FSC-H), and then the T cell population was gated individually from T2 cells by FSC vs 
SSC comparison. T cells were gated on CD3+CD34+ populations and then Ag-specific T cells 
were gated on CD8+CD4- or CD8-CD4+ populations. These CD3+CD34+CD8+CD4- or 
CD3+CD34+CD8-CD4+ populations were used as starting point for subsequent functional 
analysis. Functional parameters included CD107a, IFN, TNF, IL-2, IL-4, IL-17a, and IL-22. 
All these parameters were gated against SSC to obtain the percent frequency of 
CD3+CD34+CD8+CD4- or CD3+CD34+CD8-CD4+expressing each of them 
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Polyfunctional Flow Cytometry Data Analysis 
 
In order to obtain the levels of expression of all the possible marker combinations, 
Boolean combinatorial gating was applied to the seven markers expressed in both the 
CD3+CD34+CD8+CD4- and CD3+CD34+CD8-CD4+ population. Boolean combinatorial gating 
yielded a total of 128 marker combinations (2n n=7 27=128). This seven-parameter functional 
analysis yielded a dataset way too complex to graphically depict in FlowJoX. Comparisons of 
expression of all these marker combination between sexes and estrogen and estrogen receptor 
inhibitor treatments were also too complicated to perform using FlowJoX. Subsequent analysis 
of these data was performed using the software Simplified Presentation of Incredibly Complex 
Evaluation (SPICE). Pre-processing of the data was performed using the software Pestle. After 
combinatorial Boolean gating, Pestle offers data formatting and background subtraction of 
multivariate data sets. The polyfunctionality data obtained from Ag-specific T cells stimulated 
with T2 cells pulsed with tyrosinase was used for background subtraction. Data sets were then 
imported to SPICE for graphical analysis. While background subtraction can result in below zero 
values, SPICE has a threshold approach which will minimize systematic bias and can maximize 
the amount of information that can be gained from positive measurements [370]. Visualization of 
data includes pie charts, bar graphs, and cool plots, a type of heat map. Heat maps were chosen 
to represent the data. The mean of the percent frequency expression of each cytokine 
combination for the 15 female and 15 male donors mean values were plotted in the heat maps. 
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Animal Experiments 
 
All NOD.Cg-Mcph1Tg(HLA-A2.1)1Enge Prkdcscid Il2rgtm1Wjl/SzJ (NSG-A2) mice aged 6-8 
weeks were obtained from The Jackson Laboratory. Bilateral ovariectomies or sham surgeries 
were performed on female and male mice. Briefly, any mouse having surgery was placed on 
Carprofen gel diet (MediGel) 24 hours preceding surgery and kept on that diet for 72 hours post-
operation. Each animal also received Enrofloxacin (Bayer Animal Health) injected 
subcutaneously at 10 mg/kg as a broad-spectrum antibiotic. The animal was then anesthetized 
using Isoflurane (Abbott Labs) and placed on its sternum and prepared for surgery using 70% 
ethanol and iodine wipes. Two 1 cm skin incisions were made longitudinally over the animal’s 
fat pads, then one at the time, the fat pads were pulled from the body cavity until the ovaries 
were exposed. Ovaries were dissected away from the fat pad and the remaining uterine horns 
were placed back into the cavity (this step was skipped during sham surgeries). Skin was closed 
using 9 mm skin clips on each side. Then, the animal was placed in a clean cage with access to 
Carprofen gel diet and Enrofloxacin treatments as indicated before. Skin clips were removed 14 
days post-operation and tumor challenge was then performed.  
To generate HCC tumors, human oncogenes c-MET and -catenin, and the HCV:NS3 
antigen expressions vectors in combination with sleeping beauty (SB) transposons were used 
[371, 372]. Plasmids maps containing the expression vectors for c-Met, catenin and sleeping 
beauty transposase are described in Figure 6. The structure of the HCV NS3 expression vector is 
described in Figure 7. 9 g of pT3hMET, 9 g of pT3CAT, and 9 g of pCDNAIII-NS3 
(containing the sequence of the HCV:NS3 peptide) in combination with SB transposase at a 2:1 
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ratio were diluted in 2 mL of normal saline (0.9% NaCl), filtered through a 0.2 m filter 
(Corning), and injected into the lateral tail vein of female ovariectomized/sham mice or male 
sham mice that were around 8-9 weeks old in <7 seconds. At day 20 or day 40 after tumor 
challenge, mice were given ACT immunotherapy consisting of 10×106 sex-matched human HCV 
Ag-specific T cells via tail vein injection. Mice that received ACT were given 2.5 g of rhIL-15 
every 3 days to ensure human Ag-specific T cell survival. 20 days after T cell transfer, mice 
were sacrificed, and livers and spleens were collected for analysis. All mice were housed under 
specific pathogen-free conditions and were treated in accordance with NIH guidelines under 
protocols approved by the animal care and use committee (IACUC) of Loyola University 
Chicago (Maywood, IL). 
Cell Isolations 
 
Human Ag-specific T cells were isolated from single cell suspensions of tumors obtained 
by digesting livers with 1 mg/mL collagenase D (Roche) for 30 minutes at 37°C while shaking 
and dissociating them using a Stomacher bag (Sewer). Liver single cell suspensions were then 
subjected to a Percoll (GE Healthcare) density gradient. Briefly, cell suspensions were prepared 
in 10 mL cell culture media and underlayed with 40% and subsequently 80% Percoll to separate 
out lymphocytes from tumor cells. Cells were collected at the 40/80 interface for further analysis. 
Human Ag-specific T cells were also isolated from spleen single cell suspensions obtained by 
pushing the tissue through a 70 m nylon filter. Then, red blood cells were lysed using 
ammonium-chloride-potassium (ACK) lysis buffer (Lonza). 
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Figure 6. Vector Maps of Human c-MET and Catenin-P3T, and Sleeping Beauty 100 
Transposase-pCMV Used to Generate HCC in Mice. A) Human c-MET (9745 bp) and B) 
human Catenin (7691 bp) are shown in the black arrows. C) Human SB100 (4752 bp) is shown 
in the cyan after the T7 promoter. These vectors were previously described by Tward et al. 
PNAS. 2007. 
Figure 7. Structure of the pcDNAIII Vector Containing the HCV NS3 Sequence. The full 
sequence of the HCV non-structural protein 3 (NS3) was linked to GFP with a T2A self-cleaving 
peptide. LTR: long terminal repeat, SD: splicing donor, SA: splicing acceptor, ’: packaging 
signal. This pdNAIII vector was described by Spear et al. Cancer Immunol Immunother. 2016.  
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ELISPOT Using Tumor Cells as Targets 
 
 NSG-A2+ mice were injected with MET/CAT/HCV or MET/CAT hydrodynamically and 
tumors were left to develop for 60 days. On day 60 tumors were extracted and digested using 1 
mg/mL of collagenase D as previously described. Single cell suspensions of tumor cells were 
washed using RPMI containing 10% FBS and counted. 2.5×105 tumor cells from mice injected 
with MET/CAT/HCV or MET/CAT were then co-cultured with human female and male HCV 
Ag-specific T cells from 3 different donors in triplicates in a 1:1 ratio for 18 hours on an anti-
human IFN coated ELISPOT plate. After 18 hour co-culture plates were developed as 
previously described and spots were quantified.  
Statistical Analysis 
 
All data are represented as the mean ± standard error of the mean (SEM). All the 
statistical analyses were conducted using GraphPad Prism (version 7). For experiments that did 
not require group wise comparisons, student’s t test was used with significance set at p<0.05. For 
experiments that did require group wise comparisons, 1 or 2 way ANOVA were used with a 
Tukey’s post-hoc test with significance set at p<0.05.  
For experiments analyzing the effect of estrogen signaling on T cell polyfunctionality, 
data were analyzed using MANOVA with a Tukey’s post-hoc test with significance set at 
p<0.05. In order to test whether the effects of estrogen inhibitor treatments on the percent 
expression for a given cytokine combination vary significantly based on estrogen treatment, and 
vice versa, Michael Wesolowski, MPH (Clinical Research Office, Loyola University Chicago, 
IL) performed linear regression model. Mixed-effects linear regression models were used to 
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estimate the expression of unique cytokine combinations for various estrogen and estrogen 
inhibitor treatment combinations. Models including an estrogen main effect, an estrogen 
inhibitor main effect, and an estrogen x estrogen inhibitor interaction term were run for each 
unique cytokine combination. These models featured random intercepts to account for within-
donor correlations existing between cells and treatments related to the same donor, and 
unstructured variance-covariance structures. The estimated effects of estrogen and estrogen 
inhibitor treatment combinations, as well as the average estimated cytokine expression for each 
estrogen and estrogen inhibitor treatment combination, are reported. Post-hoc pairwise 
comparisons between each index estrogen treatment (50 & 0.5) and the reference estrogen 
treatment (0) were conducted within each estrogen inhibitor treatment stratum. Separate models 
were run for each of 83 unique cytokine combinations, and as a result, an experiment-wise 
Sidak-corrected significance level of α = 0.000618 was used to control the Type I error rate. An 
additional Sidak adjustment was used to correct p values for the multiple, post-hoc pairwise 
comparison tests. 
Mixed-effects linear regression model was described as: 
Within-Donor Model:  
𝐶𝑦𝑡𝑜𝑘𝑖𝑛𝑒 𝐶𝑜𝑚𝑏𝑖𝑛𝑎𝑡𝑖𝑜𝑛 𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝐸𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛𝑖𝑗 =  𝑏0𝑖 + 𝑏1𝑖*𝐸𝑠𝑡𝑟𝑜𝑔𝑒𝑛 𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟𝑖𝑗  + 𝑏2𝑖*𝐸𝑠𝑡𝑟𝑜𝑔𝑒𝑛𝑖𝑗  
+ 𝑏3𝑖*𝐸𝑠𝑡𝑟𝑜𝑔𝑒𝑛 𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟𝑖𝑗*𝐸𝑠𝑡𝑟𝑜𝑔𝑒𝑛𝑖𝑗  + 𝜀𝑖𝑗 
Between-Donor Model: 
𝑏0𝑖 = 𝛽0 + 𝜈0𝑖 
𝑏1𝑖 = 𝛽1 
𝑏2𝑖 = 𝛽2 
𝑏3𝑖 = 𝛽3
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CHAPTER III 
ESTROGEN SIGNALING THROUGH ER AND ER DIFFRENTIALLY IMPACTS 
HUMAN MALE AND FEMALE AG-SPECIFIC T CELL CYTOKINE PRODUCTION 
 
Introduction and Rationale 
Immunotherapy is a treatment modality that was proven to be effective in many types of 
difficult to treat cancer, and it is a promising therapy option for HCC. Treatment of HCC patients 
with checkpoint blockade immunotherapy showed some success with 20% partial response rates 
[342]. Many tumor specific antigens that can be used as targets of T cells for ACT 
immunotherapy were identified including but not limited to GPC3, -fetoprotein, MUC-1, and 
the viral proteins of HCV and HBV [350, 351, 354, 357]. Even if ACT immunotherapy brings 
hope for the treatment of HCC, critical aspects that need to be further improved upon during 
immunotherapy include facilitating greater T cell tumor infiltration, avoiding T cell exhaustion, 
and reducing adverse side effects such as cytokine storm. The role of host factors including sex 
and estrogen signaling has never been investigated in ACT immunotherapy for HCC. Adoptively 
transferred T cells are exposed to different estrogen concentrations in the body including 
physiological estrogen or low estrogen depending on the sex and reproductive state of the 
patient, and super-physiological estrogen in the TME. Considering that estrogen has a protective 
role against HCC through mechanisms involving inflammation, it can be hypothesized that 
estrogen signaling enhances T cell function and anti-tumor response which subsequently can 
enhance the efficacy of ACT immunotherapy. Estrogen signaling in immune cells is highly 
74 
 
 
dependent on concentration and estrogen receptor subtype hence it is necessary to investigate 
these factors on immune cells mediating the anti-tumor immune response in order to optimize 
immunotherapy treatment against HCC. This dissertation is based in studying the effects of 
estrogen signaling on the function of TCR transduced T cells used for immunotherapy. 
 In order to characterize the effect of estrogen signaling on Ag-specific T cells used for 
ACT immunotherapy against HCC, HCV was chosen as a model target antigen. HCV infects 
approximately 140 million people worldwide and chronic HCV infection can result in associated 
liver disease including cirrhosis and HCC [284]. Moreover, 50 to 80% of HCC cases derive from 
chronic HCV infection [373]. Even if HCV protease inhibitor anti-viral drugs Telaprevir, 
Boceprevir, and Simeprevir were developed and recently approved for clinical use [374, 375], 
the rapidly mutating HCV genome generates drug resistance in hepatocyte [376, 377]. In 
addition, many patients treated with anti-viral drugs have already developed associated liver 
disease, such as cirrhosis, that cannot be treated with these drugs. Knowing all this, a TCR that 
recognizes the HCV NS3 (amino acids 1406 to 1415) antigen was selected. This TCR, 
denominated HCV1406, was isolated from a T cell clone found in an HLA-A2+ HCV+ HCC 
patient that received an HLA-A2+ liver transplant [378]. T cells genetically modified with this 
TCR were previously shown to recognize HCV+ target cells in vitro in an HLA-A2-dependent 
manner, and to be able to reject patient-derived xenografts (PDX) tumors in vivo [51]. In the 
following sections, the effect of estrogen signaling on human male and female HCV Ag-specific 
T cell cytokine expression and production are described. 
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Results 
Ag-specific T cells from Male and Female Donors Express and Signal through ER in 
Response to Estrogen Stimulation 
 
 To study the effect of estrogen signaling on human male and female Ag-specific T cells, 
peripheral blood derived T cells from 15 healthy male and 15 healthy female donors were 
transduced with the HCV1406 TCR (Figure 5). While 5 male and 5 female donors were of 
unknown age, the remaining male and female donors were between 22 and 48 years old 
corresponding to pre-menopausal age for female donors. The HCV1406 TCR retroviral vector 
codes for a truncated version of CD34 (CD34t), which was used for transduction recognition and 
purification of transduced T cells for further in vitro and in vivo studies. Transduction of either 
male or female T cells with the HCV1406 TCR typically yielded around 30 to 60% transduction 
efficiency (Figure 8 A). After purification by magnetic bead cell sorting using the CD34 
expression as a target, studies described in this dissertation are based on the effect of estrogen on 
a population of Ag-specific T cells at > 90% purity (Figure 8 A). HCV 1406 transduced sorted T 
cells from male and female donors had very similar CD3+CD34+ mean fluoresce intensity (MFI) 
which is important to achieve to ensure that differences on HCV1406 TCR expression between 
donors did not give rise to differences on T cell activation and function (Figure 8 A). Transduced 
T cell populations from male and females showed significantly higher frequencies of CD8+ 
compared to CD4+ T cells but there were no significant differences on T cell subset distribution 
between sexes (Figure 8 B, C).   
 After transduction and CD34+ purification, male and female HCV Ag-specific T cells 
were sorted into CD4+ and CD8+ populations and ER expression was tested via western blot. 
There were no sex-differences on the expression level of ER in the bulk population or in the 
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CD4+ and CD8+ populations of Ag-specific T cells (Figure 9 A, B). CD4+ Ag-specific T cells 
from both sexes showed significantly higher expression of ER compared to CD8+ T cells and 
bulk T cell populations (Figure 9 A, B). In order to test if ER translocates into the nucleus after 
estrogen ligand stimulation, male and female Ag-specific T cells were treated with no estrogen 
(0), physiological (0.5 nM), or super-physiological (50 nM) concentrations of E2 for 0, 2, 10, 30, 
60, and 120 minutes before lysis of the cells and separation of cytoplasmic and nuclear fractions 
to tests for ER expression. ER was expressed in the cytoplasm of the cell of male and female 
Ag-specific T cells but its expression was significantly decreased after 2-minute estrogen 
treatment on female T cells (Figure 9 C, E) and after 10-minute estrogen treatment on male cells 
as demonstrated by normalizing expression to -actin as a loading control (Figure 9 C, F). On the 
other hand, ER expression in the nucleus was quickly increased in male T cells after 2-minute 
estrogen treatment (Figure 9 D, F), and increased overtime after estrogen stimulation in female T 
cells as demonstrated by normalizing expression to Lamin A/C loading control (Figure 9 D, E). 
The time course of E2 treatment revealed that nuclear translocation of ER upon E2 ligation is 
very rapid, within 2 to 10 minutes, in male and female Ag-specific T cells. This rapid 
translocation was found to be transient since cytoplasmic ER expression re-accumulated, and 
nuclear ER expression diminished over time. Cytoplasmic and nuclear ER was not 
significantly different during this time course between T cells treated with 0.5 nM or 50 nM 
estrogen concentrations indicating that ER can quickly translocate into the nucleus of male and 
female Ag-specific T cells upon ligand binding in physiological and super-physiological 
conditions.  
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Figure 8. T Cells from Male and Female Donors Were Transduced to Express the 
HCV1406 TCR to Study Ag-specific T Cell Function. A) Representative flow cytometry dot 
plots for one female and one male donor T cells before transduction showing T cell populations 
with very low CD34 expression, after transduction showing T cell populations with variable 
expression of CD34, and after CD34 magnetic bead sorting showing T cell populations over 
95% CD3
+
CD34
+
. B) Representative dot plots for CD4
+
 and CD8
+
 T cell subsets of TCR 
transduced and sorted T cells. C) CD4
+
 and CD8
+
 frequencies of TCR transduced and sorted T 
cells from 15 female and 15 male human healthy donors. Each donor plotted and SEM 
indicated. Analyzed using 2-way ANOVA with Tukey’s post-hoc. p<0.0001=****, 
p<0.001=***. 
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Figure 9. Female and Male HCV1406 TCR-transduced T Cells Express ER which 
Rapidly Translocates into the Nucleus upon 17-estradiol (E2) Stimulation. A) 
Representative western blot showing ER expression in the bulk  Ag-specific T cell population 
or sorted CD4
+
 or CD8
+
 T cells from one female and one male donor, and B) quantification of 
the relative expression of ER compared to Actin in bulk T cells, CD4
+
, and CD8
+
 sorted Ag-
specific T cells. TCR-transduced T cells were then treated with 0.5, or 50 nM E2 for 0, 2, 10, 
30, 60, or 120 minutes and ER expression was measured via western blot from protein extracts 
of C) the cytoplasm or D) the nucleus. ER expression compared to Actin cytoplasmic loading 
control or Lamin A/C nuclear loading control was quantified for Ag-specific T cells from E) 
female and F) male donors treated with 0.5 or 50 nM E2 and normalized to T cells treated with 
no estrogen (0 nM). Data represents n=4 donors, each donor plotted and the SEM indicated. 
Analyzed using 2-way ANOVA with Tukey’s post-hoc. p<0.001=***, p<0.01=**, p<0.05=*. 
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This western blot analysis was not able to be performed to test for ER nuclear 
translocation due to lack of reliable antibodies [379, 380]. ER was previously shown to be 
expressed in human CD4+ and CD8+ T cells even if it was expressed at significantly lower levels 
than ER  Knowing than ER and ER are highly homologous and have similar affinity 
for the estrogen ligand [382], it can be hypothesized that ER also translocates into the nucleus 
of Ag-specific T cells upon estrogen ligand binding. The roles of estrogen signaling through both 
ER and ER on male and female Ag-specific T cell function were studied throughout this 
dissertation. 
Estrogen Signaling through ER and ER Differentially Modulates T cell Cytokine 
Expression and Secretion  
 
 In order to determine the effect of physiological and super-physiological estrogen 
signaling through ER and ER on T cell function, Ag-specific T cells were activated with their 
HCV cognate antigen in the presence of estrogen and ER and ER selective inhibitors, and 
cytokine production was measured. The best system to assess HCV1406 TCR-transduced T cell 
activation and cytokine production would be to use HCV-expressing human liver cells or liver 
tumor cells, but these cells were not available for the experiments described. As an alternative, 
HLA-A2+ T2 cells were pulsed with the HCV NS3 antigen and used as Ag-specific T cell 
targets. T2 cells pulsed with a tyrosinase irrelevant peptide were used as controls. Male and 
female Ag-specific T cells were treated with no estrogen, physiological (0.5 nM), or super-
physiological (50 nM) estrogen in combination with 100 nM of an ER, or ER selective 
antagonists, or both inhibitors simultaneously for two hours. The ER and ER inhibitors used 
were MPP-dihydrochloride and PHTPP respectively. MPP-dihydrochloride is a selective, high 
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affinity silent antagonist of ER that displays greater than 200-fold selectivity of ER over 
ER (Ki values are 2.7 and 1800 nM at ER and ER respectively) [383, 384]. PHTPP is a 
selective ER antagonist that exhibits 36-fold selectivity for ER over ER (Ki values 139 nM 
and 2.22 M at ER and ER respectively) [384].  
Treated T cells were then co-cultured with pulsed T2 cells. Co-cultures were maintained 
for 5 hours in the presence of protein transport inhibitors to avoid secretion of markers, and then 
cells were stained and analyzed for expression of several T cell cytokines. The cytokines 
assessed included IFN, TNF, IL-2, IL-4, IL-17a, IL-22 and the lytic marker CD107a was 
assessed on the surface. These markers were chosen to represent the signature cytokines of the 
different effector and helper T cell subsets (effector CD8+, and CD4+ Th1, Th2, Th17, and Th22) 
excluding Tregs which do not mediate tumor cell killing or beneficial T helper responses for 
immunotherapy. CD8+ effector T cells commonly secrete high amounts of cytotoxic granules 
(Perforin and Granzymes), as well as IFN and TNF upon Ag stimulation and activation [385]. 
Effector CD4 Th1 cells can secrete IFN and TNF as well, while Th2 cells also secrete IL-4. 
IL-17 and IL-22 were chosen to represent the Th17 and Th22 subsets respectively. Upon 
activation, Ag-specific CD4+ and CD8+ T cells also produce IL-2 which promotes survival of 
both CD4+ and CD8+ T cells, and induces subset differentiation of CD4+ T cells 5 [385]. CD107a 
was chosen as an indicator of Granzyme B release [386]. Granzyme B is released by effector T 
cells upon antigen stimulation and activation; it is a serine protease which activates apoptosis 
once in the cytoplasm of the target cell [385, 386].  Gating strategy of these cytokines and 
CD107a for CD4+ and CD8+ HCV Ag-specific T cells is represented in Figure 10. Gates were 
selected for the CD3+CD34+ transduced T cell population and CD8+ and CD4+ T cell subsets 
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were analyzed separately. For each T cell subset each cytokine and the lytic marker CD107a 
were plotted against side scatter (SSC) and gated based on unstained controls. The dot plots in 
Figure 10 represent the data obtained for CD8+ Ag-specific T cells of one donor out of the 30 
analyzed. The majority of the donors showed highly increased frequency of CD8+ and CD4+ T 
cells expressing IFN, CD107a and TNF upon activation which correspond to a cytotoxic CD8+ 
or an effector Th1 CD4+ T cell response. Some donors also showed increased frequency of CD4+ 
T cells expressing IL-4 upon activation corresponding to Th2 responses. Surprisingly, CD8+ Ag-
specific T cells also expressed IL-4 upon antigen stimulation. IL-2 was expressed by low 
frequencies of activated T cells. Recombinant human IL-2 was added to Ag-specific T cell 
cultures during their expansion after transduction and this IL-2 supplementation could be the 
reason why activated Ag-specific T cells do not express high IL-2 upon antigen stimulation. 
Also, IL-4 is another gamma cytokine that was shown to enhance the survival of T cells and 
promote memory formation [387-389] indicating that T cells in these experiments could be 
partially surviving by IL-4 downstream signaling instead of IL-2. IL-22 and IL-17 were 
expressed in very low frequencies of T cells upon activation indicating low Th17 and Th22 
responses (Figure 10). ELISPOT or ELISA were used to measure effector and helper T cell 
cytokine secretion including TNF, IL-4, IFN, and Granzyme B from the co-cultures of 
estrogen treated Ag-specific T cells from male and female donors and T2 cells pulsed with the 
HCV antigen or the tyrosinase irrelevant peptide. While the expression or secretion of several of 
the cytokines tested were not directly affected by estrogen receptor signaling, the expression and 
secretion of three of the cytokines (TNF, IL-4, and IFN) and the lytic molecule Granzyme B 
were significantly changed upon estrogen stimulation and estrogen receptor signaling as 
described in the following sections. 
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Figure 10. Representative Gating Strategy to Measure Cytokine and CD107a Expression 
on HCV 1406 TCR-transduced T Cells. T cells were activated with T2 target cells pulsed with 
the HCV NS3 relevant antigen, T2(HCV), or an tyrosinase irrelevant peptide, T2(TYRO). 
Singlet cells were gated in the lymphocyte population, and then CD4
+
CD34
+
 transduced T cells 
were gated into CD4
+
 and CD8
+
 populations. Cytokines and CD107a were gated against side 
scatter (SSC) for both CD4
+
 and CD8
+
 transduced T cell populations. 
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Estrogen Signaling Through ER Enhances TNF Expression and Secretion in a Dose 
Dependent Manner 
 
The percent frequency of male and female transduced CD8+ T cells stimulated with the 
HCV cognate antigen expressing TNF was significantly increased upon super-physiological 
estrogen stimulation (Figure 11 B). The estrogen-mediated increase of TNF expression was 
abrogated when male and female CD8+ T cells were treated with estrogen in combination with an 
ER inhibitor, or when T cells were treated with estrogen in combination with ER and ER 
inhibitors simultaneously (Figure 11 B). On the other hand, the estrogen-mediated increase of 
TNF expression was not affected by blocking ER signaling with an R-specific inhibitor 
(Figure 11 B). A representative example of these flow cytometry results is depicted in Figure 11 
A. These data indicate that super-physiological estrogen enhances the expression of TNF in 
male and female CD8+ Ag-specific T cells through ER and not ER mediated signaling. The 
expression of TNF in CD4+ male and female Ag-specific T cells showed similar trends like the 
ones observed in CD8+ T cells but due to variability among donors resulting in larger error bars, 
significance was not achieved (Figure 11 C). There were no sex differences observed in the 
expression of TNF since similar frequencies of CD8+ and CD4+ male and female T cells 
expressed TNF upon activation (Figure 11 B, C). 
TNF secretion by male and female Ag-specific T cells stimulated with cognate or 
irrelevant antigen was measured via ELISA. Estrogen stimulation of male and female Ag-
specific T cells significantly increased TNF secretion at physiological (0.5 nM), and super-
physiological (50 nM) concentration (Figure 11 D, E).
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Figure 11. Estrogen Signaling through ER Enhances TNF Expression and Secretion in Female and Male Ag-specific T 
Cells upon Ag Stimulation. Male and female HCV Ag-specific T cells were treated with no estrogen, physiological (0.5 nM), or 
super-physiological (50 nM) estrogen in combination with 100 nM of an ER inhibitor (MPP-dihydrochloride), an ER inhibitor 
(PHTPP), or both inhibitors simultaneously for 2 hours prior to activation with T2 cells pulsed with HCV cognate antigen or a 
tyrosinase irrelevant peptide. After 5 hour activation in the presence of protein transport inhibitors, T cells were analyzed for TNF 
expression via flow cytometry intracellular staining. A) Representative dot plots for the expression of TNF in treated T cells from 
one donor. B) & C) The percent frequency of female and male activated B) CD8
+
 and C) CD4
+
 Ag-specific T cells expressing TNF 
after being treated with 0, 0.5, or 50 nM estrogen in combination with ER inhibitors.  D) & E) In order to measure TNF secretion, 
the supernatant of 18 hour co-cultures containing equal number of estrogen treated T cells and pulsed T2 target cells were tested via 
anti-human TNF ELISA. Data represents n=15 or n=4 donors, each donor plotted and the SEM indicated. Analyzed using 2-way 
ANOVA with Tukey’s post-hoc. p<0.01=**, p<0.05=* comparing the different estrogen receptor treatment groups. p<0.0001=####, 
p<0.001=###, p<0.01=##, p<0.05=# comparing estrogen treatments (0, 0.5, 50 nM) within each group. 
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 Overall these data indicate that estrogen stimulation can enhance the secretion of TNF, 
and estrogen signaling through ER can enhance the expression of TNF on CD8+ male and 
female Ag-specific T cells. 
Estrogen Signaling Through ER Modulates the Overall Expression of IL-4, and Further 
Enhances its Expression and Secretion in a Dose Dependent Manner 
 
The percent frequency of male and female transduced CD8+ T cells stimulated with their 
HCV cognate antigen expressing IL-4 was significantly increased upon estrogen stimulation at 
physiological and super-physiological concentrations (Figure 12 B). The estrogen-mediated 
increase in IL-4 expression was completely abrogated when male and female CD8+ T cells were 
treated with estrogen in combination with an ER inhibitor or with ER and ER inhibitors 
simultaneously (Figure 12 B). Not only the estrogen-mediated increase on IL-4 expression was 
abrogated but IL-4 expression was decreased to the levels observed in CD8+ T cells stimulated 
with the tyrosinase irrelevant antigen (Figure 12 B). On the other hand, blocking ER during 
estrogen stimulation showed no effect on the estrogen-mediated increase, or the overall IL-4 
expression of male and female CD8+ Ag-specific T cells (Figure 12 B). Similar results were 
obtained regarding the expression of IL-4 on estrogen stimulated CD4+ male and female Ag-
specific T cells. Estrogen stimulation significantly increased the frequency of CD4+ T cells 
expressing IL-4 upon cognate antigen activation, and the blockade of ER signaling during 
estrogen stimulation decreased IL-4 to the levels of Ag-specific T cells activated with tyrosinase 
(irrelevant peptide) (Figure 12 C). Blockade of ER signaling during estrogen stimulation had no 
effect on the estrogen-mediated increase of IL-4 expression (Figure 12 C). There were no sex 
differences observed in the expression of IL-4 since similar frequencies of CD8+ and CD4+ male 
and female T cells expressed IL-4 upon activation (Figure 12 B, C). These data indicate that 
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estrogen signaling through ER and not ER modulates the overall expression, and the estrogen-
mediated enhancement of expression of IL-4 in male and female Ag-specific T cells. 
IL-4 secretion by male and female Ag-specific T cells stimulated with cognate or 
irrelevant antigen was measured via ELISA. Estrogen stimulation at physiological (0.5 nM), and 
super-physiological (50 nM) concentrations significantly increased IL-4 secretion of male and 
female Ag-specific T cells (Figure 12 D, E). Interestingly, estrogen stimulation increased the 
secretion of IL-4 on male T cells activated with tyrosinase irrelevant antigen (Figure 12 E). This 
indicates that estrogen stimulation can directly upregulate IL-4 secretion independently from 
TCR stimulation and T cell activation. These results demonstrate that estrogen signaling through 
ER and not ER modulates the overall expression of IL-4, and estrogen stimulation at 
physiological and super-physiological concentrations enhances IL-4 expression and secretion on 
male and female activated Ag-specific T cells.  
Ideally, in order to conclude that Estrogen signaling through ER directly enhances 
expression and secretion of TNF and IL-4, a different set of experiments need to be performed 
in which human Ag-specific T cells are treated with an ER agonist instead of estrogen. The 
ER selective agonist 4,4',4''-(4-Propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT) which shows 
a 410-fold selectivity for ER over ER can be used [368, 369]. If expression and/or secretion of 
TNF and IL-4 are enhanced in male and female Ag-specific T cells treated with PPT after Ag 
stimulation to levels similar to those treated with estrogen, then ER alone may enhance the 
expression/secretion of these cytokines. This can be fully concluded if the PPT-mediated 
enhancement on the cytokine expression/production is abrogated in T cells treated with PPT and 
MPP-dihydrochloride (ER antagonist) simultaneously. 
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Figure 12. Estrogen Signaling through ER Modulates Overall IL-4 Expression and Enhances IL-4 Secretion on Male and 
Female Ag-specific T Cells upon Ag Stimulation. Male and female HCV Ag-specific T cells were treated with no estrogen, 
physiological (0.5 nM), or super-physiological (50 nM) estrogen in combination with 100 nM of an ER inhibitor (MPP-
dihydrochloride), an ER inhibitor (PHTPP), or both inhibitors simultaneously for 2 hours prior to activation with T2 cells pulsed 
with HCV cognate antigen or a tyrosinase irrelevant peptide. After 5 hour activation in the presence of protein transport inhibitors, T 
cells were analyzed for IL-4 expression via flow cytometry intracellular staining. A) Representative flow cytometry dot plots for the 
expression of IL-4 in treated T cells from one donor out of the 30 tested. B) & C) The percent frequency of female and male activated 
B) CD8
+
 and C) CD4
+
 Ag-specific T cells expressing IL-4 after being treated with 0, 0.5, or 50 nM estrogen in combination with ER 
inhibitors.  D) & E) In order to measure IL-4 secretion, the supernatant of 18 hour co-cultures containing equal number of estrogen 
treated T cells and pulsed T2 target cells were tested via anti-human IL-4 ELISA. Data represents n=15 or n=4 donors, each donor 
plotted and the SEM indicated. Analyzed using 2-way ANOVA with Tukey’s post-hoc. P<0.001=***, p<0.01=**, p<0.05=* 
Comparing the different estrogen receptor treatment groups. p<0.0001=####, p<0.001=###, p<0.01=##, p<0.05=# comparing 
estrogen treatments (0, 0.5, 50 nM) within each group. 
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On the other hand, if treating Ag-specific T cells with PPT does not enhance cytokine 
expression upon Ag-stimulation, then estrogen signaling through other receptor is mediating this 
effect. Inhibition of ER showed no effect on the estrogen-mediated enhancement of these 
cytokines’ expression indicating that ER signaling is not required for their expression. Estrogen 
signaling through GPER could be enhancing T cell cytokine expression in response to Ag. To 
investigate that possibility, male and female Ag-specific T cells need to be treated with estrogen 
in combination of a GPER antagonist. If the expression of TNF and IL-4 is decreased in T cells 
treated with estrogen in combination of a GPER antagonist compared to estrogen treated cells 
then, estrogen is enhancing TNF and IL-4 expression through GPER. GPER signaling was 
shown to upregulate expression of some cytokines such as IL-10 and IL-1 [390, 391] so there is 
a possibility that GPER signaling controls expression of other cytokines such as TNF and IL-4. 
Unfortunately, these experiments could not be performed, but these results in combination with 
the ones reported in this chapter, would indicate that estrogen signaling through ER and GPER 
enhance Ag-specific T cell cytokine expression and secretion. 
Estrogen Stimulation Enhances Ag-specific T cell IFN and Granzyme B Secretion 
 
Even if some trends were observed, the frequency of male and female CD4+ and CD8+ 
Ag-specific T cells expressing IFN was not significantly changed by estrogen stimulation and 
estrogen receptor signaling during activation as measured by flow cytometry (Figure 13 A, B). 
The trends observed indicated that estrogen stimulation increased IFN expression possibly 
through ER and not ER. Although IFN expression was not significantly affected by estrogen 
stimulation, there was a significant increase on IFN secretion upon super-physiological estrogen 
treatment in female and male CD8+ and CD4+ Ag-specific T cells activated with the HCV 
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cognate antigen as measured by ELISPOT (Figure 13 C, D, E). Physiological estrogen 
significantly increased the secretion of IFN in activated male CD4+ Ag-specific T cells (Figure 
13 D).  Interestingly, the secretion of IFN was overall higher in CD8+ and CD4+ Ag-specific T 
cells from female donors compared to male donors (Figure 13 C, D, E). While female Ag-
specific T cells showed an average of 600 to 800 IFN spots at baseline estrogen, male T cells 
showed an average of 300 IFN spots at baseline estrogen (Figure 13 C, D). Overall these data 
demonstrate that estrogen significantly enhances the secretion of IFN on male and female CD4+ 
and CD8+ T cells upon antigen stimulation even if female T cells secrete more IFN than male T 
cells in an estrogen-independent manner.  
The secretion of Granzyme B was also measured via ELISPOT on estrogen treated male 
and female activated Ag-specific T cells. There was a significant increase on Granzyme B 
secretion on male and female CD8+ Ag-specific T cells treated with super-physiological estrogen 
(Figure 14 A, B, C). The secretion of Granzyme B was also significantly increased by super-
physiological estrogen treatment on female CD4+ Ag-specific T cells, and a trend was observed 
for male CD4+ T cells even if significance was not achieved (Figure 14 A). The secretion of 
Granzyme B by female CD4+ T cells was higher than by male CD4+ T cells at baseline estrogen 
(around 100 average Granzyme B spots compared to 50) and it was increased significantly upon 
estrogen treatment to around 300 Granzyme B spots compared to only around 100 spots in male 
CD4+ T cells. Overall these results indicate that estrogen signaling enhances the secretion of 
Granzyme B in female and male CD8+ T cells, and female CD4+ T cells which secrete more 
Granzyme B than male T cells in an estrogen-independent manner
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Figure 13. Estrogen Signaling Enhances Male and Female Ag-specific T Cell IFN Secretion upon Ag Stimulation. Male and 
female HCV Ag-specific T cells were treated with no estrogen, physiological (0.5 nM), or super-physiological (50 nM) estrogen in 
combination with 100 nM of an ER inhibitor (MPP-dihydrochloride), an ER inhibitor (PHTPP), or both inhibitors simultaneously 
for 2 hours prior to activation with T2 cells pulsed with HCV cognate antigen or a tyrosinase irrelevant peptide. After 5 hour activation 
in the presence of protein transport inhibitors, T cells were analyzed for IFN expression via flow cytometry intracellular staining. 
A) & B) The percent frequency of female and male activated A) CD8
+
 and B) CD4
+
 Ag-specific T cells expressing IFN after being 
treated with 0, 0.5, or 50 nM estrogen in combination with ER inhibitors. In order to measure IFN secretion, 18 hour co-cultures 
containing equal number of estrogen treated C) female or D) male sorted CD8
+
 or CD4
+ 
T cells and pulsed T2 target cells were tested 
via ELISPOT. E) Representative ELISPOT plate image from co-cultures of CD8
+
 or CD4
+
 T cells from one female and male donor 
out of the 4 donors tested. Data represents n=15 or n=4 donors, each donor plotted and the SEM indicated. Analyzed using 2-way 
ANOVA with Tukey’s post-hoc. P<0.0001=****, p<0.01=**, p<0.05=*. 
  
91 
 
 
 
 
 
 
Figure 14. Estrogen Signaling Enhances Granzyme B Secretion in Female and Male 
CD8
+
 Ag-specific T Cells, and Female CD4
+
 Ag-specific T Cells upon Ag Stimulation. 
In order to measure Granzyme B secretion, 18 hour co-cultures containing equal number 
of estrogen treated A) female or B) male CD8
+
 or CD4
+ 
T cells and pulsed T2 target cells 
were tested via anti-human Granzyme B ELISPOT. C) Representative ELISPOT plate 
from co-cultures of CD8
+
 or CD4
+
 T cells from one female and male donor out of the 4 
donors tested. Data represents n=4 donors, each donor plotted and the SEM. Analyzed 
using 2-way ANOVA with Tukey’s post-hoc. P<0.0001=****, p<0.01=**, p<0.05=*. 
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Chapter Discussion 
 
 This chapter of the dissertation was aimed to determine the impact of sex and estrogen 
signaling in regulating Ag-specific T cell function and cytokine production. For the first time, it 
was demonstrated that estrogen signaling and sex of the donor regulate the expression and 
secretion of effector, helper, and lytic T cell cytokines such as TNF, IL-4, IFN, and Granzyme 
B in human Ag-specific T cells.  
Herein it was shown that male and female Ag-specific T cells express equivalent levels of 
the canonical estrogen receptor, ER. ER is well known to bind the estrogen ligand in the 
cytoplasm of the cell and then to translocate into the nucleus where it can regulate target gene 
expression by binding to EREs on gene promoters or by binding other transcription factor 
complexes. ER rapid nucleus translocation upon ligand binding was observed when both male 
and female Ag-specific T cells were stimulated with physiological (0.5 nM) or super-
physiological (50 nM) estrogen concentrations. This rapid translocation was transient since 
reduced nuclear ER expression, and increased cytoplasmic ER expression was observed 
overtime after estrogen treatment. This indicates that both male and female Ag-specific T cells 
can signal through ER in response to two different estrogen ligand concentrations. It is notable 
that estrogen can also bind to ER with same affinity as ER  which elicits different 
downstream effects and modulates different gene expression than ER. Due to insufficient 
antibody validation [379, 380], the nuclear translocation of ER upon estrogen binding in Ag-
specific T cells could not be tested at this time. Knowing that human T cells express ER , 
ER signaling effects on T cell function cannot be dismissed and are further studied in the 
chapters of this dissertation. Estrogen can also bind to the membrane bound GPER which 
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mediates rapid non-genomic responses such as the activation of the MAPK pathway [177]. The 
changes in cytokine secretion and expression observed in Ag-specific T cells could be the work 
of not only the canonical ERs but also be influenced by GPER. This needs to be further studied 
to better understand how to improve the beneficial signaling cascades in these T cells that will 
promote stronger antitumor responses. 
To determine the functional consequences of ER expression in T cells, cytokine 
expression and secretion was measured from antigen stimulated CD8+ and CD4+ T cells. 
Estrogen signaling through ER was shown to enhance the expression of TNF in male and 
female CD8+ Ag-specific T cells, and estrogen treatment also enhanced the secretion of TNF in 
male and female Ag-specific T cells in a concentration dependent manner. The promoter of 
TNF contains an ERE at position -1044 bp [392] indicating that the enhancement of TNF 
expression and secretion in male and female Ag-specific T cells could be mediated by canonical 
ligand-dependent genomic ER signaling (Table 2).  
Estrogen signaling through ER was shown to regulate the overall expression of IL-4 in 
male and female CD8+ and CD4+ Ag-specific T cells. The estrogen-mediated enhancement of IL-
4 expression and the overall IL-4 expression were abrogated when T cells were treated with 
estrogen in combination with an ER inhibitor, suggesting that estrogen regulates IL-4 
expression in a classical ligand-dependent genomic manner. Surprisingly, an ERE was not found 
on the promoter of IL-4 which could indicate ERE-independent ER genomic signaling. It was 
demonstrated that a significant correlation exists between the expression of ER and GATA3 in 
breast cancer cell lines and mouse T cells, and an ERE was found at position -1502 bp on the 
promoter of GATA3 (Table 2) [393-395]. GATA3 is an essential Th2 transcription factor that 
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not only drives differentiation of TCR stimulated CD4+ T cells into the Th2 subset but also 
directly induces IL-4 gene expression [396, 397]. In fact, T cells from GATA3 KO mice fail to 
develop appropriate Th2 cytokine expression including IL-4 [398, 399]. Overall this indicates 
that ER signaling regulates IL-4 expression and secretion in Ag-specific T cells through 
mechanisms that are ERE-independent possibly including the upregulation of expression of 
GATA3.  
Estrogen signaling was shown to enhance the secretion of IFN in female and male Ag-
specific T cells. IFN contains an ERE at position -8342 bp of its promoter which indicates that 
estrogen signaling through ER can enhance IFN secretion through the ligand-bound ERE-
dependent canonical pathway. In addition, an ERE was also found on the promoter of T-BET at 
position -1676 bp (Table 2). T-BET is a transcription factor known to mediate Th1 T cell 
differentiation and induce IFN expression [400, 401]. Estrogen signaling enhancement of T-
BET expression could result in subsequent IFN expression and secretion enhancement in 
activated T cells. Estrogen was also shown to enhance the secretion of Granzyme B in female 
and male Ag-specific T cells. While Granzyme B does not contain an ERE in its promoter, 
proteinase inhibitor 9 (PI-9), which is a Granzyme B inhibitor, contains one ERE at position -200 
bp of its promoter [402, 403]. This indicates that estrogen could be upregulating Granzyme B 
secretion by negatively regulating transcription of PI-9 through ER ligand-bound ERE-
dependent genomic pathway. 
Estrogen treatment increases the expression and/or secretion of TNF, IL-4, IFN, and 
Granzyme B in human Ag-specific T cells. TNF, IFN, and Granzyme B are cytokines 
commonly secreted by Type I cytotoxic CD8+ T cells and effector Th1 CD4+ T cells in response 
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to antigen stimulation. On the other hand, IL-4 is secreted by Type II CD8+ T cells and it is the 
prototypic Th2 CD4+ T cell cytokine required for Th2 T cell differentiation. The Th1 and Th2 
CD4+ T cell subset differentiation pathways can downregulate each other and are believed to be 
mutually exclusive [404, 405]. Estrogen signaling through ER can upregulate the expression 
and secretion of both Type I/Th1 and Type II/Th2 cytokines in male and female Ag-specific T 
cells. This could indicate that estrogen modulates the balance of the CD8+ Type I and Type II, 
and the CD4+ Th1 and Th2 T cell responses. Most of the effects on these cytokines were 
observed when T cells were stimulated with super-physiological estrogen (50 nM) indicating that 
the estrogen-mediated Th1/Th2 T cell response balance could happen in locally elevated 
estrogen environments including the HCC TME. In order to test if ER signaling can modulate 
the balance between Th1 and Th2 T cell subset differentiation, first, estrogen receptor binding to 
the EREs present on the GATA3 and T-BET gene promoters needs to be confirmed via 
chromatin immunoprecipitation (ChIP); and, second, enhancement of T-BET and GATA3 
expression by ER signaling needs to be confirmed by real time polymerase chain reaction (RT-
PCR) or by transducing T cells with expression vectors containing the promoters of T-BET and 
GATA3. 
Apart from their roles in Th1 and Th2 T cell differentiation, the cytokines enhanced by 
estrogen in Ag-specific T cells have important anti-tumor roles. IFN is cytotoxic to certain 
malignant cells, and it enhances MHC class I expression [406]. Granzyme B directly lyses 
malignant cells, and TNF promotes T cell activation, co-stimulation, and promotes certain 
cancer cell death [406]. IL-4 promotes T cell and B cell survival, induces Ig class switch to IgE 
and IgG in B cells, drives long-term development of CD8+ T cell memory, and in combination 
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with TGF it drives Th9 T cell differentiation which are T cells that augment anti-tumor 
responses in ACT models [387-389, 407, 408]. Overall these data indicate for the first time, that 
estrogen signaling through ER enhances expression and secretion of cytokines that enhance the 
T cell anti-tumor immune response and estrogen signaling is an important factor to consider 
when designing ACT immunotherapies for estrogen-sensitive and estrogen-producing 
malignancies like HCC.
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Table 2. Estrogen Response Elements Found in the Promoters of TNF, GATA3, IFN, TBX21(T-BET), and IP-9 Genes. Table 
shows the human (Hs) gene name, the chromosome location, the ERE sequence and its position in respect to the gene starting site. 
EREs were found in the EREfinder database described by Bourdeade et al. Mol Endocrinol. 2004.  
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CHAPTER IV 
ESTROGEN SIGNALING THROUGH ER AND ER DIFFRENTIALLY IMPACTS 
HUMAN MALE AND FEMALE AG-SPECIFIC T CELL POLYFUNCTIONALITY 
 
Introduction and Rationale 
 The results presented in the previous chapter demonstrated that estrogen signaling 
enhances the expression and secretion of T cell cytokines typically classified into the CD4+ Th1 
or Th2 subsets, or into the CD8+ Type I or Type II subsets. Despite their differences, both Type 
I/Th1 and Type II/Th2 T cell responses were shown to enhance anti-tumor immunity by 
enhancing CTL expansion and survival, and by killing tumor cells directly [409, 410].  Most 
importantly, ACT immunotherapy was shown to be most successful when CD8+ T cells were 
delivered in combination with a mixture of CD4+ Th1 cells and Th2 cells [82, 411].  More 
recently, other T cell subsets were correlated with enhanced T cell anti-tumor immune responses 
such as the IL-9 producing Th9 CD4+ T cells [412, 413], and the IL-17a producing Th17 CD4+ T 
cells [83]. Even if the anti-tumor or tumor-promoting role of IL-22 producing Th22 CD4+ T cells 
remains controversial, Th22 infiltration was correlated with tumor rejection in colorectal cancer 
[414]. The presence of multiple T cell subsets secreting varying combinations of cytokines 
indicates that the evaluation of a single cytokine at one time does not accurately characterize the 
role of estrogen signaling on the overall T cell anti-tumor function. In fact, a previous study 
demonstrated that analysis of expression of only one effector T cell cytokine, such as IFN in 
advanced stage cancer patients was not correlated with survival advantage, but once other
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cytokines, such as IL-2, were analyzed simultaneously via flow cytometry with IFN there was 
an association with clinical outcome [415]. In addition to the heterogeneity of their subset 
phenotype, T cells show differences in their functional profile or the mixture of cytokines that 
they secrete upon TCR ligation. It was found that T cells can not only be subdivided based on 
prototypic cytokine and transcription factor expression, but also based on the distinctive patterns 
of cytokines secreted after stimulation [416]. Activated T cells can be monofunctional if they 
only express one cytokine, or polyfunctional if they expressed over two different cytokines upon 
TCR stimulation.  
T cell polyfunctionality is described as the ability of one T cell to deploy a broad 
spectrum of immune programs upon antigen stimulation. These immune programs can be 
cytokines or lytic markers with polyfunctional T cells being able to, for example, secrete IFN, 
IL-2 and degranulate producing Granzyme B simultaneously. Polyfunctional CD8+ and CD4+ T 
cells were shown to be able to generate superior anti-tumor immune responses [417-420], and to 
clear viral infections better than monofunctional T cells [421, 422]. In the setting of 
immunotherapy, several studies have found enhanced numbers of tumor Ag-specific 
polyfunctional T cells in patients responding favorably to ACT, and checkpoint blockade using 
anti-CTLA-4 [423-427]. A study by Rossi et al. using CD19-targeted CAR T cells to treat acute 
lymphoblastic leukemia demonstrated that CAR-T cell polyfunctionality was correlated with 
patient clinical outcome [428]. Even if only approximately 20% of adoptively transferred CAR T 
cells were polyfunctional (able to produce >2 out of 32 different cytokines and chemokines 
simultaneously), this low frequency of polyfunctional cells was still able to produce superior 
anti-tumor immune responses compared to monofunctional T cells. Polyfunctional CD8+ CAR-T 
cells in this study produced combinations of IFN, macrophage inflammatory protein-1 (MIP-
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1) (or CCL3), IL-8, and Granzyme B simultaneously while CD4+ CAR-T cells expressed 
combinations of IFN, MIP-1, IL-8, IL-2, IL-17a, and IL-5 simultaneously [428]. T cell 
polyfunctionality was also correlated with CD8+ T cell memory formation. Memory CD8+ T 
cells were shown to be highly polyfunctional expressing cytokine combinations such as IFN+IL-
2+TNF+MIP-1+ (or CCL4), IFN+TNF+IL-2+, and IFN+IL-2+CD107a+ during antigen 
stimulation [429-432]. This indicates that the use of polyfunctional T cells could increase the 
efficacy of ACT immunotherapy by generating superior anti-tumor responses and subsequent T 
cell memory development against tumor antigens.  
Since estrogen signaling was able to enhance the secretion of several effector Th1 and 
helper Th2 cytokines in female and male Ag-specific T cells, it was hypothesized that estrogen 
signaling enhances the polyfunctionality or the ability of Ag-specific T cells to express several 
cytokines simultaneously upon antigen stimulation. In order to study the effect of estrogen 
receptor signaling on Ag-specific T cell polyfunctionality, male and female Ag-specific T cells 
were treated with physiological (0.5 nM) or super-physiological (50 nM) estrogen alone or in 
combination with an ER inhibitor (100 nM), an ER inhibitor (100 nM), or both inhibitors 
simultaneously prior to activation with T2 cells pulsed with the HCV cognate antigen or a 
tyrosinase irrelevant peptide. After 5 hour activation in the presence of protein transport 
inhibitors, multi-dimensional flow cytometry was used to measure expression of IFN, TNF, 
IL-2, IL-4, IL-17a, IL-22 and the lytic marker CD107a. This multi-functional evaluation was 
designed to reflect the changes in mono or polyfunctional phenotypes of T cell populations. The 
analysis of these seven functional markers after gating on CD3+CD34+ transduced T cells 
generated 128 possible combinations (2n, n=7, 27=128) of markers expressed by CD8+ or CD4+ T 
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cells; from monofunctional cells that only express one marker, to highly polyfunctional cells that 
expressed all 7 markers simultaneously. Since they were a total number of 12 treatments, 
including 3 estrogen conditions (0, 0.5, and 50 nM) and 4 ER inhibitor conditions (no inhibitor, 
ER inhibitor, ER inhibitor, and both inhibitors), an exceptionally complex dataset was 
generated that was difficult to analyze with basic flow cytometry software (FlowJoX).  
Analysis of polyfunctionality data using FlowJo is very limited since it restricts the 
visualization of data to one or two parameters at a time. In this case, visualization and analysis of 
7 markers requires 21 pairwise dot plots for a single Ag-stimulation condition per estrogen 
treatment. Figure 15 shows a representative example of pairwise dot plots in untreated female 
CD8+ HCV Ag-specific T cells stimulated with HCV (Figure 15 A) or tyrosinase (Figure 15 B) 
pulsed T2 target cells. Even if these comparisons are very limited, some simple observations can 
be deduced by observing the percent frequency of T cells that express two markers 
simultaneously. The highest frequency of bifunctional CD8+ cells expressed the IFN+TNF+ 
combination but IFN+ cells also expressed CD107a, or IL-4 simultaneously. Similarly, TNF+ 
cells also expressed IL-4, and some CD107a or IL-2 simultaneously. This was surprising since 
CD8+ T cells could express cytokines like IFN and TNF which are believed to be restricted to 
the type I (Th1) phenotype, simultaneously with the type II (Th2) cytokine IL-4. These data 
contradicts what is normally accepted in the field of T cell immunology concerning type I and II 
T cell populations and function. This indicates that evaluation of several functional markers and 
generation of polyfunctional T cell profiles can shine light on the study of new patterns of T cell 
function benefigureFficial for generating superior anti-tumor immune responses. 
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Figure 15. Pairwise Comparisons of Each Functional Marker Expressed by Activated CD8
+
 HCV Ag-specific T Cells. HCV 
Ag-specific T cells from one female donor were co-cultured with T2 cells pulsed with the A) HCV cognate antigen or B) a tyrosinase 
irrelevant peptide for 5 hours in the presence of protein transport inhibitors. Cells were then stained for flow cytometric analysis of 
CD3, CD34, CD8, and CD4 and functional markers CD107a, IFN, TNF, IL-4, IL-2, Il-17a, and IL-22. Gating and analysis was 
performed using FlowJoX. Uni-dimensional histograms represent the expression of each functional marker, and each dot plot 
represents pairwise comparisons between each of the 7 functional markers expressed by CD8
+
 Ag-specific T cells 
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In order to generate the frequency of T cells expressing each of the 128 different cytokine 
combinations, higher resolution multi-dimensional analysis was performed within FlowJo using 
Boolean combinatorial gates for all 7 markers. The frequencies of populations were added into 
categories comprising cells expressing 1 through 7 markers simultaneously. Percent frequencies 
of T cells expressing >2 makers simultaneously were considered polyfunctional. By grouping 
polyfunctional phenotypes into categories according to the number of markers expressed, clear 
comparisons between female and male T cells and different estrogen and inhibitor treatments can 
be made. Statistical analysis of these data can be performed using a Multivariate Analysis of 
Variance (MANOVA) which is a multivariate ANOVA with two or more continuous response 
variables. MANOVA allows analyzing CD8+ and CD4+ T cells within one sex under one 
treatment condition (either estrogen or estrogen + ER inhibitor) and compares two or more 
continuous response variables, in this case 7 different categories, or groups of T cells expressing 
1 through 7 markers simultaneously. Post-hoc pairwise comparisons between each index 
estrogen treatment (50 & 0.5) and the reference estrogen treatment (0) were conducted within 
each estrogen inhibitor treatment.  
Despite these meaningful interpretations, analysis in FlowJo lacks the ability to 
graphically represent individual polyfunctional phenotypes or display how estrogen signaling 
impacts their relative abundance. In order to compare the levels of expression of all 128 marker 
combinations, Boolean gating with FlowJo was followed by analysis in Pestle and SPICE data 
processing software packages which allow to adequately visualize individual and polyfunctional 
populations. Using the data generated from Pestle and SPICE, heat maps were created containing 
the percent frequency of cells expressing each combination of markers. Results from these 
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analyses are discussed in the following sections. Statistical analysis of the percent expression of 
each cytokine combination can be performed using MANOVA. MANOVA is used on CD8+ and 
CD4+ T cells within one sex under one treatment condition (either estrogen or estrogen + ER 
inhibitor) and compares two or more continuous response variables, in this case all the different 
(up to 83) combinations of cytokines expressed by Ag stimulated T cells. Post-hoc pairwise 
comparisons between each index estrogen treatment (50 & 0.5) and the reference estrogen 
treatment (0) were conducted within each estrogen inhibitor treatment stratum. 
Results 
 
CD8+ Ag-specific female T cells are inherently more polyfunctional than male T cells 
 
 It was observed that non-estrogen treated CD8+ and CD4+ Ag-specific T cells contained 
similar percentages of monofunctional and polyfunctional cells when stimulated with their HCV 
cognate antigen. Both populations exhibited around 30 to 40% of monofunctional and 
bifunctional cells, and around 15 to 20% of trifunctional cells. Less than 10% of CD8+ and CD4+ 
Ag-specific T cells expressed more than 4 markers simultaneously and percentages for those 
cells expressing 6 or 7 markers were so low that are not represented on the results (Figure 16). 
While there were no sex-differences on the polyfunctionality of CD4+ Ag-specific T cells when 
marker combinations were analyzed as added groups (Figure 16 B), significantly higher 
percentage of male CD8+ Ag-specific T cells were monofunctional (only expressed 1 marker) 
compared to female CD8+ T cells (Figure 16 A). A trend was observed for higher percentages of 
female CD8+ T cells expressing 3 markers simultaneously compared to male CD8+ T cells. This 
indicates that independently from estrogen signaling, female CD8+ Ag-specific T cells are 
inherently more polyfunctional than male CD8+ T cells. While these results were shown to be 
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statistically significant, there was a high variability between male donors in the percentage of 
CD8+ T cells expressing only one marker. Most of the male donors had frequencies of 
monofunctional cells similar to those of female donors, but some of the male donors showed 
very high percentage of monofunctional cells.  This variability is not surprising due to genetic 
and environmental differences between humans, and it indicates that there are differences in 
polyfunctionality between same sex donors. This could be caused by differences on age (some of 
the donors used for the experiment were of unknown age), disease background, circulating 
hormone levels, and differences on T cell activation.  
The female and male CD8+ and CD4+ Ag-specific polyfunctional responses were very 
diverse expressing a great amount of marker combinations that were polyfunctional, 
bifunctional, and monofunctional. CD8+ T cells from females and males expressed 71 different 
functional marker combinations in response to antigen stimulation (Figure 17 A). While a lot of 
these marker combinations were expressed by a very low frequency of cells, some combinations 
including TNF+ (~10-15%), IFN+TNF+ (~25-30%), IFN+ (~25%), CD107a+IFN+TNF+ 
(~7%), IFN+ IL-2+TNF+ (~5%), and IFN+IL-4+TNF+ (~4%) were expressed at higher levels. 
The only combination that shows significant differences in expression between female and male 
T cells was TNF alone which was expressed by a significantly higher frequency of male T cells 
compared to female T cells (Figure 17 A). Other combinations that showed trending differences 
in expression included CD107a+IFN+TNF+, CD107a+IFN+, IFN+IL-2+TNF+, IFN+IL-
4+TNF+, and IFN+TNF+ which were all expressed by higher frequencies on female T cells 
compared to male T cells. Taking these data together with the ones obtained in Figure 16 A, it 
can be concluded that female CD8+ Ag-specific T cells are inherently more polyfunctional upon 
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antigen stimulation than male CD8+ Ag-specific T cells. In addition, higher percentages of 
female CD8+ polyfunctional cells expressed marker combinations that are detrimental to tumors, 
such as the ones containing cytotoxic cytokines IFN TNF, and the marker CD107a, as well as 
marker combinations that include cytokines known to enhance T cell survival like IL-2 and IL-4.  
 Male and female CD4+ Ag-specific T cells expressed up to 83 different functional marker 
combinations upon antigen stimulation (Figure 17 B). As observed in the CD8+ T cell subset, 
most of the combinations were expressed by very low frequency of cells with the exception of 
the highest expressed functional combinations being IFN+TNF+ (~30%), IFN+  (~22%), 
TNF+  (~15%), IFN+ IL-4+TNF+ (~), and IFN+IL-2+TNF+ (~) (Figure 17 B). The 
only combination that showed a significant difference in expression between female and male 
CD4+ T cells was IFN alone which was expressed by a significantly higher frequency of female 
T cells compared to male T cells (Figure 17 B). Other trending differences in expression were 
observed including higher frequencies of female CD4+ T cells expressing 
IFN+TNF+ and IFN+IL-4+TNF+ compared to male CD4+ T cells. While there may be 
differences in expression on some polyfunctional phenotypes between female and male CD4+ T 
cells, significance was not achieved and taken these results with the ones observed in Figure 16 
B it can be concluded that there are no sex-differences in male and female CD4+ T cell 
polyfunctionality. 
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Figure 16. Female CD8
+
 Ag-specific T Cells are More Polyfunctional than Male 
Counterparts upon Ag Stimulation. Male and female HCV Ag-specific T cells from 15 
female and 15 male donors were co-cultured for 5 hours with T2 cells pulsed with HCV cognate 
antigen or a tyrosinase irrelevant peptide in the presence of protein transport inhibitors. Cells 
were then stained for flow cytometric analysis of CD3, CD34, CD8, and CD4 and functional 
markers CD107a, IFN, TNF, IL-4, IL-2, IL-17a, and IL-22. Using Boolean gates in FlowJoX, 
the frequency of CD8
+
 and CD4
+
 T cells expressing each combination of these 7 markers was 
generated and added into 7 functional categories. The frequencies of A) CD8
+
 , and B) CD4
+
 
female and male Ag-specific T cells expressing one through seven markers simultaneously was 
plotted. The frequencies of CD8
+
 and CD4
+
 T cells stimulated with the tyrosinase irrelevant 
peptide were used for background subtraction. Data for T cells expressing 6 or 7 markers 
simultaneously is not shown since the percent frequency was very low (<1%). Data represents 
n=15 donors, each donor plotted and SEM indicated. Data was analyzed using MANOVA and 
Tukey’s post-hoc. p<0.05=*. 
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Figure 17. Significantly Higher Percentage of Male CD8
+
 Ag-specific T Cells Express TNF in Combination with no Other 
Marker Compared to Female CD8
+
 T Cells. Significantly Higher Percentage of Female CD4
+
 Ag-specific T Cells Express 
IFN in Combination with no Other Marker Compared to Male CD4
+
 T Cells. Male and female HCV Ag-specific T cells from 
15 female and 15 male donors were co-cultured for 5 hours with T2 cells pulsed with HCV cognate antigen or a tyrosinase irrelevant 
peptide in the presence of protein transport inhibitors. Cells were then stained for flow cytometric analysis of CD3, CD34, CD8, and 
CD4 and functional markers CD107a, IFN, TNF, IL-4, IL-2, IL-17a, and IL-22. Using Boolean gates in FlowJoX, and the software 
SPICE the frequency of CD8
+
 and CD4
+
 T cells expressing each combination of these 7 markers was generated. The frequencies of 
A) CD8
+
 and B) CD4
+
 female and male Ag-specific T cells expressing each of the 128 possible markers combinations was plotted. 
Data represents the mean of n=15 donors. Data was analyzed using MANOVA and Tukey’s post-hoc. p<0.001=***, p<0.05=*. 
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Estrogen signaling through ER enhances female and male CD8+ Ag-specific T cell 
polyfunctionality 
 
 A significant decrease on the percent frequency of monofunctional male and female 
CD8+ Ag-specific T cells was observed upon estrogen treatment, especially at super-
physiological concentrations. While the percent frequency of bifunctional cells was not 
significantly changed, the percent frequency of CD8+ T cells expressing 3 markers 
simultaneously was significantly increased upon estrogen treatment (Figure 18 & 19 A). This 
indicated that estrogen signaling enhances the percentage of polyfunctional cells while 
decreasing the percentage of monofunctional cells. The estrogen-mediated enhancement of CD8+ 
male and female T cell polyfunctionality was not affected by blocking ER with a specific 
antagonist (MPP-dihydrochloride) during estrogen treatment (Figure 18 & 19 B). In fact, upon 
ER blockade, the estrogen-mediated decrease on monofunctional T cell percentage and 
increase on trifunctional percentages was even more significant at physiological estrogen 
concentrations. Thus demonstrating that ER signaling does not enhance CD8+ Ag-specific 
polyfunctionality but rather it partially inhibits it when T cells are exposed to physiological 
estrogen. Surprisingly, the estrogen-mediated enhancement of CD8+ T cell polyfunctionality was 
completely abrogated when ER signaling was blocked with a specific antagonist (PHTPP) 
(Figure 18 & 19 C). No changes in polyfunctionality were observed when male and female CD8+ 
T cells were treated with estrogen in combination with both ER and ER antagonists (Figure 18 
& 19 D). Overall these data reveal that estrogen signaling through ER enhances CD8+ male and 
female Ag-specific T cell polyfunctionality.  
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Figure 18. Estrogen Signaling through ER Enhances the Percentage of Polyfunctional 
Female CD8
+
 Ag-specific T Cells and Decreases the Percentage of Monofunctional T Cells after 
Ag Stimulation. Female HCV Ag-specific T cells from 15 donors were treated with 0, 0.5, or 50 
nM estrogen in combination with an ER inhibitor, and ER inhibitor, or both inhibitors 
simultaneously for 2 hours. After treatment, Ag-specific T cells were co-cultured for 5 hours with 
T2 cells pulsed with HCV cognate antigen or a tyrosinase irrelevant peptide in the presence of 
protein transport inhibitors. Cells were then stained for flow cytometric analysis of CD3, CD34, 
CD8, and CD4 and functional markers CD107a, IFN, TNF, IL-4, IL-2, IL-17a, and IL-22. Using 
Boolean gates in FlowJoX, the frequency of CD8
+
 T cells expressing each combination of these 7 
markers was generated and added into 7 functional categories. The frequencies of CD8
+
 female Ag-
specific T cells expressing one through seven markers simultaneously after treatment with A) 
estrogen, B) estrogen in combination with an ER inhibitor, C) estrogen in combination with an 
ER inhibitor, D) estrogen in combination of both ER and ER inhibitors were plotted. Data for 
T cells expressing 6 or 7 markers simultaneously is not shown since the percent frequency was very 
low. Data represents n=15 donors, each donor plotted and SEM represented. Data was analyzed 
using MANOVA and Tukey’s post-hoc. p< 0.001=***, p<0.05=*. 
111 
 
 
 
 
 
 
 
 
Figure 19. Estrogen Signaling through ER Enhances the Percentage of Polyfunctional 
Male CD8
+
 Ag-specific T Cells and Decreases the Percentage of Monofunctional T Cells 
after Ag Stimulation. Male HCV Ag-specific T cells from 15 donors were treated with 0, 0.5, 
or 50 nM estrogen in combination with an ER inhibitor, and ER inhibitor, or both inhibitors 
simultaneously for 2 hours. After treatment, Ag-specific T cells were co-cultured for 5 hours 
with T2 cells pulsed with HCV cognate antigen or a tyrosinase irrelevant peptide in the presence 
of protein transport inhibitors. Cells were then stained for flow cytometric analysis of CD3, 
CD34, CD8, and CD4 and functional markers CD107a, IFN, TNF, IL-4, IL-2, IL-17a, and 
IL-22. Using Boolean gates in FlowJoX, the frequency of CD8
+
 T cells expressing each 
combination of these 7 markers was generated and added into 7 functional categories. The 
frequencies of CD8
+
 male Ag-specific T cells expressing one through seven markers 
simultaneously after treatment with A) estrogen, B) estrogen in combination with an ER 
inhibitor, C) estrogen in combination with an ER inhibitor, D) estrogen in combination of both 
ER and ER inhibitors were plotted. Data for T cells expressing 6 or 7 markers simultaneously 
is not shown since the percent frequency was very low. Data represents n=15 donors, each donor 
plotted and SEM indicated. Data was analyzed using MANOVA and Tukey’s post-hoc. p< 
0.01=**, p<0.05=*. 
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 The percent frequencies of female and male CD8+ Ag-specific T cells expressing 
CD107a+ IFN+TNF+ was significantly increased by super-physiological estrogen treatment 
(Figure 20 & 21 A). The percent frequency of female CD8+ T cells expressing IFN+IL-4+TNF+ 
was also significantly increased by super-physiological estrogen treatment (Figure 20 A). On the 
other hand, the frequencies of male and female CD8+ T cells expressing TNF+IFN+, IFN+, 
and TNF+ were significantly decreased upon physiological and super-physiological estrogen 
treatments (Figure 20 & 21 A). The estrogen-induced significant changes on expression of 
polyfunctional (CD107a+IFN+TNF+), bifunctional (TNF+IFN+), and monofunctional (TNF 
or IFN alone) phenotypes were maintained when CD8+ Ag-specific T cells were treated with 
estrogen in combination with an ER inhibitor (Figure 20 & 21 B). In female CD8+ T cells, 
blockade of ER during physiological estrogen treatment significantly enhanced the expression 
of CD107a+IFN+TNF+ indicating that ER signaling could be partially inhibiting the 
expression of these three markers simultaneously (Figure 20 B). When male and female Ag-
specific T cells were treated with estrogen in combination with an ER inhibitor or with ER 
and ER inhibitors simultaneously, all significant changes on expression of monofunctional or 
polyfunctional phenotypes were abrogated (Figure 20 & 21 C, D). Overall, taking these data 
together with the results obtained in Figures 18 & 19, it can be concluded that estrogen signaling 
through ER enhances CD8+ Ag-specific T cell polyfunctionality by increasing expression of 
polyfunctional phenotypes CD107a+IFN+TNF+ and IFN+IL-4+TNF+ and decreasing 
expression of monofunctional and bifunctional phenotypes including TNF+IFN+ TNF+, and 
IFN+
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Figure 20. Estrogen Signaling through ER Increases the Percent Frequency of CD8
+
 Female Ag-specific T Cells Expressing 
CD107a
+
IFN
+
TNF
+
 and IFN
+
IL-4
+
TNF
+
 and Decreases the Percent Frequency of T Cells Expressing IFN
+
TNF
+
, 
IFN
+
, and TNF
+
. Female HCV Ag-specific T cells from 15 donors were treated with 0, 0.5, or 50 nM estrogen in combination 
with an ER inhibitor, and ER inhibitor, or both inhibitors simultaneously for 2 hours. After treatment, Ag-specific T cells were co-
cultured for 5 hours with T2 cells pulsed with HCV cognate antigen or a tyrosinase irrelevant peptide in the presence of protein 
transport inhibitors. Cells were then stained for flow cytometric analysis of CD3, CD34, CD8, and CD4 and functional markers 
CD107a, IFN, TNF, IL-4, IL-2, IL-17a, and IL-22. Using Boolean gates in FlowJoX, and the software SPICE the frequency of 
CD8
+
 T cells expressing each combination of these 7 markers was generated. The frequencies of CD8
+
 female Ag-specific T cells 
expressing each of these marker combinations after treatment with A) estrogen, B) estrogen in combination with an ER inhibitor, 
C) estrogen in combination with an ER inhibitor, D) estrogen in combination of both ER and ER inhibitors were plotted. Data 
represents the mean of n=15 donors. Data was analyzed using MANOVA and Tukey’s post-hoc. p<0.0001=****, p< 0.01=**. 
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Figure 21. Estrogen Signaling Through ER Increases the Percent Frequency of CD8
+
 Male Ag-Specific T Cells Expressing 
CD107a
+
IFN
+
TNF
+
 and Decreases the Percent Frequency of T Cells Expressing IFN
+
TNF
+
, IFN
+
, and TNF
+
. Male 
HCV Ag-specific T cells from 15 donors were treated with 0, 0.5, or 50 nM estrogen in combination with an ER inhibitor, and ER 
inhibitor, or both inhibitors simultaneously for 2 hours. After treatment, Ag-specific T cells were co-cultured for 5 hours with T2 cells 
pulsed with HCV cognate antigen or a tyrosinase irrelevant peptide in the presence of protein transport inhibitors. Cells were then 
stained for flow cytometric analysis of CD3, CD34, CD8, and CD4 and functional markers CD107a, IFN, TNF, IL-4, IL-2, IL-
17a, and IL-22. Using Boolean gates in FlowJoX, and the software SPICE the frequency of CD8
+
 T cells expressing each combination 
of these 7 markers was generated. The frequencies of CD8
+
 male Ag-specific T cells expressing each of these markers combinations 
after treatment with A) estrogen, B) estrogen in combination with an ER inhibitor, C) estrogen in combination with an ER inhibitor, 
D) estrogen in combination of both ER and ER inhibitors were plotted. Data represents the mean of n=15 donors. Data was 
analyzed using MANOVA and Tukey’s post-hoc. P<0.0001=****, p< 0.001=***, p<0.01=**, p<0.05=*. 
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Estrogen Signaling through ER Enhances Female and Male CD4+ Ag-specific T cell 
Polyfunctionality 
 
Estrogen signaling had similar effects on CD4+ T cell polyfunctionality to those observed 
in CD8+ Ag-specific T cells. Estrogen stimulation at super-physiological concentrations 
significantly decreased the percent frequency of monofunctional CD4+ T cells, and significantly 
increased the percent frequency of polyfunctional cells expressing three markers simultaneously 
(Figure 22 & 23 A). Super-physiological estrogen also significantly decreased the percentage of 
bifunctional female CD4+ T cells (Figure 22 A). ER signaling blockade had no effect of the 
estrogen-dependent enhancement of polyfunctionality of male CD4+ T cells, but it increased 
CD4+ T cell polyfunctionality at physiological estrogen concentration in female CD4+ T cells 
(Figure 22 & 23 B). Indicating that ER signaling inhibits female CD4+ T cell polyfunctionality. 
Blockade of ER or ER and ER simultaneously completely abrogated the estrogen-mediated 
increase in polyfunctionality of CD4+ male and female Ag-specific T cells (Figure 22 & 23 C, 
D). Overall these data indicate that estrogen signaling through ER increases polyfunctionality 
of male and female CD4+ T cells, and estrogen signaling through ER inhibits female CD4+ T 
cell polyfunctionality at physiological estrogen concentration.  
The percent frequencies of male and female CD4+ Ag-specific T cells expressing 
IFN+TNF+, and IFN+ or TNF+ were significantly decreased by physiological and super-
physiological estrogen treatment (Figure 24 & 25 A). The percent frequency of male CD4+ T 
cells expressing IFN+IL-4+TNF+ was also significantly increased by super-physiological 
estrogen treatment (Figure 25 A). A trending increase on the frequencies of CD4+ T cells 
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expressing IFN+ IL2+IL4+TNF+, and IFN+IL-2+TNF+ were observed upon estrogen 
treatment even if significance was not achieved. Female CD4+ Ag-specific T cells also showed a 
trending increase on expression of IFN+IFN+TNF+ upon estrogen treatment (Figure 24 A). 
Blockade of ER showed no effect on the estrogen-mediated changes on expression of 
functional phenotypes indicating that ER signaling does not affect CD4+ T cell 
polyfunctionality (Figure 24 & 25 B). On the other hand, ER blockade or ER and ER 
simultaneous blockade during estrogen treatment abrogated the estrogen-mediated decrease of 
monofunctional (IFN or TNF alone) and bifunctional (IFN+TNF+) T cell phenotypes, and 
increase in polyfunctional phenotypes such as IFN+IL-4+TNF+ (Figure 24 & 25 C, D). Overall, 
taking these data together with the results obtained in Figures 22 & 23, it can be concluded that 
estrogen signaling through ER enhances CD4+ Ag-specific T cell polyfunctionality by 
increasing expression of polyfunctional phenotypes such as IFN+IL-4+TNF+ and decreasing 
expression of monofunctional and bifunctional phenotypes including TNF+IFN+ TNF+, and 
IFN+ 
Ideally, in order to conclude that the effects of estrogen signaling on polyfunctionality are 
fully mediated by ER signaling another set of experiments need to be performed using ER 
agonists to stimulate human Ag-specific T cells instead of estrogen. The ER-specific agonist 
diarylpropionitrile (DPN) which has a 70-fold selectivity over ER (EC50 values are 0.85 nM 
and 66 nM for ER and ER respectively) [150] can be used to determine if estrogen signaling 
through ER is directly upregulating T cell polyfunctionality upon Ag stimulation. In order to 
test this, male and female Ag-specific T cells need to be treated with DPN alone, DPN in 
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combination with PHTPP (ER antagonist), and DPN in combination with PHTPP and estrogen. 
If after DPN treatment alone the polyfunctionality of T cells is enhanced to levels similar to 
those observed in estrogen treated T cells, then estrogen signaling through ER alone enhances T 
cell polyfunctionality. These data can be confirmed if T cells treated with DNP and PHTPP 
simultaneously show no increase in polyfunctionality. If treating T cells with DPN shows no 
increase on T cell polyfunctionality but treating T cells with estrogen, DNP and PHTPP do show 
an increase, then estrogen signaling through other receptor is causing the estrogen-mediated 
enhancement of polyfunctionality. Inhibition of ER during estrogen stimulation was shown to 
enhance polyfunctionality, even to higher extent than estrogen alone in some cases, indicating 
that ER has an inhibiting effect. Estrogen signaling through its other receptor, GPER, may be 
enhancing T cell polyfunctionality. In order to rule out that polyfunctionality is enhanced 
through GPER signaling, male and female Ag-specific T cells need to be treated with estrogen in 
combination of a GPER antagonist. If T cell polyfunctionality is decreased in T cells treated with 
estrogen in combination with a GPER antagonist compared to estrogen treated T cells, then 
estrogen signaling through GPER enhances T cell polyfunctionality. GPER signaling was shown 
to rapidly activate the PI3K and the MAPK pathways which are known to contribute to T cell 
cytokine secretion downstream from the TCR [177] indicating that GPER signaling could have 
an enhancing effect on TCR signaling leading to polyfunctionality. Unfortunately, these 
experiments could not be performed due to lack of time and support but these results would 
indicate that estrogen signaling through ER and GPER enhance T cell polyfunctionality 
downstream from the TCR. 
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Figure 22. Estrogen Signaling Through ER Enhances the Percentage of Polyfunctional 
Female CD4
+
 Ag-specific T Cells and Decreases the Percentage of Monofunctional and 
Bifunctional T Cells after Ag Stimulation. Female HCV Ag-specific T cells from 15 donors 
were treated with 0, 0.5, or 50 nM estrogen in combination with an ER inhibitor, and ER 
inhibitor, or both inhibitors simultaneously for 2 hours. After treatment, Ag-specific T cells 
were co-cultured for 5 hours with T2 cells pulsed with HCV cognate antigen or a tyrosinase 
irrelevant peptide in the presence of protein transport inhibitors. Cells were then stained for 
flow cytometric analysis of CD3, CD34, CD8, and CD4 and functional markers CD107a, IFN, 
TNF, IL-4, IL-2, IL-17a, and IL-22. Using Boolean gates in FlowJoX, the frequency of CD4
+
 
T cells expressing each combination of these 7 markers was generated and added into 7 
functional categories. The frequencies of CD4
+
 female Ag-specific T cells expressing one 
through seven markers simultaneously after treatment with A) estrogen, B) estrogen in 
combination with an ER inhibitor, C) estrogen in combination with an ER inhibitor, D) 
estrogen in combination of both ER and ER inhibitors were plotted. Data for T cells 
expressing 6 or 7 markers simultaneously is not shown since the percent frequency was very 
low. Data represents n=15 donors, each donor plotted and SEM represented. Data was analyzed 
using MANOVA and Tukey’s post-hoc. p<0.0001=****, p< 0.001=***, p<0.01=**, p<0.05=*. 
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Figure 23. Estrogen Signaling Through ER Enhances the Percentage of Polyfunctional 
Male CD4
+
 Ag-specific T Cells and Decreases the Percentage of Monofunctional T Cells 
after Ag Stimulation. Male HCV Ag-specific T cells from 15 donors were treated with 0, 0.5, 
or 50 nM estrogen in combination with an ER inhibitor, and ER inhibitor, or both inhibitors 
simultaneously for 2 hours. After treatment, Ag-specific T cells were co-cultured for 5 hours 
with T2 cells pulsed with HCV cognate antigen or a tyrosinase irrelevant peptide in the presence 
of protein transport inhibitors. Cells were then stained for flow cytometric analysis of CD3, 
CD34, CD8, and CD4 and functional markers CD107a, IFN, TNF, IL-4, IL-2, IL-17a, and 
IL-22. Using Boolean gates in FlowJoX, the frequency of CD4
+
 T cells expressing each 
combination of these 7 markers was generated and added into 7 functional categories. The 
frequencies of CD4
+
 male Ag-specific T cells expressing one through seven markers 
simultaneously after treatment with A) estrogen, B) estrogen in combination with an ER 
inhibitor, C) estrogen in combination with an ER inhibitor, D) estrogen in combination of both 
ER and ER inhibitors were plotted. Data for T cells expressing 6 or 7 markers simultaneously 
is not shown since the percent frequency was very low. Data represents n=15 donors, each donor 
plotted and SEM represented. Data was analyzed using MANOVA and Tukey’s post-hoc. p< 
0.001=***, p<0.01=**,  p<0.05=*. 
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Figure 24. Estrogen Signaling Through ER Decreases the Percent Frequency of  Female CD4
+
 Ag-specific T Cells Expressing 
IFN
+
TNF
+
, IFN
+
, and TNF
+
. Female HCV Ag-specific T cells from 15 donors were treated with 0, 0.5, or 50 nM estrogen in 
combination with an ER inhibitor, and ER inhibitor, or both inhibitors simultaneously for 2 hours. After treatment, Ag-specific T 
cells were co-cultured for 5 hours with T2 cells pulsed with HCV cognate antigen or a tyrosinase irrelevant peptide in the presence 
of protein transport inhibitors. Cells were then stained for flow cytometric analysis of CD3, CD34, CD8, and CD4 and functional 
markers CD107a, IFN, TNF, IL-4, IL-2, IL-17a, and IL-22. Using Boolean gates in FlowJoX and the software SPICE, the 
frequency of CD4
+
 T cells expressing each combination of these 7 markers was generated. The frequencies of CD4
+
 female Ag-
specific T cells expressing one through seven markers simultaneously after treatment with A) estrogen, B) estrogen in combination 
with an ER inhibitor, C) estrogen in combination with an ER inhibitor, D) estrogen in combination of both ER and ER inhibitors 
were plotted. Data for T cells expressing 6 or 7 markers simultaneously is not shown since the percent frequency was very low. Data 
represents the mean of n=15 donors. Data was analyzed using MANOVA and Tukey’s post-hoc. p<0.0001=****, p< 0.001=***, 
p<0.01=**, p<0.05=*. 
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Figure 25. Estrogen Signaling Through ER Increases the Percent Frequency of CD4
+
 Male Ag-specific T Cells Expressing 
IFN
+
IL-4
+
TNF
+
 and Decreases the Percent Frequency of T Cells Expressing IFN
+
TNF
+
, IFN
+
, and TNF
+
. Male HCV 
Ag-specific T cells from 15 donors were treated with 0, 0.5, or 50 nM estrogen in combination with an ER inhibitor, and ER 
inhibitor, or both inhibitors simultaneously for 2 hours. After treatment, Ag-specific T cells were co-cultured for 5 hours with T2 cells 
pulsed with HCV cognate antigen or a tyrosinase irrelevant peptide in the presence of protein transport inhibitors. Cells were then 
stained for flow cytometric analysis of CD3, CD34, CD8, and CD4 and functional markers CD107a, IFN, TNF, IL-4, IL-2, IL-
17a, and IL-22. Using Boolean gates in FlowJoX and the software SPICE, the frequency of CD4
+
 T cells expressing each combination 
of these 7 markers was generated. The frequencies of CD4
+
 male Ag-specific T cells expressing each of the markers combinations 
after treatment with A) estrogen, B) estrogen in combination with an ER inhibitor, C) estrogen in combination with an ER inhibitor, 
D) estrogen in combination of both ER and ER inhibitors were plotted. Data represents the mean of n=15 donors. Data was 
analyzed using MANOVA and Tukey’s post-hoc. p< 0.001=***, p<0.01=**,  p<0.05=*. 
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Estrogen Signaling through ER Enhances the Percent Frequency of Ag-specific T cells 
Expressing Polyfunctional Marker Combinations 
 Up to this section of the results, polyfunctionality data were statistically analyzed for 
CD4+ and CD8+ T cells within each sex separately for each of the estrogen or estrogen + 
inhibitor treatments individually. This indicates that statistical significance was reported by 
comparing the percent frequency of T cells expressing each marker combination when treated 
with estrogen alone (0.5 nM or 50 nM) or in combination with each ER inhibitor or both 
simultaneously to the percent frequency of T cells expressing each marker combination when 
treated with 0 nM estrogen in combination with each inhibitor or both separately. In order to 
statistically analyze the interaction of estrogen and estrogen receptor inhibitor treatment on the 
expression of each of the combination of cytokines, a mixed-effect linear regression model was 
used. The estrogen main effect, estrogen inhibitor main effect, and estrogen x estrogen inhibitor 
interaction were run for every unique marker combination. An n=10 is needed for statistically 
analyzing each main effect/interaction so an n=30 was achieved by analyzing Ag-specific T cells 
from 15 female and 15 male donors together. Analyzing the data from male and female Ag-
specific T cells together has its limitations since the effect of sex in the expression of each 
marker combination is not taken into account but, based on previous data, it was demonstrated 
that estrogen signaling affects the polyfunctionality of male and female T cells similarly. Also, 
the bulk Ag-specific T cell population was analyzed instead of analyzing CD8+ and CD4+ T cell 
subset separately since during HCC immunotherapy T cells are infused into patients as a mixed 
population and superior anti-tumor immune responses are achieved when both functional subsets 
are found infiltrating the tumor, indicating a combined CD8+ and CD4+ T cell anti-tumor 
function [352].  
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IFN+IL-4+TNF+ was one of the cytokine combination that demonstrated a significant 
interaction effect between estrogen and estrogen inhibitor treatments (p = 0.0002). This indicates 
that the effect of estrogen treatment on IFN+IL-4+TNF+ expression varies significantly based 
on each estrogen inhibitor treatment, and vice versa. Physiological and super-physiological 
estrogen treatment significantly enhanced the percent frequency of cells expressing IFN+IL-
4+TNF+ (4.4731% and 5.1938% compared to 3.3751% in 0 nM treated T cells) (Table 3). The 
percent frequency of T cells expressing IFN+IL-4+TNF+ was significantly decreased when T 
cells were treated with 0.5 or 50 nM estrogen in combination of an ER inhibitor was added 
(3.2479% and 2.9269%) or both ER and ER inhibitors are added (3.182% and 2.9945%) 
(Table 3). On the other hand, the percent frequency of T cells expressing IFN+IL-4+TNF+ 
significantly increased when T cells were treated with 0.5 nM or 50 nM estrogen in combination 
with an ER inhibitor (5.0915% and 5.5498%) (Table 3). This indicates that physiological and 
super-physiological estrogen signaling through ER enhances the expression of IFN+IL-
4+TNF+, while signaling through ER significantly inhibits expression of IFN+IL-4+TNF+. 
Other cytokine combinations that demonstrated a significant interaction effect between 
super-physiological estrogen and estrogen inhibitor treatments (p<0.000618). This indicates that 
the effect of super-physiological estrogen concentration on the expression of IFN+IL-2+IL-4+IL-
17a+TNF+, and IL-2+IL-4+TNF+varies significantly based on each estrogen inhibitor 
treatment, and vice versa. The percent frequency of T cells expressing these marker 
combinations were significantly increased when treated with physiological (0.5 nM) or super-
physiological (50 nM) estrogen concentrations (Table 4). A significant decrease on the frequency 
of cells expressing IFN+IL-2+IL-4+IL-17a+TNF+, and IL-2+IL-4+TNF+ was observed when T 
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cells were treated with super-physiological estrogen in combination with an ER inhibitor, or 
ER and ER inhibitors simultaneously when compared to those cells treated with estrogen only 
(Table 4). A significant increase on the frequency of cells expressing IFN+IL-2+IL-4+IL-
17a+TNF+, and IL-2+IL-4+TNF+ was observed when T cells were treated with super-
physiological estrogen in combination with an ER inhibitor (Table 4). Overall these result 
indicate that estrogen signaling through ER enhances the expression of polyfunctional 
combinations IFN+IL-2+IL-4+IL-17a+TNF+, and IL-2+IL-4+TNF+ in Ag-specific T cells 
while estrogen signaling through ER inhibits the expression of these polyfunctional 
combinations. 
 Significant interaction effect between super-physiological estrogen and estrogen inhibitor 
treatments (p<0.000618) were also found for Ag-specific T cells expressing only IFN+ or 
TNF+ in combination with no other marker. Percent frequency of T cells expressing only IFN+ 
or TNF+ were significantly decreased when treated with physiological (0.5 nM) or super-
physiological (50 nM) estrogen concentrations (Table 4). A significant increase on the frequency 
of cells expressing only IFN+ or TNF+ was observed when T cells were treated with super-
physiological estrogen in combination with an ER inhibitor, or ER and ER inhibitors 
simultaneously when compared to those cells treated with estrogen only. A significant decrease 
on the frequency of cells expressing only IFN+ or TNF+ was observed when T cells were 
treated with super-physiological estrogen in combination with an ER inhibitor (Table 4).  
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Table 3. Estimated Effects of Estrogen and Estrogen Inhibitor Treatment on the Percent 
Frequency of Ag-specific T Cells Expressing IFN
+
IL-4
+
TNF
+
. The 95% confidence interval 
mean estimates for the percent frequency of Ag-specific T cells expressing IFN
+
IL-4
+
TNF
+ 
is 
represented for each estrogen treatment (0.5, 50 nM) compared to 0 nM treatment, and for each 
estrogen treatment (0.5 or 50 nM) in combination with either ER or ER inhibitors or both 
simultaneously, compared to estrogen treatment in combination with no inhibitor (none). 
Significant at p=0.000618.  
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Table 4. Adjusted Effects of Estrogen and Estrogen Inhibitor Treatment on Unique 
Cytokine Combination Expression. The 95% confidence interval mean estimates for the 
percent frequency of Ag-specific T cells expressing IFN
+ 
IL-2
+
IL-4
+
IL-17a
+
TNF
+
, IFN
+
, 
IL-2
+
IL-4
+
TNF
+
, and TNF
+ 
is represented for each estrogen treatment (0.5, 50 nM) 
compared to 0 nM treatment, and for each estrogen treatment (0.5 or 50 nM) in combination 
with either ER or ER inhibitors or both simultaneously, compared to estrogen treatment in 
combination with no inhibitor (none). Significant at p=0.000618.  
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Overall these result indicate that estrogen signaling through ER enhances the expression of 
monofunctional combinations IFN+ or TNF+ in Ag-specific T cells while estrogen signaling 
through ER inhibits the expression of these monofunctional combinations. 
Overall these statistical analysis indicates than in a human HCV Ag-specific population 
comprised of a mixture of CD4+ and CD8+ T cells that are activated with the HCV cognate 
antigen, estrogen signaling through ER significantly enhances the percentage of T cells 
expressing polyfunctional phenotypes such as IFN+IL-4+TNF+, IFN+IL-2+IL-4+IL-
17a+TNF+, and IL-2+IL-4+TNF+ and inhibits the expression of mono-functional phenotypes 
such as IFN+ or TNF+. On the other hand, estrogen signaling through ER significantly 
inhibits the percentage of cells expressing polyfunctional phenotypes while enhancing the 
percentage of cells expressing mono-functional phenotypes. This results demonstrate that 
estrogen signaling through ER enhances the polyfunctionality of Ag-specific T cells for 
immunotherapy. 
Chapter Discussion 
 
This chapter of the dissertation was aimed to determine the impact of sex and estrogen 
signaling in regulating Ag-specific T cell polyfunctionality. Here it was found that female CD8+ 
T cells are inherently more polyfunctional than male CD8+ T cells indicating that sex 
intrinsically impacts CD8+ T cell function upon antigen stimulation. In addition, it was shown 
that estrogen signaling through ER and not ER enhances male and female CD8+ and CD4+ 
Ag-specific T cell polyfunctionality. Overall these results report, for the first time, the impact of 
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estrogen stimulation on T cell polyfunctionality, and recognize specific functional phenotypes 
that are directly affected by estrogen receptor signaling in Ag-specific T cells.  
T cell polyfunctionality was evaluated by measuring the expression of cytokines IFN, 
TNF, IL-2, IL-4, IL-17a, and IL-22 and the lytic marker CD107a. Analysis of these factors 
yielded highly complex multi-dimensional data sets that were analyzed using software packages 
FlowJo, Pestle, and SPICE which allowed for graphical representation of the data and allowed to 
make comparison between sexes and estrogen receptor inhibitor treatment groups. It was found 
that male and female CD8+ and CD4+ Ag-specific T cells are highly diverse on their phenotypic 
and functional complexity. Female CD8+ Ag-specific T cells were more polyfunctional than 
male CD8+ T cells upon antigen stimulation expressing higher degrees of functional phenotypes 
such as CD107a+IFN+TNF+, IFN+IL-2+TNF+, and   IFN+TNF+ indicating strong type I T 
cell responses. On the other hand, significantly higher percentages of male CD8+ Ag-specific T 
cells expressed TNF+ compared to female T cells. This indicates that male CD8+ Ag-specific T 
cells also produce strong type I effector responses but T cells are less likely to express several 
markers simultaneously.  
Despite the sex differences on CD8+ T cell polyfunctionality, estrogen signaling showed 
equal effects modulating the polyfunctionality of male and female CD8+ and CD4+ Ag-specific T 
cells. Estrogen signaling through ER significantly increased the frequency of T cells expressing 
trifunctional phenotypes like CD107a+IFN+TNF+, and IFN+IL-4+TNF+ and significantly 
decreased the frequency of T cells expressing bifunctional or monofunctional phenotypes 
including IFN+TNF+, IFN+, and TNF+. ER signaling enhances the expression of 
polyfunctional phenotypes that include effector type I cytokines that enhance the T cell anti-
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tumor immune response, the lytic marker CD107a indicating T cell degranulation, and the type II 
cytokine IL-4 which promotes T cell survival and memory formation. Since polyfunctional CD8+ 
and CD4+ T cells were shown to generate superior anti-tumor immune responses [417, 423, 428, 
433], it can be hypothesized that female CD8+ T cells can modulate stronger anti-tumor immune 
responses compared to male CD8+ T cells. Based on the findings in this chapter it can also be 
hypothesized that estrogen signaling through ER can modulate stronger CD8+ and CD4+ T cell 
anti-tumor immune responses through enhancement of their polyfunctionality.  
Estrogen signaling through ER was also shown to enhance the polyfunctionality of the 
whole Ag-specific T cell population containing CD4+ and CD8+ T cells and independently of the 
sex of the 30 donors tested. Physiological and super-physiological estrogen signaling through 
ER enhanced the percent frequency of Ag-specific T cells expressing IFN, TNF, and IL-4 
simultaneously upon activation. Surprisingly, estrogen signaling through ER significantly 
inhibited the percent of Ag-specific T cells expressing this polyfunctional phenotype. Super-
physiological concentrations of estrogen significantly increased the percentage of Ag-specific T 
cells expressing INF+IL-2+IL-4+ and IL-17a+TNF+IL-2+IL-4+TNF+ and the super-
physiological estrogen-mediated enhancement of expression was abrogated when ER was 
blocked, but significantly enhanced when ER was blocked. Opposite results were obtained for 
monofunctional phenotypes IFN+ and TNF+ which were significantly decreased upon estrogen 
treatment, but significantly increased when physiological estrogen signaling through ER was 
inhibited. On the other hand, the percent of Ag-specific T cells expressing monofunctional 
phenotypes IFN+ and TNF+ was significantly decreased when ER was blocked indicating that 
super-physiological estrogen signaling through ER enhances monofunctional phenotypes. 
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Overall, these results indicate that estrogen signaling through ER enhances the 
polyfunctionality of the bulk Ag-specific T cell population in a dose-dependent manner, while 
estrogen signaling through ER inhibits the polyfunctionality of the bulk Ag-specific T cell 
population. Previously, ER signaling was shown to enhance expression of specific cytokines, 
IFN, TNF and IL4, through its genomic pathway. This could indicate that ER is enhancing 
Ag-specific T cell polyfunctionality through modulating T cell pathways and genes that promote 
polyfunctionality.  
T cell polyfunctionality is induced by TCR ligation of the antigen-MHC complex 
resulting in subsequent T cell activation, proliferation and cytokine production. Upon antigen 
ligation the TCR gets phosphorylated by lck and the kinase ZAP70 is recruited to 
phosphorylation sites. ZAP70 then activates several signaling pathways that modulate T cell 
function and cytokine expression. The three major pathways activated downstream from the 
TCR are the MAP kinase pathway, the NFB pathway, and the NFAT pathway [6]. NFAT and 
NFB are transcription factors that translocate into the nucleus when activated by TCR 
downstream signaling and modulate expression of immune genes and cytokines [6]. The MAP 
kinase pathway induces the expression of the transcription factor c-Fos which together with Jun 
form the dimeric transcription factor complex AP-1 [6]. AP-1 can also modulate expression of 
immune genes and cytokines. While the effect of ER on TCR downstream signaling remains 
unknown, there are studies confirming a relationship between estrogen signaling and activation 
of the MAPK, NFAT, and NFB pathways. While the specific estrogen receptor was not 
reported, estrogen signaling was shown to induce rapid activation of the MAP kinase pathway in 
mammalian cells [434]. Estrogen activation of the MAPK pathway is preceded by a rapid 
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increase in cytosolic Ca2+ concentration indicating that estrogen promotes Ca2+ release from the 
intracellular storages [435, 436]. The estrogen-mediated increase of cytosolic Ca2+ can also 
activate NFAT [437]. NFAT is activated via dephosphorylation by the Ca2+-dependent 
phosphatase calcineurin [438].  This indicates that estrogen can enhance intracellular Ca2+ levels 
which result on subsequent activation of the MAPK and NFAT pathways. Estrogen was also 
shown to rapidly activate the NFB pathway in endothelial and breast cancer cells [439].  While 
treating cells with estrogen ligand enhanced NFB signaling, ER and ER were shown to 
inhibit NFB binding to DNA target sites in myocardial cells impeding NFB target gene 
expression, and to enhance expression of the NFB inhibitory protein IK [440, 441]. The 
controversial effect of estrogen signaling on NFB seems to be cell dependent and it cannot be 
ruled out that estrogen signaling through ER enhances NFB signaling. 
In addition to the evidence supporting that estrogen activates these TCR downstream 
signaling pathways, EREs were found in the promoters of genes coding for important TCR 
downstream signaling proteins like lck, ZAP70 and c-Fos. Lck contains an ERE at position 3451 
bp of its promoter, and ZAP70 contains an ERE at position 4305 bp of its promoter, and c-Fos 
contains an ERE at location -3411 of its promoter (Table 5) [442]. This indicates that 
transcription of these genes could be regulated by ligand and ERE-independent ER canonical 
genomic signaling. Overall, given that ER enhances T cell polyfunctionality which is induced 
by TCR signaling, and knowing that estrogen signaling can enhance TCR signaling proteins 
expression and activation of downstream pathways it can be hypothesized that ER enhances 
human male and female Ag-specific T cell polyfunctionality by enhancing overall TCR 
signaling.  
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 In order to exclude the possibility that ER mediated enhancement of CD8+ and CD4+ 
Ag-specific T cell polyfunctionality is caused by changes on monofunctional and polyfunctional 
T cell survival and proliferation rather than enhancement of the TCR signaling, cell viability and 
proliferation staining need to incorporated into these experiments. Survival of monofunctional 
and polyfunctional Ag-specific T cells after antigen stimulation can be assessed by a viability 
dye and compared between estrogen and ER inhibitor treatments. Ag-specific T cell proliferation 
can be accessed via Ki67 staining and equally compared between estrogen and ER inhibitor 
treatments. 
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Table 5. Estrogen Response Elements Found in the Promoters of LCK, ZAP70, and FOS. Table shows the human (Hs) gene 
name, the chromosome location, the ERE sequence and its position in respect to the gene starting site. EREs were found in n the 
EREfinder database. c-Fos ERE was previously reported by Weisz & Rosales, Nucleic Acids Res, 1990. 
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CHAPTER VI 
ESTROGEN ENHANCES T CELL SURVIVAL, TUMOR INFILTRATION AND ANTI-
TUMOR FUNCTION DURING IMMUNOTHERAPY FOR HCC 
 
Introduction and Rationale 
 
The protective role of estrogen against HCC is widely accepted and supported by the 
observation that the HCC female-biased survival is significantly reduced after menopause [311]. 
Post-menopausal females undergoing estrogen hormone-replacement therapy have a decreased 
risk of HCC and increased survival rates compared to non-estrogen users [311]. Previous studies 
demonstrated that the protective activity of estrogen against HCC is mediated through inhibition 
of expression and signaling of IL-6 and inactivation of the STAT3 pathway in hepatocytes and 
Kupffer cells, as well as inhibition of tumor-associated macrophages, which all result in 
reduction of chronic inflammation of the liver and subsequent transformation [293, 318, 443]. 
The effect of estrogen on other immune cells present in the TME that impact anti-tumor immune 
responses and may have critical bearings on the success of ACT immunotherapy, including T 
cells, remains unclear and understudied. Since higher frequencies of infiltrating lymphocytes 
including CD4+ and CD8+ T cells have been correlated with increased survival in HCC patients 
[333, 334], it is important to study the role of estrogen signaling regulating the function of T 
cells in the HCC TME. The previous chapters of this dissertation demonstrated that estrogen 
signaling through ER enhances the expression of specific cytokines including IFN, TNF, and 
IL-4, in Ag-specific T cells upon TCR ligation and estrogen signaling through ER significantly 
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enhances the polyfunctionality, or the ability to express several functional markers 
simultaneously, of human male and female Ag-specific T cells activated by their cognate 
antigen. These results indicate that estrogen signaling through both ER and ER contribute to 
enhancing Ag-specific T cell function in response to antigen stimulation.  
ACT immunotherapy using genetically modified T cells including CAR-T cells and 
TCR-transduced T cells showed some success for treating HCC in preclinical models, and in 
early stage clinical trials. However, due to high fibrosis and cirrhosis, HCC tumors are hard to 
penetrate physically by Ag-specific T cells [444] therefore, currently the clinical results in 
treating HCC remain unsatisfactory. In addition, the HCC TME comprises immunosuppressive 
stromal cells and molecules including checkpoint molecules that promote tumor growth by 
exhausting T cells [444]. These data indicate that there is a high need for ways to improve the 
anti-tumor function of Ag-specific T cells in order to generate more successful ACT 
immunotherapy for HCC. Since estrogen has a protective role against HCC through mechanisms 
involving inflammation, and can enhance cytokine production and polyfunctionality of T cells in 
vitro, it was hypothesized that the protective role of estrogen against HCC is partially due to the 
estrogen-mediated enhancement of the T cell anti-tumor immune response. Estrogen receptor 
signaling was shown to enhance T cell activation, proliferation, and survival in models of 
autoimmune disease [233], indicating that estrogen could further strengthen the efficacy of ACT 
immunotherapy for HCC. In this chapter of the dissertation, the impact of estrogen signaling on 
tumor growth and T cell function is assessed during ACT immunotherapy using human HCV 
Ag-specific T cells to treat a HCV+HCC generated in mice. 
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Results 
The ideal target tumor tissue to be used for studying the role of estrogen during ACT 
immunotherapy for HCC would be patient derived xenografts (PDX) from HCV+HCC HLA-A2+ 
patients. PDX are transplanted into immune-deficient mice which then receive ACT 
immunotherapy with human HCV Ag-specific T cells, and tumor rejection can be measured as 
well as T cell function. Unfortunately, HCV+HCC xenografts from HLA-A2+ patients were not 
available to be used for the following experiments so a genetic HCC mouse model was used 
instead. HCC can be generated in mice by forcing the expression of human oncogenes c-MET 
(MET) and −catenin (CAT) in hepatocytes by sleeping beauty (SB) transposase-mediated 
somatic integration [445]. SB100 is retrovirally transduced into the liver in combination with 
transposon containing vectors for MET and CAT. SB recognizes and binds to inverted repeats 
flanking the MET and CAT sequences, excises the sequences, and inserts them into a new 
location containing a TA dinucleotide in the hepatocyte genome (Figure 26) [445]. This is a 
previously described clinically relevant HCC model that relies on the co-activation of MET and 
CAT which often occur in human HCC cases [371, 446, 447]. Co-delivery of both MET and 
CAT simultaneously on mouse livers using the sleeping beauty transposase system induces HCC 
within 40 to 60 days [372]. In order to include the HCV specific antigen in these HCC tumors 
that could be recognized by human Ag-specific T cells, a pcDNAIII expression vector containing 
the sequence of the full length HCV NS3 (Figure 7) [51, 358] was also delivered in combination 
with MET and CAT. Using this model, HCC tumors expressing the HCV NS3 antigen were 
generated. Ideally these tumors generated in mice would be treated syngeneically using mouse 
HCV Ag-specific T cells. On the other hand, considering that the effects of estrogen cytokine 
production and polyfunctionality were observed specifically in human T cells, it was decided to 
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use human male and female HCV Ag-specific T cells to perform ACT immunotherapy for HCC 
in these mice.  In order to test human T cells in the mouse system, the strain of mice used were 
the NSG-A2+ mice which are completely immune-deficient HLA-A2 expressing mice. NSG-A2+ 
mice lack functional mature B cells, T cells, NK cells and have defective DCs and macrophages, 
which prevents them from targeting and depleting or “rejecting” adoptively transferred human T 
cells. Furthermore, human T cells were shown to survive and be fully functional in NSG-A2+ 
mice [448-450], indicating this is a valid mouse model for the study of human T cell based 
immunotherapy. 
 
 
Figure 26. Mechanisms of Sleeping Beauty 100 (SB100)-mediated Transposition. Diagram 
of SB100 transposase-mediated cut-and-paste transposition of the sequences of the oncogenes 
MET and CAT into hepatocyte’s genome. A transposon, defined by the mirrored sets of red 
double arrows (IR/DRs) is shown on each end of the plasmid containing the sequence of MET 
and CAT oncogenes. The transposon harbors the expression cassette consisting of a promoter 
(blue square) that can direct the transcription of MET and CAT. SB100 binds to the IR/DRs and 
cuts the transposons out of the plasmid. A DNA molecule, in this case genomic DNA in mouse 
hepatocytes, containing the TA sequence becomes the recipient of the transposed transposon. In 
this process the TA sequence at the insertion site is duplicated.  
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While the MET-CAT HCC tumor model was previously used to study HCC oncogenesis 
and pharmacological drug design and delivery, it has never been used before to study ACT 
immunotherapy. To ensure that human HCC Ag-specific T cells could recognize the HCV 
antigen presented in  the context of HLA-A2 in mouse HCC cells, HCV+HCC tumors generated 
in NSG-A2+ mice were digested into a single cell suspension and incubated with male and 
female human Ag-specific T cells. T cell activation in response to target tumor antigen was 
measured via IFN release by ELISPOT. It was observed that female and male Ag-specific T 
cells secreted IFN in response to HCV+HCC cells but not in response to HCV-HCC cells 
generated in mice challenged with MET/CAT (Figure 27). These resulting data demonstrate that 
human Ag-specific T cells can recognize HCV antigen expressing HCC tumors generated in 
mice but do not respond to hepatocytes or tumor cells in the absence of the cognate Ag. The lack 
of response to tumors missing HCV Ag expression rules out the possible off-antigen reactivity to 
mouse tissue. Overall these results indicate that HCC Ag-specific T cells can be safely used to 
treat HCC bearing mice with ACT immunotherapy. 
In order to study the role of estrogen signaling in the T cell anti-tumor immune response 
generated during ACT immunotherapy in vivo, physiological estrogen was removed via 
ovariectomy (OVX) which consists of surgically ablating the ovaries of female mice. The ovaries 
are the main source of estrogen in the body of female mice and removing them was shown to 
significantly reduce the serum estrogen concentration to levels similar to those observed in male 
mice [451]. Physiological estrogen serum concentration in female mice is around 30-60 pg/mL 
and ovariectomy was shown to reduce this concentration to around 1.5-3 pg/mL [451, 452].  
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These serum estrogen concentrations can be correlated to the ones found in human females 
before (30-800 pg/mL) and after menopause (less than 20 pg/mL). Ovariectomy of female mice 
was considered a clinically relevant model to study the effect of physiological estrogen presence 
or absence during ACT for HCC. Sham surgeries omitting the ablation of the ovaries were 
performed in control female and male mice to take into account possible effects of surgery-
mediated inflammation on all experimental groups. Before tumor challenge, mice were left to 
stabilize for 3 weeks which is the minimum time reported for accumulated serum estrogen 
concentration to significantly decrease after ovariectomy [453, 454]. 
Figure 27. Human HCV Ag-specific T Cells Secrete IFN in Response to HCV
+
 HCC Cells 
Generated in NSG-A2
+
 Mice. NSG-A2
+
 mice were challenged with c-MET and -catenin 
human oncogenes in combination with an expression vector for the HCV NS3 peptide to 
generate HCV-expressing HCC. HCC were left to develop for 60 days and then were collected 
and digested into a single cell suspension. Tumor cells were co-cultured with human male or 
female HCV Ag-specific T cells at a 1:1 ratio for 18 hours, and IFN secretion was measured 
via ELISPOT. A) Female and male Ag-specific T cells secreted IFN in response to HCV 
expressing-HCV but not to HCV
-
HCC. B) ELISPOT plate demonstrating IFN secretion from 
three different female and three different male donors (D1, D2, D3). Data represents n=3 
donors, each donor plotted and the standard error of the mean indicated. Data was analyzed 
using 2-way ANOVA with Tukey’s post-hoc. No significance was observed. 
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Estrogen Inhibits Tumor Growth during Adoptive T cell Transfer Immunotherapy 
 
Using mice at 6-8 weeks old, treatment groups consisted of ovariectomized females, 
sham females and sham males were challenged with MET and CAT oncogenes in combination 
with the HCV NS3 expression vector. After tumor initiation, at day 20 or day 40 after 
MET/CAT/HCV injection, sham/OVX females and sham males received ACT immunotherapy 
of 107 sex-matched human HCV Ag-specific T cells via tail vein. 20 days after ACT 
immunotherapy, livers were collected and analyzed for tumor presence, and T cells were isolated 
from livers and spleens for analysis. All mice in these experiments received HCV Ag-specific T 
cells generated from one male and one female healthy donor. Phenotypical analysis of the Ag-
specific T cells before adoptive transfer demonstrated similar percentage and MFI of 
CD3+CD34+ in male and female T cells indicating equal anti-HCV TCR expression in both sexes 
(Figure 28 A). While female Ag-specific T cells showed a 1:1 CD8+:CD4+ ratio, the male T cells 
showed a 2:1 CD8+:CD4+ (Figure 28 B). The percentage of CD8+ T cells expressing intracellular 
Granzyme B was approximately 70% in female T cells compared to 85% in male T cells 
indicating a higher percentage of CTLs in transferred male Ag-specific T cells (Figure 28 C). 
Both male and female CD4+ T cells expressed low percentages of T-BET and high percentages 
of GATA3 indicating low Th1 and high Th2 CD4+ populations (Figure 28 D, E). Approximately 
18% of female T cells expressed RORt compared to only 2% of male T cells indicating a higher 
Th17 population in female CD4+ Ag-specific compared to male T cells (Figure 28 F). 
Surprisingly a high percentage of both male and female CD4+ T cells expressed FoxP3 (50-55%) 
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indicating a high Treg population (Figure 28 G). These data indicate that the Ag-specific T cells 
transferred into female mice consisted of a more heavily CD4+ helper T cell population including  
 
 
 
 
high percentage of Th2 and Th17 cells, while Ag-specific T cells transferred into male mice 
consisted of a more CD8+ CTL population. 
Figure 28. Phenotype of Human Female and Male Ag-specific T Cells Used for ACT 
Immunotherapy. Flow cytometry dot plots representing the percent frequency of human 
female and male T cells that were A) CD3
+
CD34
+
. B) Percent frequency of female and male 
CD3
+
CD34
+
 that were either in the CD8
+
 or CD4
+ 
subset. C) Percent frequency of 
CD3
+
CD34
+
CD8
+
 female and male T cells expressing Granzyme B. Percent frequency of 
CD3
+
CD34
+
CD4
+
 T cells expressing D) T-BET, E) GATA3, F) RORt, and G) FoxP3.  
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HCC tumors in mice are commonly quantified by measuring the ratio of tumor over body 
weight [455]. Since mice used for these experiments were a range of ages, and male mice were 
bigger than female mice, no significant differences in tumor over body weight ratios were found 
between sexes or treatment groups. It is important to note that the transformed livers were three 
times heavier than livers of non-challenged mice, healthy livers weighting approximately 1.5 
grams and fully transformed livers weighting approximately 4 grams. Alternatively, to using the 
ratio of liver tumor:body weight, the BCLC staging classification was used to compare tumor 
burden between experimental groups. According to this staging method, HCC tumors are 
classified into four different categories according to the number of tumors, the size of the tumors, 
the presence of vascular invasion, and the spread of nodules or presence of extrahepatic 
metastases [320]. According to these parameters, HCC tumors are considered stage 0 (very early 
stage) when only one small nodule <2 mm is found, stage A (early stage) when between 1 and 3 
small nodules are found, stage B (intermediate stage) when several nodules >3 mm are found, 
stage C (advanced stage) when several large nodules are found and there is portal invasion, or 
stage D (terminal stage) when several large nodules are present and there is extrahepatic spread 
[319-321]. Extrahepatic spread in mice HCC models is described as presence of metastases in 
the lungs, the spleen, the kidneys, and the heart [456]. HCC tumors that were left to develop for 
20 days before ACT were on the very early stage (stage 0) since tumor nodes were not detected. 
Only OVX females and sham males, which have minimal estrogen levels, that did not receive 
ACT showed transformation of the liver and tumor node presence (Figure 29 B lower panel). 
This indicates that ACT immunotherapy prevented tumor development since none of the mice 
that received ACT had tumor nodules present compared to untreated mice (Figure 29 B upper 
panel).  
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Tumors that were left to develop for 40 days prior to ACT were in very advanced HCC 
stage and resulted in an almost complete transformation of the liver (Figure 29 C). HCC tumors 
were multinodular, nodules were very large, and some mice even presented tumor nodules on the 
spleen which were characterized as metastases (represented on Figure 29 C), indicating that these 
tumors were in the intermediate (stage B), advanced or very advanced stages (stage C and D). In 
mice that did not receive ACT immunotherapy, tumor burden was greater in OVX females and 
sham males compared to sham females (Figure 29 C lower panel). Tumor burden was overall 
reduced in mice that received ACT indicating T cell tumor recognition and killing. Sham females 
treated with ACT immunotherapy showed less tumor burden than OVX females and sham males 
counterparts (Figure 29 C upper panel). These data overall support the hypothesis that estrogen 
has a protective roll against HCC. The HCC tumor burden in ACT treated mice was quantified 
and showed that even if tumor burden was improved with ACT immunotherapy, OVX females 
had the overall worst diagnosis when compared to sham females or sham males. A significantly 
greater percentage of ACT treated OVX female mice developed HCC tumors in the very advance 
stage D (multinodular and spleen metastasis presence) compared to sham females (Figure 29 D). 
HCC tumor burden on OVX females treated with ACT was also worse compared to sham males 
showing higher percentage of mice in the very advanced stage even if significance was not 
achieved. Overall, sham females that received immunotherapy showed significantly less 
advanced tumor burden compared to OVX females, and trending less advanced tumor burden 
compared to sham males (Figure 29 D). These results indicate that removal of endogenous 
estrogen enhances HCC tumor burden and decreases ACT immunotherapy efficacy.
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Figure 29. Removal of Endogenous Estrogen via Ovariectomy Enhances HCC Tumor Burden and Reduces ACT 
Immunotherapy Efficacy. A) Experimental set up. B) Representative pictures of livers of sham females, OVX females, and sham 
males that were challenged with MET and CAT oncogenes in combination with an HCV antigen expression vector. Upper panels 
show livers of mice that received ACT immunotherapy with sex-matched human HCV Ag-specific T cells 20 days after tumor 
challenge and that were sacrificed 20 days after therapy administration. Lower panels show mice counterparts that did not receive 
ACT immunotherapy. C) Representative pictures of mice that received ACT immunotherapy with sex-matched human HCV Ag-
specific T cells 40 days after tumor challenge and were sacrificed 20 days after therapy administration. Arrows point at tumor nodules. 
Small panel shows a representative picture of a spleen metastasis (MET). D) HCC tumor burden was determined using the BCLC 
staging based on the number of nodules, the percent transformation of the liver, and presence of spleen metastases in mice that 
received ACT 40 days after tumor challenge compared to untreated mice. ACT day 20: n=6 sham females, n=7 OVX females, n=10 
sham males. ACT day 40: n=5 sham females, n=5 OVX females, n=6 sham males. Data was analyzed with 2-way ANOVA with 
Tukey’s post-hoc. p<0.05. 
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Estrogen Presence during Adoptive T cell Transfer Immunotherapy Enhances Human CD4+ 
Ag-specific T cell Tumor Infiltration 
 
After assessing tumor burden, HCC tumors were digested and T cells were isolated from 
whole tumors and analyzed via flow cytometry in order to determine Ag-specific T cell tumor 
infiltration. T cells obtained from the tumors of each mouse were analyzed separately and no 
tumors were pooled together. Even if the Ag-specific T cell numbers recovered were low they 
were sufficient for analysis and for making meaningful comparisons. Significantly greater 
numbers of human Ag-specific T cells were found infiltrating the livers of sham females, an 
average of approximately 2000-4000 cells,  compared to OVX females, an average of 1500-2000 
cells, at both time points of ACT  (Figure 30 B). A trend was observed indicating increased 
numbers of infiltrating T cells in sham females compared to sham males but significance was not 
achieved (Figure 30 B). The number of infiltrating CD8+ Ag-specific T cells was not 
significantly different in early stage tumors treated with ACT immunotherapy at day 20 after 
tumor challenge. On the other hand, significantly higher numbers of infiltrating CD8+ T cells 
were found in advanced tumors of sham females, an average of approximately 1700 cells, 
compared to OVX females and males that received ACT immunotherapy at day 40 after tumor 
challenge, >500 cells (Figure 30 C). The numbers of infiltrating CD4+ Ag-specific T cells were 
significantly higher in sham females compared to OVX females and males at both time points of 
ACT (Figure 30 D). Overall, these data indicates that endogenous estrogen enhances tumor 
infiltration of CD4+ Ag-specific T cells no matter on tumor burden, and enhances the infiltration 
of CD8+ Ag-specific T cells in advanced tumors. 
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Figure 30. Endogenous Estrogen Enhances Human Ag-specific T Cell Tumor Infiltration. 
Human Ag-specific T cells were adoptively transferred into OVX/sham female or sham male 
mice 20 or 40 days after HCC tumor challenge, and then isolated from tumors 20 days after 
transfer for flow cytometric analysis. A) Representative flow cytometry dot plots containing 
the gating strategy performed to analyze HCV Ag-specific T cells isolated from tumors of one 
female sham, one female OVX, and one male sham mouse. Total number of B) CD3
+
CD34
+
, 
C) CD3
+
CD34
+
CD8
+
, or D) CD3
+
CD34
+
CD4
+
 HCV Ag-specific T cells found infiltrating the 
liver of sham females, OVX females, and sham males that were treated with ACT 
immunotherapy either 20 or 40 days after tumor challenge. ACT day 20: n=6 sham females, 
n=7 OVX females, n=10 sham males. ACT day 40: n=5 sham females, n=5 OVX females, n=6 
sham males. Each mouse plotted and the standard error of the mean indicated. Data were 
analyzed by 1way-ANOVA and Tukey’s post-hoc. p<0.001=***, p<0.01**, p<0.05=*. 
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The subset distribution of CD4+ Ag-specific T cells infiltrating the tumors of OVX and 
sham females was analyzed via flow cytometry staining. No significant differences were found 
on expression of any of these transcription factors between sham and OVX females indicating 
that endogenous estrogen does not affect CD4+ T cell subset differentiation during ACT 
immunotherapy. High percent frequency of CD4+ T cells infiltrating the livers of female sham 
and OVX mice expressed GATA3 and RORt compared to other transcription factors, which are 
the prototypic transcription factors for the Th2 and Th17 CD4+ T cell subsets (Figure 31).  
 
 
 
 
Figure 31. The CD4
+
 Ag-specific T Cell Subset Distribution was not Affected by Removal 
of Endogenous Estrogen. Human CD4
+
 Ag-specific T cells isolated from livers of sham and 
OVX female mice were intracellularly stained for the transcription factors T-BET, GATA3, 
RORt, and FOXP3 which correspond to the Th1, Th2, Th17, and Treg subsets respectively. A) 
Representative histograms showing the expression of T-BET, GATA3, RORt, and FOXP3 in 
tumor infiltrating CD3
+
CD34
+
CD4
+
 T cells from one sham female and one OVX female mouse. 
Percent frequencies of tumor infiltrating CD3
+
CD34
+
CD4
+
 T cells from sham females and 
OVX females that received ACT immunotherapy B) 20 days or C) 40 days after HCC tumor 
challenge. ACT day 20: n=6 sham females, n=7 OVX females. ACT day 40: n=5 sham females, 
n=5 OV females. Each mouse plotted and the standard error of the mean indicated. Male group 
is not included since not enough CD4
+
 T cell numbers were present infiltrating the liver to 
perform this analysis.  
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Surprisingly, low frequency of CD4+ T cells, less than 10%, expressed the transcription 
factor T-BET indicating low percentage of Th1 CD4+ Ag-specific T cells infiltrating the tumors 
of sham and OVX mice.  Low frequencies of CD4+ T cells, less than 10%, expressed FoxP3, 
indicative of lack of immunosuppressive regulatory Tregs, infiltrating the tumors of sham and 
OVX females (Figure 31). These results indicate that CD4+ T cells infiltrating the tumors of 
female mice belonged mostly to the Th2 and Th17 subsets. 
In order to demonstrate that the significant differences in CD4+ Ag-specific T cell 
infiltration between sham females and sham males were not due to the differences in CD8+:CD4+ 
ratios observed in Ag-specific T cells populations before transfer (Figure 28), opposite sex ACT 
immunotherapy was performed. Female mice received 107 male human Ag-specific T cells, and 
male mice received 107 female human Ag-specific T cells on day 20 after tumor challenge. On 
day 20 after ACT immunotherapy, livers were collected, and Ag-specific T cells were isolated. It 
was observed that female and male mice that received opposite sex ACT had similar numbers of 
CD3+CD34+ Ag-specific T cells infiltrating the tumor, approximately 2500 to 4000 TILs (Figure 
32 B). The numbers of infiltrating CD8+ Ag-specific T cells were comparable in male and 
females that received opposite sex ACT, m approximately 1200 TILs (Figure 32 C). On the other 
hand, female mice that received male human Ag-specific T cells had significantly greater 
number, around 500, of infiltrating CD4+ Ag-specific T cells compared to males, around 200, 
that received human female  T cells (Figure 32 C). These results indicate that females have 
increased CD4+ Ag-specific T cell tumor infiltration independently of the sex of the T cell donor. 
These results in combination with the ones presented in Figure 30 indicate that endogenous 
estrogen enhances tumor infiltration of CD4+ T cells from male and female source.  
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Figure 32. Endogenous Estrogen Enhances Tumor Infiltration of CD4
+
 Ag-specific T Cells 
Independently of the Donor’s Sex. Female and male NSG-A2
+
 mice were challenged with 
MET-CAT-HCV oncogenes and 20 days after they received ACT immunotherapy with T cells 
of the opposite sex. 20 days after ACT immunotherapy, livers were collected and T cells were 
analyzed via flow cytometry. A) Representative dot plots of infiltrating Ag-specific T cells from 
one female (received male T cells) and one male (received female T cells) mouse. B) Total 
number of CD3
+
CD34
+
 Ag-specific T cells found in the liver of female and male mice. Total 
number of C) CD3
+
CD34
+
CD8
+ 
or D) CD3
+
CD34
+
CD4
+
 T cells found infiltrating the liver of 
female or male mice. Data represents n=5 sham females, n=5 sham males. Each mouse plotted 
and the standard error of the mean indicated. Data analyzed with Student’s t test. p<0.05=*. 
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Estrogen Presence during Adoptive T cell Transfer Immunotherapy Enhances Human CD4+ 
Ag-specific T cell Survival 
 
In order to determine if the overall survival of adoptively transferred cells outside of the 
tumor was affected by estrogen removal, the number of circulating human T cells present in the 
spleen was quantified. While no differences were observed in mice that received ACT 20 days 
after tumor challenge and were bearing early stage tumors, there were significantly higher 
numbers of CD3+CD34+ and CD3+CD34+CD8+ T cells in the spleens of sham female mice with 
advanced stage tumors compared to OVX females and males which received ACT 40 days after 
tumor challenge (Figure 33 B, C). CD3+CD34+CD4+ T cell numbers were significantly higher in 
the spleens of sham female mice compared to OVX females and males at both time points of 
ACT immunotherapy and independently of tumor stage (Figure 33 D). These data demonstrate 
that estrogen enhances the persistence of adoptively transferred Ag-specific T cells. Estrogen 
removal is deleterious for T cell survival with an even more significant impact on the survival of 
the CD4+ T cell subset. 
Ideally, conclusions of these experiments would be supported by data measuring the 
effect of endogenous estrogen on the viability and proliferation state of tumor infiltrating and 
circulating T cells in order to determine if decreased CD4+ numbers found in the tumors and 
spleens of OVX females and sham males are due to increased T cell apoptosis or decreased 
proliferation. To test this, HCC tumors and spleens from sham/OVX females and sham males 
can be fixed and sectioned, and then stained for human CD4+ to detect the T cells in combination 
with staining for fragmented DNA (a feature of apoptotic cells) by terminal deoxynucleotidyl 
transferase dUTP nick-end labeling (TUNEL) [457].
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Figure 33. Endogenous Estrogen Enhances Human Ag-specific T Cell Survival. Human Ag-specific T cells were adoptively 
transferred into OVX/sham female or sham male mice 20 or 40 days after HCC tumor challenge, and then isolated from spleens 20 days 
after transfer for flow cytometric analysis. A) Representative flow cytometry dot plots containing the gating strategy performed to 
analyze HCV Ag-specific T cells isolated from spleens of one female sham, one female OVX, and one male sham mouse. Total number 
of B) CD3
+
CD34
+
, C) CD3
+
CD34
+
CD8
+
, or D) CD3
+
CD34
+
CD4
+
 HCV Ag-specific T cells found in the spleens of sham females, OVX 
females, and sham males that were treated with ACT immunotherapy either 20 or 40 days after tumor challenge. ACT day 20: n=6 sham 
females, n=7 OVX females, n=10 sham males. ACT day 40: n=5 sham females, n=5 OVX females, n=6 sham males. Each mouse plotted 
and the standard error of the mean indicated. Data were analyzed by 1way-ANOVA and Tukey’s post-hoc. p<0.0001=****, 
p<0.001=***, p<0.01**, p<0.05=*. 
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 If CD4+ T cells in OVX mice show increased TUNEL staining compared to sham females, then 
estrogen inhibits CD4+ T cell apoptosis. This could happen through enhancing of expression of 
anti-apoptotic genes such as Bcl-2. Lack of estrogen during ACT, removes the protective effect 
of the hormone in enhancing expression of anti-apoptotic genes. If similar TUNEL staining is 
found in CD4+ T cells from sham and OVX mice, then it would be concluded that removal of 
endogenous estrogen would have no effect on the apoptosis of CD4+ T cells. This could be due 
to CD4+ T cells dying through other mechanisms such as necrosis, or could simply be that 
estrogen does not modulate CD4+ T cell survival. In this case, enhanced proliferation would be 
the reason for increased CD4+ T cell numbers observed in the presence of estrogen which should 
be confirmed in conjunction with proliferation staining using Ki67. If CD4+ T cells in female 
sham mice show increased Ki67 staining compared to OVX mice, then it can be resolved that 
estrogen enhances the proliferation of CD4+ T cells. T cell proliferation is induced through Ag 
recognition and TCR activation and downstream signaling thus indicating the estrogen could be 
regulating TCR downstream signaling. Based on data presented in previous chapters, estrogen 
enhanced CD4+ T cell cytokine production and polyfunctionality which are downstream of the 
TCR indicating that estrogen enhancing proliferation through TCR-mediated signaling is the 
most likely scenario. In addition, estrogen could be enhancing signaling of pathways such as 
MAP kinase which enhance T cell proliferation independently from the TCR. On the contrary, if 
Ki67 staining is equally found in CD4+ T cells from both sham and OVX mice, then it would 
have to be considered that estrogen may not modulate CD4+ T cell proliferation. In this case 
reduced number of CD4+ T cells found in OVX mice could be due to reduced survival which 
would rule out an effect of estrogen on proliferation/TCR signaling enhancement. However, it 
should also remain a consideration that Ki67 staining is a single snap shot of time in the overall 
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process and may need to be repeated at multiple time points after adoptive transfer in order to 
truly determine whether proliferation occurs in the TME.  If enhanced proliferation occurs in the 
lymph nodes but T cells do not survive infiltration to the TME, the result of the stain may not be 
able to be observed through the current measurement. If CD4+ T cells are positive for both Ki67 
and TUNEL staining in the absence of estrogen, then this could be due to cells proliferating but 
not surviving due to apoptosis-induced proliferation. This could indicate T cell exhaustion due to 
constant Ag stimulation, and estrogen being protective against T cell exhaustion which would be 
beneficial for immunotherapy. 
Estrogen Enhances Tumor Infiltrating Lymphocyte Activation during Immunotherapy 
 
Next, estrogen’s ability to modulate T cell activation of infiltrating adoptively transferred 
T cells was tested. In order to measure T cell activation, Ag-specific T cells were stained for cell 
surface expression of CD69 and CD25. CD69 and CD25 are activation markers which 
expression is upregulated after antigen stimulation and TCR signaling activation [458]. A 
significantly greater percentage of Ag-specific T cells expressing CD25 was found infiltrating 
the livers of sham females compared to the estrogen depleted, OVX females at both time points 
of ACT (Figure 34 B). Similarly, significantly greater frequency of Ag-specific T cells 
infiltrating sham female tumors expressed CD69 than the ones infiltrating the tumors of OVX 
female at both time points of ACT (Figure 34 C). Significantly greater percentage of TILs from 
sham females expressed CD69 compared to TILs found in sham males (Figure 34 C). These data 
demonstrate removing endogenous estrogen diminishes the activation state of TILs. 
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Figure 34. Removal of Endogenous Estrogen Diminished Ag-specific T Cell Activation 
State. Human Ag-specific T cells infiltrating the livers of sham females, OVX females, and 
sham males were isolated and stained for CD25 and CD69 extracellular markers. A) 
Representative flow cytometry dot plots of CD3
+
CD34
+
 TILs expressing CD25 or CD69 from 
one sham female, one OVX female, and one shame male mouse. B) Expression of CD25 in 
tumor infiltrating Ag-specific T cells from sham/OVX females and sham males that received 
ACT immunotherapy 20 or 40 days after tumor challenge. C) CD69 expression CD25 in tumor 
infiltrating Ag-specific T cells from sham/OVX females and sham males that received ACT 
immunotherapy 20 or 40 days after tumor challenge. ACT day 20: n=6 sham females, n=7 OVX 
females. AdTx day 20: n=6 sham females, n=7 OVX females, n=10 sham males. ACT day 40: 
n=5 sham females, n=5 OVX females, n=6 sham males. Each mouse plotted and the standard 
error of the mean indicated. Data were analyzed by 1way-ANOVA and Tukey’s post-hoc. 
p<0.01=**, p<0.05=*. 
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Endogenous Estrogen Enhances TIL Cytotoxic and Helper Cytokine Production during 
Immunotherapy 
 
 Ag-specific T cells found infiltrating the livers of HCC challenged sham/OVX females 
and sham males expressed diverse levels of CD25 and CD69 indicating differential T cell 
activation state and TCR signaling in response to antigen. Differences in T cell activation and 
TCR signaling can result in altered T cell cytokine expression and T cell polyfunctionality in 
response to antigen.  It was previously demonstrated that estrogen signaling enhances the 
secretion of certain cytokines including Granzyme B, IFN, TNF, and IL-4, upon T cell 
activation. In order to investigate if estrogen presence during immunotherapy affects TIL 
cytokine production, equal numbers of human Ag-specific TILs from sham/OVX females and 
sham males were co-cultured in vitro with target T2 cells pulsed with HCV cognate Ag or 
tyrosinase irrelevant peptide. Activated TILs were then stained extracellularly for CD107a (a 
lytic marker indicative of Granzyme B degranulation), and intracellularly for IFN, TNF, IL-4. 
As predicted, minimal numbers of Ag-specific TILs expressed any of these cytokines when co-
cultured with T2 cells pulsed with tyrosinase (Figure 35 A). No significant differences in the 
percentage of HCV activated CD8+ Ag-specific TILs expressing IFN, TNF D107a were 
found between sham females, OVX females, and sham males (Figure 35 B). Significantly greater 
numbers of female sham CD8+ Ag-specific TILs expressed IL-4 in comparison to OVX female 
TILs (Figure 35 B). This indicates that endogenous estrogen enhances the expression of IL-4 in 
CD8+ Ag-specific TILs upon antigen stimulation. Significantly higher numbers of CD4+ TILs 
from sham females expressed IFN, TNF IL-4 and CD107a compared to OVX female TILs 
(Figure 35 C). 
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Figure 35. Removal of Endogenous Estrogen Enhances Expression of Th1 and Th2 Cytokines in CD4
+
 TILs. Isolated TILs 
from livers of sham/OVX females and sham males were co-cultured with T2 cells expressing the HCV antigen for 5 hours in the 
presence of protein-transport inhibitors, cytokine expression was then measured by flow cytometry staining. A) Representative 
histograms of CD3
+
CD34
+
CD4
+
 Ag-specific T cells from one sham and one OVX female expressing each of the cytokines after 
stimulation with HCV cognate antigen or tyrosinase irrelevant peptide. B) Total number of CD3
+
CD34
+
CD8
+
 human Ag-specific 
TILs from sham/OVX females and sham males expressing IFN, TNF, IL-4 or CD107a that were transferred 40 days after tumor 
challenge. C) Total number of CD3
+
CD34
+
CD4
+
 human Ag-specific TILs from sham and OVX females expressing IFN, TNF, IL-
4 or Cd107a that were transferred either 40 days after tumor challenge. ACT day 40: n=5 sham females, n=5 OVX females, n=6 sham 
males. Each mouse plotted and the standard error of the mean indicated. Data were analyzed by 1way-ANOVA and Tukey’s post-
hoc. p<0.05=*. 
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This demonstrates that removing endogenous estrogen significantly reduces the expression of 
cytotoxic and helper cytokines in CD4+ Ag-specific TILs activated with their cognate Ag.  
Removal of Endogenous Estrogen Decreases CD4+ TIL Polyfunctionality during 
Immunotherapy  
 
To assess if polyfunctionality of adoptively transferred T cells is enhanced and/or 
regulated by the presence and availability of endogenous estrogen, TILs from sham and OVX 
females and sham males were activated using T2 cells as described before. Activated T cells 
were then stained using fluorescent antibodies against six different intracellular cytokines 
(TNF, IFN, IL-2, IL-4, IL-17a, and IL-22), and the cell surface lytic marker CD107a as 
described in Chapter V. All the different 128 combinations of these markers that were expressed 
simultaneously by activated TILs were calculated using tandem analysis with FlowJoX Boolean 
gates, Pestle, and SPICE. Then, the percent frequencies of TILs expressing each marker 
combination were added into 7 categories depending on the number of markers expressed 
simultaneously, from one through seven markers. T cells were considered polyfunctional if they 
expressed more than two markers simultaneously. The frequencies of cells expressing 6 and 7 
markers simultaneously were under 1% so they were not depicted on the graphs in Figure 36. 
Significantly higher frequency of CD8+ female TILs, regardless of the estrogen level, expressed 
3 or 4 markers simultaneously compared to males (Figure 36 A). A significantly higher 
frequency of male CD8+ TILs expressed two markers simultaneously compared to sham and 
OVX female TILs (Figure 36 A). These data demonstrate that adoptively transferred CD8+ 
female T cells are inherently more polyfunctional than male T cells regardless of physiological 
estrogen presence. A significantly higher frequency of CD4+ TILs from sham females expressed 
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three markers simultaneously compared to OVX female TILs (Figure 36 B), demonstrating that 
removal of endogenous estrogen reduces CD4+ T cell polyfunctionality. 
 
 
 
 
 
 
Figure 36. Female CD8
+
 Ag-specific TILs are More Polyfunctional than Male CD8
+
 TILs 
Independently of Estrogen, but Removal of Endogenous Estrogen Diminishes Female 
CD4
+
 TIL Polyfunctionality. Human CD8
+
 and CD4
+
 Ag-specific T cells were isolated from 
HCC livers of sham females, OVX females, and sham male mice and co-cultured with T2 target 
cells at a 1:1 ratio for 5 hours in the presence of protein transport inhibitors. Then, cells were 
intracellularly stained for cytokines TNF, IFN, IL-2, IL-4, IL-17a, and IL-22 and the lytic 
marker CD107a. Using FlowJoX Boolean combinatorial gates the % frequency of T cells 
expressing every combination of these 7 markers simultaneously was generated and added into 
7 categories. A) The percent frequency of CD3
+
CD34
+
CD8
+
 TILs that expressed one through 
five markers simultaneously when activated with their cognate antigen. B) The percent 
frequency of CD3
+
CD34
+
CD4
+
 TILs that expressed one through five markers simultaneously 
when activated with their cognate antigen.  ACT day 40: n=5 sham females, n=5 OVX females, 
n=6 sham males. Each mouse plotted and the standard error of the mean indicated. Data were 
analyzed by MANOVA and Tukey’s post-hoc. p<0.0001=****, p<0.001=***, p<0.01=**, 
p<0.05=*. 
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 Analysis of all the possible marker combinations simultaneously expressed showed that 
significantly higher frequencies of sham female CD4+ T cells expressed combinations including 
CD107a+IFN+TNF+, IFN+IL-2+TNF+ and IFN+IL-17+TNF+ than OVX female T cells 
(Figure 37). On the other hand, even if significance was not achieved, higher frequencies of 
OVX female CD4+ TILs expressed combinations including IFN alone, TNF alone, or 
IFN+TNF+ (Figure 37). Overall, these data demonstrate that endogenous estrogen enhances the 
expression of polyfunctional phenotypes of three markers in CD4+ TILs used for 
immunotherapy. In addition, removal of endogenous estrogen enhances the expression of mono- 
and bifunctional phenotypes in CD4+ TILs found after ACT immunotherapy. 
  Overall, the data presented in this chapter demonstrate that estrogen removal during ACT 
immunotherapy for HCC reduces Ag-specific T cell survival and tumor infiltration, impairs T 
cell activation and decreases CD4+ T cell cytokine production and polyfunctionality. These 
results were obtained by comparing sham female to OVX female mice. Surgically removing the 
ovaries not only eliminates the main source of estrogen on the body but was also shown to 
decrease progesterone and increase testosterone serum levels [459]. In order to conclude that 
estrogen mediates T cell function during ACT immunotherapy, the effects of progesterone and 
testosterone on T cell function need to be ruled out. In order to test this, a second set of 
experiments in which estrogen is added back to OVX females during ACT immunotherapy needs 
to be performed. Estrogen can be given back orally or subcutaneously via estradiol capsules to 
obtain physiological estrogen concentrations in the serum of OVX females [460]. If adding back 
estrogen to OVX mice via estradiol capsules enhances Ag-specific T cell tumor infiltration, 
activation state, cytokine production and polyfunctionality to levels similar to those found in 
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sham females, then estrogen signaling alone mediates all these aspects of T cell function. This 
would indicate that estrogen can directly enhance the efficacy of ACT immunotherapy. Based on 
the results obtained in the experiments testing the effects of estrogen signaling in vitro that 
indicated estrogen enhances expression of T cell cytokines and polyfunctionality in response to 
Ag-stimulation this is the most likely scenario. If rescuing estrogen in OVX mice does not 
enhance Ag-specific T cell function to levels similar to those seen in sham female mice, then 
estrogen alone does not mediate T cell function. This could indicate that the reduction in 
progesterone or the increase in testosterone serum concentrations induced by ovariectomy are 
detrimental for T cell tumor infiltration, activation, cytokine production, and polyfunctionality. 
Progesterone was previously shown to exert immunosuppressive effects on human T cells during 
pregnancy by inhibiting IFN expression [461], promoting naïve T cell differentiation into Tregs 
[462], and by inhibiting Th1 differentiation [463] so it is not expected that the removal of ovaries 
and subsequent decrease in serum progesterone impairs T cell function. Testosterone was also 
shown to have immunosuppressive effects on T cells with humans with high testosterone levels 
exhibiting lower activation-induced pro-inflammatory cytokine production [464], decreased Th1 
differentiation [465], and increased IL-10 secretion by CD4+ T cells [466]. This indicates that the 
increase of serum testosterone after ovariectomy could mediate the reduced T cell proliferation, 
survival, cytokine production and polyfunctionality observed in OVX mice. Antagonistic effect 
of testosterone and estrogen on T cell function is also a possibility that could be tested by giving 
sham mice testosterone capsules with levels similar to those observed in males or OVX females, 
or alternatively treating OVX mice with a testosterone blocker and comparing T cell function 
during immunotherapy with sham females.  
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Figure 37. Removal of Endogenous Estrogen Diminishes the Frequency of CD4
+
 Ag-
specific TILs Expressing CD107a
+
IFN
+
TNF
+
, IFN
+
IL-2
+
TNF
+
 and IFN
+
IL-
17a
+
TNF
+
. Human CD8
+
 and CD4
+
 Ag-specific T cells were isolated from HCC livers of 
sham and OVX females and co-cultured with T2 target cells at a 1:1 ratio for 5 hours in the 
presence of protein transport inhibitors. Then, cells were intracellularly stained for cytokines 
TNF, IFN, IL-2, IL-4, IL-17a, and IL-22 and the lytic marker CD107a. Using FlowJoX 
Boolean gating and the software SPICE all the possible combinations of these 7 markers 
expressed simultaneously by T cells were generated. The heat map shows the mean % frequency 
of CD3
+
CD34
+
CD4
+
 Ag-specific TILs obtained from 5 mice that expressed each of the marker 
combinations depicted on the left. ACT day 40: n=5 sham females, n=5 OVX females. Data 
were analyzed by MANOVA and Tukey’s post-hoc. p<0.01=**, p<0.05=*. 
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Chapter Discussion 
 
 This chapter of the dissertation was aimed to characterize the effects of sex and estrogen 
on the T cell anti-tumor immune response generated during ACT immunotherapy. A forced 
oncogene expression HCC model in combination with a HCV NS3 antigen expression vector 
was used to generate HCV-expressing liver tumors in mice. Using this novel model, it was 
demonstrated that estrogen enhances the anti-tumor function of HCV Ag-specific T cells by 
increasing T cell tumor infiltration, survival, cytokine expression, and polyfunctionality. While 
some of these effects were observed in both CD8+ and CD4+ T cell populations when advanced 
stage tumors were present, enhanced T cell anti-tumor function was specially observed in the 
CD4+ T cell subset. Removal of estrogen during ACT immunotherapy decreased CD4+ Ag-
specific T cells infiltration and survival, and decreased overall CD4+ T cell functions including 
cytokine production and polyfunctionality. These results indicate that estrogen signaling during 
ACT immunotherapy could improve the anti-tumor immune response of CD4+ male and female 
Ag-specific T cells. 
 Using this HCV+HCC tumor model, it was first demonstrated that estrogen has a 
protective role against HCC where sham female mice, which have circulating physiological 
estrogen levels, showed reduced tumor burden compared to ovariectomized female and males, 
which had minimal circulating estrogen. While these results do support the findings of previous 
studies that estrogen has a protective effect on hepatocytes directly, more importantly, it was 
found that ACT immunotherapy using HCV Ag-specific T cells reduced HCC tumor burden. 
Furthermore, the differences were maintained based on the presence of physiological estrogen, in 
sham females, or very low estrogen, in OVX females and males. Thus suggesting that ACT 
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immunotherapy for HCC is enhanced by estrogen, and estrogen signaling should be considered 
in the development and optimization of T cell based immunotherapies. ACT immunotherapy 
using Ag-specific T cells was tested in mice 20 days after tumor challenge which developed 
early stage tumors when not treated, and no visible tumors when treated with ACT. On the other 
hand, mice that were treated with ACT immunotherapy 40 days after tumor challenge developed 
very advanced HCC tumors. The effect of ACT immunotherapy on tumor burden was partial 
with some of the ACT treated mice still presenting very advanced tumors. This could be due to 
the highly the fibrotic and cirrhotic HCC TME which was previously shown to inhibit T cell 
tumor infiltration and subsequent T cell anti-tumor responses [467]. Another possibility being 
CD8+ T cells getting exhausted due to continuous antigen stimulation by HCV expression in 
these large tumors.  
Tumor burden in ovariectomized females was far greater than in control females and 
surprisingly also greater than in males. This indicates that female adoptively transferred T cells 
for immunotherapy require physiological estrogen stimulation to generate a superior anti-tumor 
immune response. It was previously reported that HCC incidence and mortality significantly 
increase in post-menopausal women compared to pre-menopausal women and post-menopausal 
estrogen users. The results obtained in this study indicate that the increase in cancer incidence 
after menopause may be partially mediated by the dampening of T cell anti-tumor immune 
responses. Therefore, when designing of immunotherapies for post-menopausal women, their 
lack of physiological estrogen, and consequent reduced T cell anti-tumor responses need to be 
taken into account. 
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Part of the mechanism of enhanced therapeutic outcome can be demonstrated by the 
finding that estrogen enhanced T cell survival and T cell infiltration of HCC tumors. 
Specifically, estrogen enhanced the persistence of CD4+ T cells which were found in greater 
number in the spleen and infiltrating the tumors of sham females which have physiological 
estrogen compared to OVX females and males. It was previously reported that CD4+ helper T 
cells are critical for maintenance of CTL responses during cancer and infection [78-80].  CD4+ T 
cells are not only necessary for supporting CD8+ T cell survival but it has been shown that CD4+ 
T cell subsets Th1 Th2 and th17 are required for successful anti-tumor immune responses [468-
470]. It was found that the majority of the CD4+ T cells that persisted in females were from the 
Th2 and Th17 subsets ruling out immunosuppression by Tregs. The effect of estrogen signaling on 
CD8+ T cells was found to be controversial since it mainly affected their survival and infiltration 
when advanced tumors were present. This could indicate that estrogen signaling is especially 
important for CD8+ T cells survival and function in environments where strong immune 
tolerance and T cell exhaustion is being mediated by the tumor. Also, HCC tumors where shown 
to produce high local estrogen concentrations indicating that super-physiological estrogen could 
affect CD8+ T cells greater than physiological estrogen. 
In addition to infiltration, significantly higher frequencies of TILs from estrogen 
competent females expressed activation markers CD25 and CD69 than those of estrogen 
depleted females or males. Expression of CD69 and CD25 is upregulated upon T cell activation 
via TCR signaling, and is maintained during antigenic stimulation [471]. Estrogen signaling 
through ER and ER was shown to enhance some important signaling molecules downstream 
from the TCR like NFb, AP-1, and the NFAT pathways [211, 472, 473]. Up-regulation of these 
169 
 
 
 
activation markers indicate that estrogen enhances TCR signaling in response to Ag stimulation 
and subsequently increases the T cell activation state. Estrogen regulation of TCR signaling 
components and T cell activation was previously shown in a colitis model for autoimmunity 
[233], indicating that these findings not only apply to T cell function in cancer but also during 
autoimmunity. 
Functionally, expression of cytotoxic cytokines including IFN and TNF and the lytic 
marker CD107a was increased in antigen stimulated CD4+ TILs from sham females compared to 
OVX females. Expression of the Th2 cytokine IL-4 was also increased in antigen stimulated 
CD4+ and CD8+ TILs from sham females compared to OVX females. While IFN, TNF are 
cytokines expressed by cytotoxic and Th1 effector T cells, IL-4 is expressed mainly by T2 helper 
T cells. Estrogen can enhance the expression of these cytokines which are in the two ends of the 
inflammatory spectrum indicating that estrogen may be regulating the balance between 
cytotoxic/effector and Th2 helper T cell responses agreeing with the results obtained in the 
previous chapters in which estrogen signaling effect on Ag-specific function was investigated  in 
vitro. 
In combination with the results from previous chapters indicating that estrogen enhances 
CD4+ and CD8+ cytokine production directly as well as increases T cell polyfunctionality, results 
of this chapter demonstrate similar effects directly on T cells in vivo.  Specifically, estrogen 
enhanced the polyfunctionality of CD4+ TILs. The frequency of CD4+ Ag-specific T cells 
expressing three markers simultaneously in a polyfunctional manner was significantly higher in 
estrogen intact females compared to OVX, estrogen depleted females. Three marker 
combinations that were greatly expressed in CD4+ TILs in the presence of physiological estrogen 
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included CD107a+IFN+TNF+, IFN+IL-17a+TNF+, and IFN+IL-2+TNF+. These 
combinations include markers that are required for superior T cell anti-tumor immune responses, 
indicating that estrogen enhances anti-tumor immunity during ACT immunotherapy.   
Overall, the studies in this chapter demonstrate that physiological estrogen removal 
during ACT immunotherapy for HCC has a detrimental effect on T cell survival and anti-tumor 
function. These effects are especially observed on the CD4+ T cell subset indicating that estrogen 
signaling enhances the survival, tumor infiltration and polyfunctionality of CD4+ T cells. CD4+ T 
cells were previously shown to be critical for generating superior T cell anti-tumor responses, 
and for enhancing the efficacy of ACT immunotherapy by supporting CTL survival, function and 
by destroying tumor cells directly.  The results presented demonstrate a previously unappreciated 
role of estrogen signaling on CD4+ T cell function that is an avenue to enhancing infiltration, 
effectiveness, and survival of adoptive transferred T cells for immunotherapy. 
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CHAPTER VII 
OVERALL DISCUSSION AND FUTURE DIRECTIONS 
Discussion 
 
 Adoptive cell transfer immunotherapy using TCR gene-modified or Ag-specific T cells is 
rapidly evolving field. Several pre-clinical and clinical studies have had various levels of 
efficacy using TCR transduced T cells to treat different solid tumors and hematopoietic 
malignancies. Although evidence suggests the use of genetically modified Ag-specific T cells 
can be effective, several challenges remain in order to improve these therapeutics. While many 
studies have focused on optimizing Ag-specific T cells to overcome the immunosuppressive 
TME and to enhance tumor infiltration and Ag recognition, other host factors that can affect Ag-
specific T cells during ACT immunotherapy remain understudied.  
Evidence of this lack in research includes characterizing and an in depth understanding of 
the effects of sex and sex hormone receptor signaling on Ag-specific T cell function. Sex 
influences multiple aspects of adaptive immunity in humans. T cell populations and T cell subset 
phenotypes vary significantly depending on sex. Females have greater CD4+ T cell counts and 
higher CD4+:CD8+ ratios whereas age-matched males have higher CD8+ T cell frequencies [181-
184]. Females have higher numbers of activated and proliferating T cells in peripheral blood 
compared to males, and transcriptional analyses demonstrates that activated female T cells 
upregulate more antiviral and pro-inflammatory genes compared to T cells from males [185]. 
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While some of these sex-differences in T cell phenotype are genetically and 
environmentally mediated, a lot of these differences heighten or decrease with puberty and 
reproductive senescence indicating a sex hormone receptor involvement. Estrogen is considered 
the female sex hormone and it is present at physiological concentration (0.5 nM) in females and 
at low concentrations in males and post-menopausal females (<0.1 nM). Estrogen signaling was 
shown to affect the differentiation, maturation, and function of T cells as described in the 
introduction of this dissertation. For example, estrogen signaling was shown to enhance T cell 
differentiation [203, 474], to increase the secretion of cytokines such as IL-10 and IFN , 
and to induce the expression of the Treg transcription factor FoxP3 [196]. Throughout available 
scientific literature, most of the important aspects concerning the role of estrogen on T cells were 
investigated in autoimmunity models and at hormone concentrations limited to physiological and 
pregnancy estrogen levels. Other ranges of estrogen dosages were not investigated. Knowing that 
sex and estrogen have direct effects on T cell differentiation and function, it is important to 
carefully characterize their effects on Ag-specific T cells for immunotherapy in order to identify 
possible mechanisms that can be targeted to enhance T cell anti-tumor immune responses and 
immunotherapy efficacy.  
 The effects of sex and estrogen signaling on T cells and other immune cells result in 
differences on pathogenesis of diseases that arise from immune cell function dysregulation, like 
autoimmunity, or diseases that are heavily controlled by immune responses, like infections and 
cancer. One malignancy that shows a pronounced sex-bias and is heavily affected by estrogen is 
HCC. HCC is significantly more prevalent in males compared to pre-menopausal females [360, 
361]. Post-menopausal females that are not undergoing estrogen HRT are also more prone to 
develop HCC than pre-menopausal females and estrogen users [311]. The protective role of 
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estrogen against HCC was shown to be partially mediated by estrogen receptor signaling 
inhibition of IL-6-mediated chronic inflammation and tumor associated macrophage polarization 
[293, 318]. While this research beautifully demonstrated the anti-HCC role of estrogen, the 
impact of estrogen signaling on other HCC tumor infiltrating immune like T cells remains 
unclear and needs further investigation. ACT immunotherapy using genetically modified T cells 
showed some success on treating HCC in pre-clinical models and clinical trials but the efficacy 
of ACT fighting HCC remains unsatisfactory. These data indicate that there is a high need for 
ways to improve the anti-tumor function of Ag-specific T cells in order to generate more 
successful ACT immunotherapy for HCC. The work performed in this dissertation was aimed to 
characterize the role of estrogen signaling on T cell function in vitro, and during ACT 
immunotherapy against HCC in vivo. In the following sections, the results obtained and their 
implications for T cell biology and tumor immunology are discussed.  
First, the effect of estrogen signaling was studied on the function of Ag-specific T cells in 
vitro. It was observed that estrogen stimulation, especially at super-physiological concentrations, 
was able to modulate Ag-specific T cell cytokine expression and secretion in response to cognate 
Ag stimulation. Estrogen signaling through ER and not ER enhanced the expression and/or 
secretion of TNF, IFN, and Granzyme B in Ag-specific T cells from males and females in a 
dose dependent manner in response to Ag stimulation. IFN, TNF, and Granzyme B are 
cytokines produced by cytotoxic CD8+ T cells and Th1 CD4+ T cells and can directly destroy 
tumor cells. IFN is cytotoxic to certain malignant cells, and it enhances MHC class I expression 
[406]. Granzyme B directly lyses malignant cells, and TNF promotes T cell activation, co-
stimulation, and promotes certain cancer cell death [406]. Estrogen signaling through ER and 
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not ER completely controlled the expression of IL-4 in response to Ag stimulation and, in 
addition, it was shown to enhance IL-4 expression and secretion in Ag-specific T cells from 
males and females in a dose dependent manner. IL-4 promotes T cell and B cell survival, induces 
Ig class switch to IgE and IgG in B cells, drives long-term development of CD8+ T cell memory, 
and in combination with TGF it drives Th9 T cell subset differentiation which are T cells that 
augment anti-tumor responses in ACT models [387-389, 407, 408]. Overall these data 
demonstrate for the first time that estrogen signaling through ER enhances the expression and 
secretion of cytokines that promote stronger CD4+ and CD8+ T cell anti-tumor responses hence 
estrogen signaling through ER can enhance the efficacy of ACT immunotherapy. Most 
importantly, the largest effects of ER signaling enhancing cytokine expression were observed at 
super-physiological estrogen concentrations which mimic the elevated estrogen concentrations in 
the HCC TME. This indicates that infiltrating T cells from male and females will could be 
generating stronger anti-tumor responses in response to estrogen stimulation in the TME. 
EREs were found in the promoters of TNF and IFN indicating that ER ligand-bound 
ERE-independent signaling could be enhancing transcription of these genes in response to 
estrogen stimulation. In addition, an ERE on the promoter of T-BET, a transcription factor that 
induces IFN expression, was found indicating that ER signaling could be also upregulating 
transcription of T-BET. Apart from inducing IFN expression, T-BET is well known to promote 
Th1 differentiation while suppressing Th2 differentiation. No ERE was found on the promoter of 
IL-4 which was surprising due to the strong effects of ER signaling on IL-4 expression 
observed in T cells in response to Ag stimulation. Considering IL-4 related genes, an ERE was 
found on the promoter of GATA3, a transcription factor that induces IL-4 expression. This 
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indicates that ER could enhance IL-4 expression by enhancing GATA3 transcription through a 
ligand-bound ERE-dependent signaling. GATA3 is well known to promote Th2 differentiation. 
Based on these results, estrogen signaling through ER enhances expression of prototypic Th1 
and Th2 cytokines indicating that estrogen signaling does not favor differentiation towards one 
subset over the other, but it most likely plays a balancing role between Th1 and Th2 T cell 
responses. Estrogen signaling not only enhances expression of cytokines that generate stronger 
anti-tumor immune responses and facilitate T cell survival, but it balances cytotoxic type I and 
survival type II T cell responses. Type I and type II T cell responses were both shown to enhance 
the anti-tumor immune response during ACT immunotherapy, especially when both CD4+ helper 
Th1 and Th2 cells and cytotoxic CD8+ T cells were transferred as a mixture into patients 
indicating a synergistic effect between them [82, 475].  Studies in the past have reported 
contradicting evidence on the effect of estrogen on T cell cytokine production. While some 
groups demonstrated an inhibitory effect of estrogen on the expression of TNF and IL-4, other 
groups simultaneously reported enhancing effects of estrogen signaling on the expression of 
these cytokines. The effects observed were concentration dependent, and some studies reported 
that pregnancy estrogen levels (higher than physiological) induce IL-4 expression and inhibit 
TNF expression, while physiological estrogen levels induce TNF and IFN expression. Based 
on this evidence, it was believed that physiological estrogen signaling promotes type I T cell 
responses and Th1 CD4+ T cell function while pregnancy estrogen promotes type II T cell 
responses and Th2 CD4+ T cell function. The results reported in this dissertation help clarify 
some of the contradicting evidence in the field and demonstrate for the first time that in the case 
of human Ag-specific T cells from both sexes, the effect of estrogen is concentration and 
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receptor independent and that at both physiological and super-physiological concentrations 
induce Th1 and Th2 T cells responses in a dose dependent manner (Figure 38). 
An attribute of genetically modified T cells that was previously correlated with enhanced 
clinical outcome is their ability to express multiple functional markers simultaneously in 
response to Ag stimulation, or their polyfunctionality. One clinical study in which patients with 
aggressive refractory non-Hodgkin’s lymphoma were treated with CD19 CAR-T cells 
demonstrated that highly polyfunctional T cells mediated stronger anti-tumor immune responses 
and tumor rejection compared to those with lower polyfunctionality. Polyfunctionality of CAR-T 
cells was determined immediately before CAR-T cell infusion by measuring the expression of 32 
different effector, cytotoxic, helper, and chemotactic cytokines upon Ag stimulation. Cells that 
expressed >2 of these markers simultaneously were considered polyfunctional. Polyfunctional 
CD8+ and CD4+ CAR-T cells expressed combinations of markers including but not limited to 
IFN, Granzyme B, IL-8, IL-17a, and IL-2 [428]. While T cell populations only showed 
approximately 20% of polyfunctional cells, they correlated with clinical outcome significantly 
more than those patients that received monofunctional CAR-T cells [428]. Polyfunctionality of 
Ag-specific T cells also correlated with better disease outcome when patients were treated with 
immunotherapy in combination with other cancer therapies such as chemotherapy. B cell 
lymphoma challenged mice were treated with chemotherapy and then given ACT 
immunotherapy with polyfunctional or monofunctional CD4+ Ag-specific T cells. Mice showed 
reduced tumor burden when they were given adoptive transfer of polyfunctional Ag-specific 
CD4+ T cells compared to monofunctional CD4+ T cells and compared to mice treated with 
chemotherapy alone [417]. T cell polyfunctionality was also shown to correlate to clinical 
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prognosis and response to immunotherapeutic interventions in solid tumors including melanoma 
and breast cancer. Advanced melanoma patients that were treated with Ipilumab (anti-CTLA-4 
Ab) showed better disease prognosis when polyfunctional tumor Ag-specific CD4+ and CD8+ T 
cells were present infiltrating the tumor compared those patients with infiltrating monofunctional 
T cells. CD4+ and CD8+ polyfunctional cells expressed combinations of markers including but 
not limited to IFN, TNF, IL-2, and Granzyme B [426]. In addition, polyfunctional but not 
monofunctional tumor-reactive CD8+ T cells accumulated in the peripheral lymphocyte pool of 
those patients with advanced melanoma that were treated with autologous TIL immunotherapy 
and showed significant tumor regression compared to non-responders [476]. These 
polyfunctional CD8+ T cells persisted up to 1 year after infusion and even if they expressed PD-
1, they proved to be cytotoxic when re-stimulated with tumor Ag [476]. Polyfunctional CD8+ 
Ag-specific T cells were found infiltrating the tumors of breast cancer patients, and when 
isolated, polyfunctional CD8+ TILs were shown to retain cytotoxic ability against tumor target 
cells despite high PD-1 expression compared to monofunctional CD8+ TILs [477]. Overall, these 
studies demonstrated that CD8+ and CD4+ Ag-specific T cell polyfunctionality not only 
correlates with stronger T cell anti-tumor responses and increased tumor rejection, but also with 
augmented persistence of cytotoxic T cells that can exert strong responses in response to Ag 
stimulation long time after infusion. Since estrogen signaling was shown to directly enhance the 
expression of several cytokines in Ag-specific T cells, it was hypothesized that estrogen 
signaling increases Ag-specific T cell polyfunctionality which can result in better 
immunotherapy efficacy. 
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Figure 38. Proposed Mechanism I: Estrogen Signaling Through ER Enhances Expression of TNF, IFN, and IL-4 and 
Modulates the Balance Between Th1/Type I and Th2/Type II T Cell Responses and Differentiation. Estrogen signaling through 
ER gnomically enhances the expression and secretion of Type I/Th1 cytokines IFN and TNF and the Type II/Th2 cytokine IL-4. 
ER is also able to genomically enhance the expression of Th1 transcription factor T-BET and Th2 transcription factor GATA3 
through the EREs on their promoters. Overall this leads to the hypothesis that estrogen signaling through ER mediates balance 
between Type I and Type II, and Th1 and Th2 T cell differentiation. 
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Considering these facts, the effect of estrogen signaling regulating Ag-specific T cell 
polyfunctionality in response to antigen stimulation was determined by activating human male 
and female HCV Ag-specific T cells with target cells expressing the HCV Ag. One of the most 
striking results found in this dissertation was that estrogen signaling through ER and nor 
ER enhances male and female CD8+ and CD4+ Ag-specific T cell polyfunctionality. Estrogen 
signaling through ER increased the percentage of Ag-specific T cells that expressed three 
markers simultaneously in response to Ag stimulation and decreased the percentage of T cells 
that expressed only one marker in response to Ag stimulation. The marker combinations that 
were shown to be enhanced by ER signaling when CD4+ and CD8+ T cells were analyzed 
separately included CD107a+IFN+TNF+ and IFN+IL-4+TNFa+ which are combinations 
including cytotoxic/effector and Th2 T cell cytokines, again known to mediate stronger anti-
tumor immune responses and T cell survival. ER signaling reduced the percentage of T cells 
expressing IFN+TNF+, and IFN+ or TNF+ in combination with no other marker. This does 
not mean that expression of these markers is overall downregulated by ER, but it means that 
expression of these markers in combination with other markers such as IL-4 and CD107a is 
enhanced. Interestingly when the data was analyzed for the bulk Ag-specific T cell population 
without dividing it into CD8+ and CD4+ subsets, additional polyfunctional marker combinations 
were shown to be affected by estrogen signaling through ER and ER. Estrogen signaling 
through ER was shown to increase the percentage of Ag-specific T cells expressing 
polyfunctional marker combinations such as IFN+IL-4+TNFa+, IFN+IL-2+IL-4+IL-17a+TNF+, 
and IL-2+IL-4+TNF+. Strikingly, inhibition of ER during estrogen stimulation enhanced the 
percentage of T cells expressing these polyfunctional combinations even more than estrogen 
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alone, indicating that ER signaling actually inhibits Ag-specific T cell polyfunctionality. While 
these polyfunctional phenotypes were expressed by low percentage of cells, other studies 
confirmed that even if there is a small percentage of polyfunctional cells in a T cell population, 
stronger anti-tumor responses are still achieved compared to highly monofunctional T cell 
populations [428, 433]. Estrogen signaling through ER was shown to decrease the percentage 
of Ag-specific T cells expressing monofunctional marker combinations such as IFN+ and 
TNF+. On the other hand, inhibition of ER during estrogen stimulation decreased the 
percentage of T cells expressing these monofunctional combinations even more than estrogen 
alone indicating that ER signaling actually promotes expression of monofunctional phenotypes 
over polyfunctional ones. The effect of estrogen signaling on Ag-specific T cell 
polyfunctionality had been never studied before and these are completely novel findings that 
could help in the design of stronger immunotherapies.  
T cell polyfunctionality was reported to be induced by TCR signaling and antigen 
sensitivity. T cells that are stimulated with low sensitivity antigens display reduced TCR 
downstream signaling activation and are less polyfunctional than those activated with high 
sensitivity antigens [421, 478]. These data leaded to the hypothesis that estrogen signaling 
through ER enhances TCR downstream signaling and subsequent polyfunctionality. Some TCR 
downstream signaling molecules were shown to be estrogen sensitive. For example, lck, ZAP70, 
and c-Fos contain EREs on their promoters indicating possible ER genomic regulation of their 
expression. Also, estrogen was shown to enhance other TCR downstream pathways such as the 
MAP kinase, the NFAT, and the NFB pathways [436, 437, 439]. This indicates that ER 
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signaling could be enhancing TCR downstream signaling pathways which subsequently result in 
polyfunctionality (Figure 39).  
Another important implication of T cell polyfunctionality is that it promotes T cell 
memory formation. In vaccination studies against viruses, bacteria, and parasites the 
polyfunctionality of pathogen Ag-specific T cells after vaccination was not only associated with 
favorable disease outcome but also with higher effector function and effector memory formation 
[479-482]. Long-lasting polyfunctional memory cells are found at low frequencies in the 
peripheral circulation but they can rapidly proliferate and elicit strong effector response upon 
Ag-stimulation [483].  ER signaling could be promoting the development of more 
polyfunctional memory Ag-specific T cells during ACT immunotherapy, indicating an 
enhancement of long-lasting anti-tumor T cell responses. This is not only important to destroy 
the primary tumor and possible metastatic sites but also in order to prevent relapse. The ER-
mediated enhancement of polyfunctional T cells could mean the generation of more long-lasting 
memory Ag-specific T cells that are reactive to a specific tumor Ag and circulate the circulation 
of patients surveilling for new tumor sites expressing that Ag and eliminating them. Overall, this 
indicates that ER signaling could not only enhance the short-term efficacy of immunotherapy 
but also enhance immunotherapy over time through the generation of highly polyfunctional 
memory cells (Figure 39). 
Interestingly the effect of estrogen signaling on cytokine production and 
polyfunctionality was observed equally in Ag-specific T cells from male and female donors. This 
indicates that estrogen signaling through ER and ER exerts the same effects on T cells no 
matter on the sex of the donor. Estrogen signaling can be used as a way of enhancing ACT 
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immunotherapy in both males and female patients. This is especially important for males and 
post-menopausal females that have enhanced incidence rates of cancer such as HCC. 
During ACT immunotherapy both cytotoxic CD8+ and CD4+ Ag-specific T cells target 
tumor cells. Cytotoxic CD8+ directly lyse the tumor cells by secretion of perforin and Granzyme 
B upon Ag stimulation. With the exception of Tregs which are immunosuppressive, CD4+ T cells 
(Th1, Th2, and Th17 subsets) can either directly eliminate tumor cells through cytotoxic 
mechanisms or indirectly by modulating other immune infiltrating cells found in the TME. For 
example, CD4+ Th cells can express CD40L which interacts with CD40 on DCs and promotes 
the expression of MHC and other co-stimulatory molecules [484]. Furthermore, CD4+ Th cells 
can directly enhance CTL anti-tumor responses. CD4+ Th cells secrete IL-2 which is a growth 
factor that enhances survival and helps recruit CTLs to the tumor site [484]. IFN production by 
CD4+ Th1 cells results in the upregulation of MHC molecules on tumor cells leading to 
enhanced T cell (CTL and Th) recognition [484]. In addition to being required for the generation 
of optimal primary CTL responses, a number of studies have shown a critical need for CD4+ T 
cells in the generation and maintenance of memory CD8+ T cells [484]. Overall these data 
indicate that functional CD8+ and CD4+ T cells are required for the generation of superior anti-
tumor responses during immunotherapy. Since estrogen signaling was showed to enhance the 
function of both female and male CD8+ and CD4+ T cells, it was hypothesized that it also 
enhances the CD8+ and CD4+ anti-tumor responses during immunotherapy for HCC in vivo.
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Figure 39. Proposed Mechanism II: Estrogen Signaling through ER Enhances Ag-specific T Cell Polyfunctionality through 
Enhancement of TCR Downstream Signaling Pathways. Estrogen signaling through ER enhances male and female Ag-specific 
T cell polyfunctionality by genomically inducing the expression of TCR downstream signaling molecules like lck, ZAP70, and c-Fos 
through the ERE on their promoters, and by enhancing signaling through the MAP kinase, the NFAT and the NFB pathways. 
Enhancement of these pathways through ER results of the expression of polyfunctional combination of several markers 
simultaneously by one T cell, which can subsequently lead to memory T cell formation. 
184 
 
 
The role of estrogen signaling during ACT immunotherapy was then studied in vivo. 
Female mice, with physiological circulating estrogen concentrations, and ovariectomized female 
mice and male mice, with minimal circulating estrogen concentrations, were challenged with 
HCV+HCC and given ACT with sex-matched HCV Ag-specific human T cells. First, HCC 
tumor burden was assessed and, as expected, male mice showed increased tumor burden 
compared to sham females. OVX females showed the most advanced tumor burden compared to 
sham males and females due to loss of the protective role of estrogen against HCC. ACT 
immunotherapy reduced tumor burden on sham and OVX females and males indicating 
therapeutic potential. OVX females still showed very advanced tumors after ACT treatment, 
indicating that loss of estrogen not only enhanced tumor burden but also decreased the T cell 
anti-tumor responses generated during immunotherapy. Analysis of the phenotype of infiltrating 
T cells revealed reduced tumor infiltration of Ag-specific T cells, especially CD4+ T cells, in 
OVX females and males. Lack of physiological estrogen during ACT immunotherapy not only 
reduced tumor infiltration but also overall CD4+ T cell survival. In addition, lack of 
physiological estrogen during ACT immunotherapy hindered Ag-specific T cell activation state. 
TILs isolated from sham and OVX females and sham males were then activated with target cells 
expressing their cognate Ag and cytokine expression and polyfunctionality were measured.  
While CD8+ T cells did not show significant differences in polyfunctionality between sham and 
OVX female TILs, they showed an overall reduction on IL-4 expression in OVX females further 
indicating that estrogen directly regulates IL-4 expression in Ag-specific T cells. CD4+ TILs 
from OVX females showed decreased expression of IL-4, TNF, IFN, and the lytic marker 
CD107a compared to sham females. Furthermore, polyfunctionality of CD4+ TILs was also 
decreased in the absence of physiological estrogen with significantly lower percentages of OVX 
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female TILs expressing 3 markers simultaneously compared to sham female CD4+ TILs. Overall, 
these results indicated that physiological estrogen signaling during ACT immunotherapy 
enhances the survival, tumor infiltration, and function of CD4+ Ag-specific T cells. Considering 
the important role of CD4+ T cells both directly targeting tumor cells and enhancing CD8+ T cell 
function and survival, estrogen signaling was found to be an important factor to consider into 
enhancing the efficacy of ACT immunotherapy. 
In summary, the results presented in this dissertation are encouraging that estrogen 
signaling on Ag-specific T cells could serve as a way to enhance the efficacy of immunotherapy 
for HCC. Estrogen signaling through ER was found to enhance the expression of key T cell 
effector cytokines including IFN, TNF, and Granzyme B on Ag-specific T cells from male and 
female donors when activated with their cognate Ag in vitro and in vivo. IFN, TNF, and 
Granzyme B are required for tumor cell destruction. Estrogen signaling through ER was also 
shown to completely regulate the expression of the Th2 cytokine IL-4 on male and female Ag-
specific T cells activated with their cognate Ag in vivo and in vitro which is not only necessary 
for Th2 differentiation but promotes T cell survival and memory formation. Enhancement of 
these cytokines is believed to represent the ability of ER signaling to regulate the balance 
between Th1 and Th2 differentiation or type I and type II T cell responses. Estrogen signaling 
through ER was shown to enhance T cell polyfunctionality on male and female Ag-specific T 
cells activated with their cognate Ag.  ER signaling is believed to enhance TCR downstream 
signaling pathways which result on increased T cell polyfunctionality (Figure 40). Notably 
estrogen effects on T cell cytokine production were observed at physiological and super-
physiological concentrations in a dose dependent manner. Using an in vivo model for HCC, it 
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was found that physiological estrogen not only has a protective role against HCC, but it also 
enhances ACT immunotherapy. Estrogen presence during ACT immunotherapy for HCC was 
found to increase the tumor infiltration, survival, activation state, cytokine production and 
polyfunctionality of Ag-specific T cells. These effects were especially observed on the CD4+ T 
cell subset. Reduction of CD4+ T cell survival, cytokine expression, and polyfunctionality in the 
absence of physiological estrogen reduces ACT immunotherapy efficacy by not only lacking 
proper CD4+ anti-tumor responses but also by the lack of support to the CD8+ subset anti-tumor 
responses. Overall these results showed that estrogen signaling at physiological and super-
physiological concentrations can enhance the function of male and female CD8+ and CD4+ Ag-
specific T cells. This regulation of T cell function is especially important during immunotherapy 
in vivo, where physiological estrogen enhanced survival, tumor infiltration, and function of CD4+ 
Ag-specific T cells which result on enhanced immunotherapy efficacy through the support of 
CD8+ anti-tumor responses. In conclusion, estrogen signaling on Ag-specific T cells could 
enhance the efficacy of ACT immunotherapy to treat cancer in male and female patients. 
Future Directions 
 
The questions posed, results observed, and findings drawn from the data generated in this 
dissertation are novel and unique and provide critical information that will open the doors to new 
advancements in clinical outcomes as well as new research endeavors in the field of 
immunotherapy. The focus of this study was to characterize and mechanistically understand the 
biology of sex and estrogen signaling on Ag-specific T cell activation, function and survival in 
the context of cancer treatment. 
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Figure 40. Overall Proposed Mechanism: Estrogen Signaling through ER and ER Enhances Ag-specific T Cell Function 
Resulting in the Enhancement of ACT Immunotherapy Efficacy. Estrogen signaling though ER results in the enhancement of 
expression of key Type I/Th1 and Type II/Th2 cytokines and estrogen signaling through ER results in the enhancement of male and 
female Ag-specific T cell polyfunctionality. Physiological estrogen enhances the survival, tumor infiltration, activation, and function 
of CD4
+
 Ag-specific T cells in vivo which results in stronger anti-tumor immune responses during ACT immunotherapy. 
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My data, as presented, clearly demonstrates that although T cells are intrinsically different due to 
sex, meaning T cells from male donors are intrinsically different from T cells isolated from 
female donors, estrogen signaling has a profound effect on the function of T cells from both 
males and female donors. Therefore, it can be concluded that estrogen signaling mediates similar 
effects on the function of T cells independently of sex. Estrogen signaling occurs upon ligation 
of its nuclear receptors, ER and ER and results in enhanced function of Ag-specific T cells 
that can be used for immunotherapy in vitro and in vivo. These are very encouraging findings 
that indicate estrogen signaling can be used as a mean of enhancing ACT immunotherapy for 
both male and female cancer patients. In this dissertation, human Ag-specific T cells were 
acutely treated with estrogen (2-hour treatment) which elicited an enhancement of T cell 
cytokine production and polyfunctionality, especially at super-physiological concentrations. 
According to these findings, genetically modified T cells from cancer patients used for ACT 
immunotherapy can be assessed for function in response to Ag stimulation, and if patients’ T 
cells do not express and produce important cytokines for anti-tumor function including but not 
limited to, IFN, TNF, or Granzyme B, then they can be acutely treated with super-
physiological estrogen concentrations prior to infusion. This estrogen treatment will enhance the 
effector functions through ER ligation, and the polyfunctionality, specifically the combined 
simultaneous production of anti-tumor effector and helper molecules, of T cells through 
ER ligation which will result in generating stronger and more durable anti-tumor immune 
responses once transferred into the patient.  
Since adoptively transferred T cells will be circulating in the patients for long periods of 
time, it is possible that an acute estrogen treatment will not be enough to maintain enhanced T 
cell function in the long run. Because T cells benefit from estrogen presence for longer time 
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periods, estrogen could be added to patient’s T cells cultures during the in vitro Ag-specific T 
cell expansion performed prior to adoptive cell transfer.  This approach could be first tested in 
mice, where HCV Ag-specific T cells are given physiological or super-physiological estrogen 
during the 3 to 5-day expansion performed prior to ACT immunotherapy. The effect of these 
prolonged treatments would need to be tested on T cell subset distribution and function. Based 
on the results obtained in this dissertation, prolonged estrogen treatment could affect the CD4+ T 
cell subset distribution skewing it towards the Th1 and Th2 subsets. On the other hand, profound 
differences in T cell function are expected after prolonged estrogen stimulation including 
enhanced cytokine production and polyfunctionality. Long-term high concentration estrogen 
exposure was shown to downregulate the expression of ER and ER both mRNA and protein 
levels in breast cancer cells and non-reproductive estrogen target tissues [485-487]. This 
estrogen-regulated feedback loop directly inhibits the transcription of the ERs through ligand-
bound ER genomic signaling. The suppressive effects of estrogen on ER expression were 
observed after 6 hour estrogen stimulation and remained for 24 to 48 hours [485]. Decreased 
expression of ERs on Ag-specific T cells would mean loss of the beneficial ER signaling 
mediated enhancement of T cell cytokine production and polyfunctionality. Overall, indicating 
that acute estrogen treatment of Ag-specific T cells would be a better approach than long-term 
estrogen exposure.  
The work of this dissertation also determined the different roles of ER compared to 
ER signaling on T cell function. While ER enhanced the expression and secretion of specific 
cytokines, one of the most intriguing discoveries of this study indicated that ER increases the 
overall T cell polyfunctionality through mechanisms believed to enhance TCR downstream 
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signaling. Knowing that ER signaling results in enhanced T cell function and polyfunctionality 
which can result in enhanced T cell memory formation, ER signaling can be used to generate 
polyfunctional and long-lasting Ag-specific T cell responses. In order to enhance ER signaling, 
Ag-specific T cells could be treated with an ER-specific agonist prior to adoptive transfer. In 
addition, the ER-specific agonist could be delivered intra-tumorally during ACT 
immunotherapy to enhance the function of infiltrating Ag-specific T cells. Delivering the ER 
agonist into the TME would not only affect T cells but also tumor cells and other infiltrating 
immune cells. In the context of HCC, estrogen signaling was shown to inhibit tumor growth and 
TAM polarization which means that delivering an ER agonist may exert anti-tumor functions as 
well as inducing stronger T cell anti-tumor immune responses. While this would work when 
tested in NSG-A2+ mice deficient of other infiltrating immune cells, the role of ER signaling on 
the function of other immune cells in the TME including B cells, MDCSs, and DCs is unknown 
and would need to be further investigated. In order to limit the beneficial effect of ER signaling 
to T cells, human Ag-specific T cells can be genetically modified to overexpress ER. ER 
overexpression would ensure estrogen ligand binding to and activation of ER signaling over 
other estrogen receptors, including ER and GPER, present in the T cells. Enhanced ER 
signaling in T cells would increase polyfunctionality, production of several anti-tumor cytokines 
simultaneously by T cells, and increased T cell memory formation hence enhancing the efficacy 
of ACT immunotherapy. This would be especially important for malignancies such as HCC 
which can produce high concentrations of local estrogen, or malignancies located on sexual 
tissues like the ovaries or the breasts. 
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In addition to providing ways to enhancing immunotherapy to treat cancer, the results 
obtained in this study can enhance the treatment of other diseases such as infections and auto 
immune diseases. Treatment of infections using ACT immunotherapy showed some success in 
pre-clinical and clinical studies treating viral infections to which vaccines do not exist, or that 
exhibit drug resistance including HIV, CMV, and Epstein-Barr virus (EBV) infections [488-
490]. In spite of some success, ACT immunotherapy for viral infections was sometimes rendered 
unsuccessful due to large viral loads which were not able to be completely eliminated by 
transferred T cells due to T cell exhaustion under to continuous Ag stimulation, and by reduced 
transgenic T cell proliferation leading to reduced T cell numbers [491]. Interestingly, ACT 
immunotherapy for HIV infected patients using cytotoxic CD8+ T cells was shown to require 
production of high amount of Granzyme B [492], and the presence of functional helper CD4+ T 
cells [493, 494]. The results of this dissertation showed that both the secretion of Granzyme B by 
CD8+ Ag-specific T cells, and the persistence and anti-tumor function of CD4+ T cells were 
enhanced by estrogen signaling. This indicates that ACT immunotherapy for HIV could be 
enhanced by estrogen signaling enhancing the function of CD4+ and CD8+ T cells. 
CD4+ T cell subsets were shown to be able to mediate several aspects of autoimmune 
inflammation. While Th1 and Th17 cells drive the chronic autoimmune response, Tregs were 
shown to exert immunosuppressive functions in other T cell functions during autoimmunity 
[495]. In some autoimmune diseases such as RA it was shown that Tregs function is severely 
impaired [495]. The results presented in this dissertation indicated that estrogen enhances T cell 
function including pro-inflammatory cytokine production and polyfunctionality. Based on these 
findings, removal of estrogen or inhibition of ER and ER signaling on T cells may relieve the 
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pathogenesis of autoimmunity. The use of ER and ER antagonists separately and 
simultaneously during autoimmunity in mouse models may reduce the secretion and expression 
on pro-inflammatory cytokines and reduce the differentiation of activated T cells towards the 
Th1 and Th2 subsets.  
In summary, the findings of this dissertation demonstrate that estrogen signaling is an 
important factor to consider in the design and optimization of T cell-based immunotherapies for 
cancer and infections. In addition, characterizing the role of estrogen signaling on T cell function 
may have far reaching importance in terms of regulating T cells during autoimmune disease or 
even as a result of chronic inflammation due to Ag stimulation. The results in this dissertation 
have provided a new foundation in which to augment T cell-based therapy efficacy for several 
cancers and other further diseases. 
Clinical Trial Design 
 
 The studies performed in this dissertation revealed that physiological (0.5 nM) and super-
physiological (50 nM) estrogen signaling through ER enhances the expression and secretion of 
specific Type 1/Th1 cytotoxic effector T cell cytokines such as IFN and Granzyme B, as well as 
Type 2/Th2 helper T cell, cytokines including TNF and IL-4, on HCV Ag-specific T cells from 
male and female donors. It was also shown that estrogen signaling through ER at both 
physiological and super-physiological concentrations enhanced overall T cell polyfunctionality, 
or the ability of HCV Ag-specific T cells from male and female donors to express more than two 
functional markers upon Ag stimulation. In vivo, it was shown that physiological estrogen 
enhances the infiltration, survival, activations state, cytokine expression, and polyfunctionality of 
Ag-specific TILs, especially of the CD4+ subset, after ACT immunotherapy against HCC. 
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Overall, these data indicate that estrogen signaling could improve the efficacy of ACT 
immunotherapy against HCC by enhancing the anti-tumor function, tumor infiltration, and 
survival of adoptively transferred Ag-specific T cells. Since the in vivo studies performed in 
humanized mice were proven to be successful, and tumor reduction was greatly achieved in 
females containing physiological estrogen (SHAM females) compare to estrogen-depleted 
females (OVX females) and males in a safe manner, a clinical trial can be designed to evaluate if 
estrogen could enhance Ag-specific T cell function and reduce tumor burden during ACT 
immunotherapy for patients suffering from HCC. 
 For this clinical trial, HLA-A2+ pre-menopausal (containing physiological estrogen) and 
post-menopausal (estrogen-depleted) women and age-matched men suffering from chronic HCV 
infection-derived HCC will be recruited. Circulating T cells from these patients will be collected 
from blood samples and transduced with the 1406 HCV TCR as described before and sorted to 
obtain a > 99% pure transduced T cell population. Then, Ag-specific T cells will be expanded in 
vitro using irradiated Ag-presenting cells expressing the HCV cognate Ag. Before transfer, Ag-
specific T cells from pre- and post-menopausal women and men will be treated with either no 
estrogen, physiological (0.5 nM), or super-physiological (50 nM) estrogen overnight. According 
to the data obtained in the pre-clinical studies, short-term estrogen treatment was enough to 
enhance Ag-specific T cell function including cytokine expression and polyfunctionality upon 
Ag stimulation. Acute estrogen treatment will also prevent the estrogen-mediated self-
downregulation of expression of ER and ER observed after long-term estrogen exposure [485-
487]. Patients from each respective group will be receive local liver stereotactic radiation therapy 
to a total dose of 50 Gy in four 12.5 Gy fractions to control tumor burden before immunotherapy 
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and to enhance tumor Ag presentation [496], then they will receive one dose of 10x106 Ag-
specific T cells/kg treated with either no estrogen, physiological, or super-physiological estrogen. 
After adoptive transfer, patients will receive low-dose rhIL-2 (30 g/m2) every five days to 
ensure Ag-specific T cell survival [497]. Tumor burden will be monitored via liver ultrasound 
and serum concentration of -fetoprotein (AFP) [498]. Tumor burden will be compared on 
patients from each respective group that received Ag-specific T cells treated with estrogen 
compared to untreated T cells. Blood samples will be collected periodically to observe the 
phenotype and counts of Ag-specific T cells remaining on the patients’ circulation. Number of 
remaining CD4+ and CD8+ Ag-specific T cells and their phenotype (Type I/II, Tregs, Th1/2/17/22) 
will be measured, their activation state will be assessed via flow cytometry by staining for 
activation markers (CD25, CD69, CD44, and CD62L), and their function will be measured upon 
Ag re-stimulation ex vivo to observe if Ag-specific T cells are under exhaustion conditions. Also, 
over 3 months after ACT, survivor patients will be tested for Ag-specific T cell memory 
formation by collecting blood samples and surveilling for T cell central memory markers 
(CD45RO+CCR7-CD28-CD27-) as well as their ability to elicit effector responses upon HCV Ag 
re-stimulation. Since estrogen signaling through ER enhances T cell polyfunctionality, which is 
correlated with T cell memory formation [476], greater number of central memory T cells are 
expected to be found in pre-menopausal women and post-menopausal women and men whose T 
cells were estrogen treated. 
According to the pre-clinical data previously observed, men and post-menopausal women 
that receive untreated Ag-specific T cells will have the worse tumor burden compared to pre-
menopausal women. Tumor burden will decrease in men and post- and pre-menopausal women 
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that receive estrogen treated Ag-specific T cells in a dose dependent manner comparing 
physiological to super-physiological estrogen treated T cells. Ag-specific T cells from pre-
menopausal women will show enhanced survival, especially those in the Th1 and Th2 CD4+ 
subsets, as well as enhanced cytokine expression and polyfunctionality compared to those from 
post-menopausal women and men. Survival and infiltration of Ag-specific T cells should 
increase in a dose dependent manner with estrogen treatment in all three patient groups. If 
possible, a liver biopsy will be collected after ACT immunotherapy in order to analyze the 
phenotype and function of TILs (including activation state, subset differentiation, and infiltration 
level), which it is predicted to be better in the presence of physiological estrogen (pre-
menopausal women), and in patients that received estrogen-treated T cells. 
If estrogen treated T cells elicit enhance anti-tumor responses and significantly reduce 
tumor burden more than untreated T cells, a second clinical trial will be performed in order to 
determine if signaling through ER, ER, or both receptors simultaneously is necessary for the 
estrogen-mediated enhancement of the Ag-specific T cell anti-tumor immune response. In that 
case, HLA-A2+ pre- and post-menopausal women and age-matched males suffering from HCV-
derived HCC will receive ACT immunotherapy of Ag-specific T cells that were treated with an 
ER-specific agonist (PPT), and ER-specific agonist (DNP), or both simultaneously overnight 
at a concentration of 100 nM. Then, treated Ag-specific T cells will be infused into the patients 
of each group as described before, and tumor burden, T cell survival, phenotype, and function 
will be assessed. Since it was shown that estrogen signaling through ER  enhances overall Ag-
specific T cell polyfunctionality, it can be predicted that patients that receive Ag-specific T cells 
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treated with an ER agonist will show enhanced anti-tumor immune responses and reduced 
tumor burden compared to those patients that received ER agonist-treated T cells. 
These clinical studies will help determine if estrogen signaling can be used to enhance the 
efficacy of ACT immunotherapy. This is especially important because it will show that short-
term estrogen or ER-specific agonist treatment of Ag-specific T cells and not the whole patient, 
which is safe and easy to achieve, can alone increase the T cell anti-tumor immune response. In 
the case of men and post-menopausal women which show the highest incidence rates for HCC, 
estrogen treatment of the Ag-specific T cells will offer a simple yet effective way to enhance a 
cancer treatment that while has shown promising results, it is still inefficient in removing large 
solid tumors.  
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